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Abstract
Meta-analysis of microarray studies to produce an overall gene list is relatively straightforward
when complete data are available. When some studies lack information, providing only a
ranked list of genes, for example, it is common to reduce all studies to ranked lists prior to
combining them. Since this entails a loss of information, we consider a hierarchical Bayes
approach to meta-analysis using different types of information from different studies: the
full data matrix, summary statistics or ranks. The model uses an informative prior for the
parameter of interest to aid the detection of differentially expressed genes. Simulations show
that the new approach can give substantial power gains compared to classical meta analysis
and list aggregation methods. A meta-analysis of 11 published ovarian cancer studies with
different data types identifies genes known to be involved in ovarian cancer, shows significant
enrichment, while controlling the number of false positives.
Independence of genes is a common assumption in microarray data analysis, and in the
previous model, although it is not true in practice. Indeed, genes are activated in groups called
modules: sets of co-regulated genes. These modules are usually defined by biologists, based
on the position of the genes on the chromosome or known biological pathways (KEGG, GO for
example). Our goal in the second part of this work is to be able to define modules common to
several studies, in an automatic way. We use an empirical Bayes approach to estimate a sparse
correlation matrix common to all studies, and identify modules by clustering. Simulations
show that our approach performs as well or better than existing methods in terms of detection
of modules across several datasets. We also develop a method based on extreme value theory to
detect scattered genes, which do not belong to any module. This automatic module detection
is very fast and produces accurate modules in our simulation studies. Application to real data
results in a huge dimension reduction, which allows us to fit the hierarchical Bayesian model
to modules, without the computational burden. Differentially expressed modules identified
by this analysis present significant enrichment, indicating promising results of the method for
future applications.
Key-words: clustering, empirical Bayes estimation, hierarchical Bayesian model, high-dimensional
data, large covariance matrix estimation, MCMC, meta-analysis, microarray gene expression
data, modules.
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Résumé
Les méta-analyses de puces à ADN utilisées dans le but d’identifier une liste globale de
gènes sont relativement faciles à conduire lorsque les données complètes sont disponibles.
Cependant, de nombreuses études omettent de mettre leurs jeux de données à disposition, ne
publiant que la liste résultante de l’analyse. Il est donc courant d’obtenir des listes ordonnées
de gènes pour chaque étude qui sont ensuite combinées. Cette étape provoque inévitablement
une perte d’information. Afin d’y remédier, nous avons développé un modèle hiérarchique
Bayesien pour la méta-analyse utilisant différents types d’information provenant de diverses
études. Ainsi nous considérons que des matrices d’expression de gènes, des statistiques
ou des rangs des différentes études considérées peuvent être collectés. Le modèle utilise
une densité à priori pour le paramètre d’intérêt qui facilite la détection des gènes exprimés
différemment. En comparaison aux méthodes classiques de méta-analyse et de combinaison
de rangs, les simulations montrent que cette nouvelle approche aboutit à une augmentation
de la puissance statistique. Une méta-analyse de 11 études publiées sur le cancer ovarien
mettant à disposition les différents types de données considérés dans ce travail a permis
d’identifier des gènes connus pour être actifs dans le cancer ovarien tout en contôlant le
nombre de faux positifs. De plus, les gènes détectés présentent un enrichissement biologique
significatif.
Alors que l’indépendance des gènes est souvent supposée dans les analyses de données de
puces à ADN, ainsi que dans le modèle précédent, l’hypothèse n’est pas vérifiée en pratique.
En effet, les gènes tendent à être activés par groupes de gènes co-régulés, que l’on nomme
modules. Ceux-ci sont généralement définis en collaboration avec des biologistes. Ils peuvent
être basés sur la position des gènes sur le chromosome ou d’après des voies biologiques
(KEGG, GO par exemple). Dans la seconde partie de ce travail, nous nous appliquons à
définir de manière automatique des modules communs à plusieurs études. Pour cela, nous
utilisons une approche Bayesienne empirique afin d’estimer une matrice de corrélation éparse
commune à un ensemble d’études. Les modules sont ensuite identifiés par clustering. En
termes de détection de modules communs à plusieurs jeux de données, nous montrons par
des simulations que notre approche obtient des performances similaires ou supérieures aux
méthodes existantes. En outre, une méthode basée sur la théorie des valeurs extrêmes permet
d’identifier les gènes épars, qui n’appartiennent à aucun module.
Notre étude de simulations a montré que cette détection automatique est particulièrement
rapide, simple et efficace. En effet, les modules définis sont précis et justes. Appliquée à des
données réelles, il en résulte une réduction de la dimension permettant d’ajuster plus facile-
vii
ment et rapidement le modèle développé dans la première partie de ce travail, en utilisant
cette fois les modules au lieu des gènes. Cette méthode nous a permis d’identifier des mo-
dules exprimés différemment entre les individus atteints de cancer et les individus sains qui
présentent un enrichissement biologique significatif. Les résultats obtenus suggèrent donc
qu’elle est prometteuse pour d’éventuelles applications à d’autres types d’études.
Mots-clés : clustering, estimation Bayesienne empirique, estimation de matrices de covariance
en grandes dimensions, expression de gènes, MCMC, méta-analyse, modèles hiérarchiques
Bayesiens, modules, puces à ADN.
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1 Preliminaries
1.1 Introduction
Understanding the role and identifying the genes involved in the mechanisms of a given
biological process is a central topic in biomedical research. Identifying the genes related to
serious diseases such as cancer allows better understanding and helps in finding suitable
treatments or better methods for early detection. By providing a way to look at all genes of
the genome simultaneously, microarrays are particularly appropriate for this kind of study.
They also allow the comparison of different tissues, thus enabling the identification of genes
specific to a given tissue. Microarray data are not new: according to Chon and Lancaster
(2011), the first time a collection of distinct DNA in arrays was used for expression profiling
was in Kulesh et al. (1987), whereas the first complete eukaryotic genome on a microarray was
published in 1997 (Lashkari et al., 1997). More and more studies use microarray data in order
to detect genes differentially expressed between several groups of tissues, but such data are
highly variable and the results obtained are often non-reproducible or not robust to even the
mildest perturbations (Ramasamy et al., 2008). This large variability may be due to improper
analysis or inadequate control of false discoveries, and is exacerbated by a small sample size
compared to the number of genes, which is usually in the tens of thousands. It is therefore
valuable to combine the results of different microarray studies that address the same question.
Combination of study results has been applied in a great variety of fields and especially
in biomedicine, where sample sizes are usually quite small. Such methods are generally
called meta-analysis, and are defined as statistical analyses that combine similar study results
in an automatic way (Sutton et al., 2000). Meta-analysis is different from literature review,
where one simply extracts and compares results from different studies through discussion, or
pooled analysis, where one treats the data as if they came from the same study. Meta-analysis
combines study results in a quantitative way, increasing power and reinforcing the results.
Since the first meta-analysis of microarray data (Rhodes et al., 2002) was performed, many
methods have been developed for this purpose, as we shall see in Section 2.1. Ramasamy et al.
(2008) provide guidelines to conduct a meta-analysis on microarray data, while Stevens and
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Doerge (2005) give indications for Affymetrix data. Meta-analysis requires that studies address
the same question, so study selection is one of the most important steps in a meta-analysis. It
is made easier for microarray data through the use of public repositories, as we will explain in
Section 1.4. Data, especially raw data, are not always easy to collect, which is a major difficulty
in meta-analyses. When study results are not of the same type, a common way of integrating
information consists in transforming the data to the least informative summary, usually ranks,
which are then combined using list aggregation methods, presented in Section 2.2. This
reduction results in a clear loss of power, as most of the available information is not used.
Being able to combine heterogenous data types, while using all the information available and
maintaining high power, is one of the main motivations for the work in this thesis, as we will
further explain in Section 1.5.
Microarray data are often used in cancer studies, where the aim is to find genes differentially
expressed between cancer and normal tissues, or genetic profiles of patients more responsive
to some treatment. In this thesis, we are interested in ovarian cancer, which is common and
has a high mortality rate. Some biological background about microarray data and ovarian
cancer is presented in Sections 1.2 and 1.3.
1.2 Microarray data
A microarray is an array of thousands of spots on which specific portions of genes, called
probes, are deposited. A solution of DNA from a particular biological sample, called the
target, is prepared and labeled, and then the array is washed with it. The idea is that the target
solution contains sequences of DNA which are complementary to those deposited on the array
and will therefore hybridize, or match, with the complementary sequences (Draghici, 2003). It
is then possible to measure the amount of target DNA hybridized on the array. The higher the
amount of hybridized DNA, the higher the gene expression in the sample. Depending on the
technology used, the protocol can change slightly. Here, we describe two of the most common
arrays, cDNA arrays and oligonucleotide arrays. The first, also called spotted DNA array or
two-color arrays (Figure 1.1a), takes mRNA from two different biological samples and reverse
transcribes them to cDNA, which is then labeled using dyes of two different colors, one for
each sample. The array is a glass slide, which is composed of hundreds of thousands of spots,
each containing a different DNA sequence. The array is then washed with the labeled cDNA
from the two samples. If a cDNA probe is complementary to the DNA, they will hybridize. With
the help of a scanner, fluorescence is quantified, indicating the amount of gene expression
from each sample at each spot. Two samples are hybridized on the same array using different
dyes (red and green). Each entry of the data matrix is the log2 ratio of the two intensities,
allowing comparison of the quantity of expression of the gene in each sample. In order for
these ratios to be comparable between arrays, they need to be normalized, generally through
scaling and median centering, or loess normalization (Guerra and Goldstein, 2009). The
normalized log ratios are then ready for analysis.
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(a) cDNA array (b) Oligonucleotide array (c) Oligonucleotide array
Figure 1.1 – cDNA and oligonucleotide arrays: (a): protocol for cDNA array1. 1: choice of cell
population, 2: mRNA extraction and reverse transcription, 3: fluorescent labeling of cDNA, 4:
hybridization to a DNA microarray, 5: scanning the hybridized array, 6: scanned image.
(b): oligonucleotide array2: actual size of GeneChip is 1.28×1.28 cm, 500 000 cells on each array,
millions of DNA strands built up in each cell, actual strand is 25 base pairs.(c): oligonucleotide
arrays, non-hybridized and hybridized DN Shining a laser light at gene chip arrays causes
tagged DNA fragments that hybridized to glow.
Oligonucleotide arrays (Figures 1.1b-1.1c) use mRNA, which is reverse transcribed to cDNA
and transformed to labeled cRNA. The most commonly used oligonucleotide array is the
Affymetrix GeneChip, which holds million of spots, each composed of oligonucleotides of
25 bases called probes. Each gene is represented by a set of 11 to 20 pairs of probes on the
array. The first type of each pair is called a perfect match (PM), and is taken from a gene
sequence. The second type of the pair is called a mismatch (MM), and is similar to the PM but
with the middle base changed (Parmigiani et al., 2003). The cRNA contained in the sample
solution hybridizes with the probes on the array, and scanning the chips gives a measure of
the intensity of each probe, which is recorded in a CEL file. The role of MM is to measure
non-specific hybridizations and background noise, so the intensity of interest is only that from
the PM. Contrary to cDNA arrays, only one sample is hybridized on each chip. There exist
many methods for normalizing Affymetrix data, but the most common, and the one we will
use in this thesis, is robust multi-chip analysis (Irizarry et al., 2003), which we call RMA. It uses
only the perfect matches and ignores the mismatches, corrects the perfect match background
(BG) on the raw scale and performs quantile normalization of log2(PM
?) = log2(PM−BG).
Then it assumes an additive model
log2(PM
?
i j )=αi +β j +ei j ,
where αi is the effect of chip i , β j is the effect of probe j and ei j are the independent and
identically distributed errors with zero mean (Irizarry et al., 2003). The parameters α and β
are estimated robustly, using median polish or robust linear modeling.
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1.2.1 Enrichment analysis
The most studied problem in the analysis of microarray gene expression data is to identify
genes that are differentially expressed between several conditions. The differential expression
of each gene is usually quantified by some statistic, for which significance is declared if the
corresponding p-value, corrected for multiple testing, is below a pre-chosen threshold. This
procedure is fairly automatic and does not require any biological knowledge. However the
results obtained, i.e., a list of differentially expressed genes, should have biological meaning.
The analysis performed to assess the biological meaning of a candidate list of genes is called
gene set enrichment analysis, and is reviewed in Hung et al. (2012), Irizarry et al. (2009) and
Goeman and Bühlmann (2007), among others. The authors describe two sets of methods
for including biological knowledge into data analyses. In both, gene sets are defined prior
to the analysis, based on biological processes. The Gene Ontology (The Gene Ontology
Consortium, 2008) is one such database, and groups genes according to their biological
role under three ontologies: biological process, molecular function and cellular component.
KEGG pathways (Kanehisa and Goto, 2000, Kyoto Encyclopedia for Genes and Genomes) is
another database, and consists of sixteen different parts categorized into system information,
perturbed systems information, genomic information, and chemical information. The goal of
KEGG is to link genes to higher level functions. Information from several such databases are
accessible through the MSig repositories (Liberzon et al., 2011).
The first enrichment method presented by Goeman and Bühlmann (2007) tests significance
of over representation of biologically meaningful genes in the candidate list compared to
the pre-defined list. One starts by creating a 2×2 table, where each cell counts the number
of genes present in both lists, only one list, or none, and tests the null hypothesis of no
enrichment using a hypergeometric distribution. This method has been used by Falcon and
Gentleman (2007), through the GOstats Bioconductor R package, and has been made very
accessible and easy to use by the development of DAVID (Huang et al., 2008), which is an
online bioinformatics tool to systematically extract biological information from large gene
lists. The candidate gene list submitted requires the choice of a cutoff to separate differentially
expressed genes from the rest of the list. If we denote by G the gene universe (the entire set of
genes), SGO a set of genes from, say, GO ontologies, and L a list of interesting genes, then we
can obtain the distribution of the observed genes as presented in Table 1.1. Significance of the
gene set can be assessed by a χ2 test, a hypergeometric test, or Fisher’s exact test. This method
has the advantage of being simple and does not require a particular score for each gene: an
ordered list of gene names is sufficient. However, it does require a fixed list, meaning that one
needs to define a threshold above which genes are declared differentially expressed.
The second method, which Irizarry et al. (2009) called the aggregate score approach, assigns
a score to each gene set based on the scores of the genes belonging to that set. It assumes
that each gene is attributed a score indicating its differential expression, like a z-score or a
1http://www.cs.wustl.edu/~jbuhler/research/array/
2http://images.yourdictionary.com/micro-array
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Table 1.1 – Distribution of the genes under the hypergeometric setup. G is the gene universe,
L is the list of interesting genes and SGO is the set of genes from a GO ontology.
in L not in L
in SGO n11 n12 |SGO|
not in SGO n21 n22 |G|− |SGO|
|L| |G|− |L| |G|
t-statistic, based on two sample t-test for instance. One of the most common methods in this
category is gene set enrichment analysis (Mootha et al., 2003; Subramanian et al., 2005, GSEA),
which focuses on groups of genes that share biological functions like chromosomal location
or regulation. GSEA is based on the Kolmogorov–Smirnov test and can be summarized as
follows (Hung et al., 2012):
1. rank all genes and select a set of contiguous genes, which is the candidate list;
2. calculate the enrichment score for each gene, which is defined as a weighted Kolmogorov–
Smirnov statistic. The score is increased if the gene is in the pre-defined set and de-
creased otherwise, by a magnitude proportional to the correlation of the gene with the
phenotype;
3. estimate the significance level of the enrichment score by permutation of the sample
labels, which keeps the gene correlation structure;
4. repeat the procedure for another candidate gene list;
5. correct for multiple testing (Benjamini and Hochberg, 1995).
Due to the permutations required to estimate the null distribution, i.e., to assess significance
of the enrichment score, GSEA is computationally intensive. Irizarry et al. (2009) circumvent
this by using an aggregate score which has a known distribution under the null hypothesis
(either a normal or a chi-squared, depending on the version), so p-values are easy to obtain.
Their method assumes that each gene is attributed a score which is normally distributed under
the null hypothesis of no differential expression.
In Chapter 5, when analysing enrichment of the gene list obtained from our model, we will
use the first type of approach, as it would be too computationally intensive to apply GSEA
and we don’t know the distribution of the scores attributed to each gene in our list. We
therefore compare the enrichment of our list of genes with gene sets defined from the Gene
Ontology (The Gene Ontology Consortium, 2008) or from KEGG (Kanehisa and Goto, 2000).
5
Chapter 1. Preliminaries
Table 1.2 – Surgical staging of ovarian carcinomas. Stages presented here are FIGO (Federation
of International Gynecology and Obstetrics) stages (Merck, 2014).
Staging
Stage I Tumor limited to the ovaries
IA Tumor limited to one ovary; no tumor on the external surface and capsule intact.
IB Tumor limited to both ovaries; no tumor on the external surface and capsules intact.
IC Stage IA or IB but with tumor on the surface of one or both ovaries,
with capsule ruptured, or with malignant cells in ascites or in peritoneal washings.
Stage II Tumor involving one or both ovaries with pelvic extension or metastases.
IIA Extension and/or metastases to the uterus, fallopian tube, or both.
IIB Extension to other pelvic tissues.
IIC Stage IIA or IIB but with malignant cells in ascites or in peritoneal washings
Stage III Tumor involving one or both ovaries with histologically confirmed
peritoneal matastases outside the pelvis
IIIA Microscopic peritoneal metastases outside the pelvis and negative lymph nodes.
IIIB Macroscopic peritoneal metastases outside the pelvis that are ≤2 cm in diameter
and negative lymph nodes.
IIIC Abdominal peritoneal metastases that extend beyond the pelvis
and are > 2 cm in diameter and/or regional lymph node metastases.
Stage IV Distant metastases to the liver or outside the peritoneal cavity.
1.3 Ovarian Cancer
According to Merck (2014), ovarian cancer is the fifth most frequent cause of death from cancer
in women and the second most frequent from gynecological cancers. In 2013, about 22 200
new cases were discovered and 14 000 women died from it (Merck, 2014). Ovarian cancer is
called a “silent killer” as it generates no, or only non-specific symptoms, and therefore is hard
to detect at an early stage. The 5-year survival rate is as low as 10–20% when the cancer is
detected at an advanced stage, whereas it reaches 70–100% for early stage detection.
The most common type of ovarian cancer is epithelial ovarian cancer, which arises on the
surface (or epithelium) of the ovary. This type represents about 80% of all ovarian cancers,
other types arising in germ cells or in sex cord and stromal cells. However, the epithelial type
can itself be divided into five subtypes based on biological behavior, response to treatment
and overall prognosis (Jacob et al., 2009). Staging can also be useful to distinguish cancers
within a given subtype. The different characteristics for each stage are described in Table 1.2.
Even with this large heterogeneity among cancer types and subtypes, all patients are treated
the same way. First a hysterectomy and a bilateral salpingo-oophorectomy is applied and then
a post-operative chemotherapy composed of carboplatin and paclitaxel follows (Merck, 2014).
As seen above, ovarian cancer is very heterogenous, and due to its high mortality rate it has
been extensively studied. A large number of studies concerning ovarian cancer have been pub-
lished, many of which use high-throughput technologies such as genomics and proteomics.
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According to Jacob et al. (2009), 237 studies using various -omic technologies were published
between 1999 and 2007. Indeed, those techniques allow analysis of the expression of thou-
sands of genes in only one experiment and thus are really useful for analyzing the specificities
of ovarian cancer. These publications identified genes or molecular profiles specific to ovarian
cancers. However, these results are often highly variable and may not be directly comparable.
It is even possible that the final lists of differentially expressed genes provided by different
studies do not overlap at all, which raises the problem of the reproducibility and reliability
of such lists. All these criteria are a great motivation to study this cancer more deeply, by
integrating the results of studies about ovarian cancer in a fairly automatic way.
1.4 Data collection
In order to integrate results from different sources, it is necessary to select studies looking at
the question of interest. The more information available, the more reproducible the results,
which makes access to raw data particularly useful. Genomic data are more and more easily
accessible with the development of public databases, which bring together studies (often
with a link to the article), raw data, and sometimes information about the patients involved
in the study. The Gene Expression Omnibus (GEO), for instance, created in 2000, aims to
cover the broadest spectrum of high-throughput experimental methods (Edgar et al., 2002).
Each dataset is accessible via a unique number and is classified under three categories: the
platform (list of probes indicating which genes are present in the experiment), the series (a set
of samples which form a dataset), and samples (measures of gene expression). In 2013, GEO
hosted over 32 000 public series, comprising more than 800 000 samples from 1600 different
organisms, with a constantly increasing submission rate (Barrett et al., 2013). Another public
repository that we will use for collecting data is Array Express (Brazma et al., 2003), which is a
database for microarray gene expression data that uses the Minimum Information About a
Microarray Experiment (Brazma et al., 2001, MIAME). The MIAME criteria were introduced in
2001 by the Microarray Gene Expression Database Group (MGED), and consists in describing
the information necessary to ensure interpretability of the experimental results obtained using
microarrays, and to allow independent verification. It consists of six points (MGED, 2010):
1. raw data for each hybridization;
2. final processed data for the set of hybridizations in the experiment;
3. essential sample annotation including experimental factors and their values;
4. experimental design including sample data relationships;
5. sufficient annotation of the array; and
6. essential laboratory and data processing protocols.
The MIAME criteria aids integration of datasets and ensures reproducibility.
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There also exist other public repositories or more specific data collections, such as the Stanford
Microarray Database (Stanford, 2010) or Oncomine (Rhodes et al., 2004). Sometimes, datasets
are provided directly by the authors via their webpage, so articles need also to be looked at
when recording datasets. One can look in Pubmed (NCBI, 2010), Cochrane (Cochrane, 2010)
or Medline for example, in order to find publications relevant to the question of interest.
When looking for datasets to be included in an analysis, it is first important that they address
the same scientific question. Then data need to be extracted from the studies, and can be of
different types: image files, already preprocessed matrices of gene expression values, or final
lists of summary statistics or ranks. Of course, access to raw data allows one to preprocess
and analyze all the datasets in a similar way, thus reducing yet another source of variability. It
also gives access to the largest amount of information one can obtain from the data. However,
publication of raw data is far from systematic. Larsson and Sandberg (2006) noted that raw
data were available for only 34% of the samples on GEO, many of which did not meet the
necessary quality standards. Even if since 2006 the proportion of available raw data is very
likely to have increased, it is far from always being the case that raw data are available, implying
a huge loss of information. Jacob et al. (2009) point out that authors frequently publish only
lists of significant genes, which are of limited utility for meta-analysis.
After data collection, data annotation must be harmonized across studies. Patients can
sometimes appear several times under different IDs, or variables with the same name may
describe different quantities and vice versa. Some studies give little or no information about
inclusion-exclusion criteria concerning the patients or the tissues involved. As data are
built on different platforms, probe-to-gene mapping may also be problematic, as it should
be consistent across studies. To get rid of these problems, the strategy usually consists in
considering each study separately and harmonizing between studies by hand as much as
possible, or setting some possibly arbitrary assumptions.
1.5 Purpose of the thesis
The first motivation of this thesis was to study ovarian cancer; more precisely, to detect genes
differentially expressed between serous ovarian cancer and normal samples. As outlined in
Section 1.3, this cancer has a high mortality rate and it therefore seems important to better
understand the genes involved. Even with many published studies analyzing ovarian cancer
data, we saw in Section 1.4 that it was not always easy to find datasets that provide the raw
matrix of gene expression values. Studies publish their results in a form which may vary from
the ordered list of top k genes to the values of some statistic for each gene. When first looking
for datasets comparing serous ovarian cancer and normal control samples, we could not find
many, due to the fact that we were only interested in one particular subtype, and only a small
proportion provided raw data. The rest had either lists of summary statistics, or published
ordered lists of gene names. Integrating heterogeneous data types is not straightforward, as
current methods requires homogeneous data types. Meta-analysis (Section 2.1) combines
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similar study results in an automatic way and therefore discards results that are not in the
appropriate format. List aggregation reduces all data to the least informative support (usually
ranks) before combination (Section 2.2). However either discarding or transforming to the
least informative support may lead to a huge loss of information, and we want to integrate
all study results, exploiting the information they provide. Jacob et al. (2009) highlight the fact
that meta-analysis methods require access to raw data, and that extension to combination of
heterogeneous data would make fuller use of the available data.
Our goal in this work is to combine four heterogeneous types of information: matrices of
gene expression values, full or partial lists of z-scores, and partial lists of ranks. We develop
a hierarchical Bayesian model, presented in Chapter 3, where each type of data is modeled
separately and then combined through a single parameter γ. A prior on this parameter is
then carefully chosen to aid the detection of differentially expressed genes. Model efficiency is
assessed using simulated microarray data in Chapter 4. A real data illustration is presented in
Chapter 5, where our model is applied to serous ovarian cancer, in order to detect differentially
expressed genes between cancer and normal samples.
Even if our model seems to perform well on both simulated and real data, it assumes inde-
pendence of the genes, which is not true in practice, and it cannot handle the entire gene set,
owing to computational restrictions. To overcome these problems, we consider modules, i.e.,
groups of genes that are correlated and usually have similar functions. We develop a method
for automatic module detection which is based on the estimation of a common sparse correla-
tion matrix followed by clustering. Using modules instead of genes considerably decreases the
dimension of the problem, thus increasing power, and as modules are independent, they are
better suited for our model. Estimation of the common correlation matrix will be discussed in
Chapter 6, while module selection and application of the model to the detection of differen-
tially expressed modules are presented in Chapter 7. Conclusions are given in Chapter 8, and
calculations, additional results and lists of notations and parameters used in the models and
the simulations are in Appendix A.
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2 Data combination
2.1 Meta-analysis
High dimensional data are more and more common, especially in biomedicine. However,
even if we are able to measure more and more variables, sample sizes do not usually follow the
same growth, and are much smaller than the number of features, typically due to costs, logistic
or ethical issues. It is thus common that datasets have a number of variables in the order of
the tens of thousands, while the number of samples remains in the hundreds. In such setting,
a simple analysis is not likely to have high power, as it will certainly be highly variable and not
reproducible. When several studies of the same question are available, it may therefore be
interesting to look at their results and identify the similarities. Combination of study results
increases power and provides more reliable and reproducible results. Such statistical analysis,
called meta-analysis, combines the research findings of the studies included, in a systematic
way (Sutton et al., 2000). Meta-analysis is very easy to use due to its systematic nature, and
it can handle a large number of studies, which is why it has been so much used. It allows
the discovery of effects that may have been missed in single study analysis, while preventing
over-interpretation of the differences across studies. Selection of studies to include in a meta-
analysis remains an open question. Indeed the selection can be intentional, if one selects
only studies with a particular design for example, or due to publication bias, where studies
having positive results are more likely to be published, and subsequently selected. In both
cases selection can bias the results.
Microarray data are one example of high dimensional data, where meta-analysis seems to
be especially appropriate to reduce the variability of the results. Although it seems quite
simple, pooling the raw data and treating them as a single study is often a bad idea because of
Simpson’s paradox, which can lead to false or contradictory results. Combining final decisions,
as whether a gene is differentially expressed or not, by taking the intersection of Venn diagrams,
for example, might lead to a very small or even an empty set of genes.
In this section, we first review some of the common methods of meta-analysis, mostly fol-
lowing Sutton et al. (2000), and we then focus on meta-analysis for microarray data, for
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which a good reference is Guerra and Goldstein (2009). Other references for meta-analysis
are Kulinskaya et al. (2008) and Whitehead (1997).
2.1.1 Methods for meta-analysis
Before combining study results, it is important to define measures of outcome to be calculated
for each of the studies separately. They depend on the type of data at hand and on the type
of question one wishes to answer. They can be odds, summary statistics, p-values or ordinal
outcomes.
Fixed and random effects models
Fixed and random effects models can use most of these types. The fixed effects model assumes
that all population effect sizes are equal, in other words, there is no heterogeneity between
the studies. This is a strong assumption, which can be tested through a heterogeneity test.
When the test is rejected, a random effects model should be preferred, as it assumes that the
studies estimate different effect sizes, and therefore takes the between-study, as well as the
within-study, variance into account.
The general fixed effects model uses an inverse variance weighted combination of the mea-
sures of outcome. The idea is that each study estimate is given a weight which is inversely
proportional to its variance. Suppose that b1, . . . ,bn are the observed effect sizes of the n
independent studies to be combined, and vi denotes the variance of bi . Then the combined
effect is given by
b =
∑n
i=1 wi bi∑n
i=1 wi
, wi = 1
vi
.
An estimate of the variance of b and a (1−α)% confidence interval can be easily obtained as
var
(
b
)
= 1∑n
i=1 wi
, b ∈
[
b− z1−α/2
√
var
(
b
)
; b+ z1−α/2
√
var
(
b
)]
,
where z1−α/2 is the (1−α/2) quantile of the standard normal distribution. The fixed ef-
fects model assumes homogeneity between studies, which can be tested using Cochran’s
test (Cochran, 1950). Under the null hypothesis of homogeneity,
Q =
n∑
i=1
wi
(
bi −b
)2 ∼
H0
χ2n−1.
If homogeneity cannot be assumed, a random effects model, which adds a variation term to
the fixed effects model to take heterogeneity into account, is used. The random effects model
assumes that bi = θi +²i , where bi is the estimate of the effect size, θi represents the true effect
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size, and ²i is the estimation error. We define
s2w =
1
n−1
n∑
i=1
w2i −nw2, w =
1
n
n∑
i=1
wi , U = (n−1)
(
w − s
2
w
nw
)
,
τ2 =
{
0, Q ≤ n−1,
Q−(n−1)
U , Q > n−1,
w?i =
1
1/wi +τ2
.
The combined estimate bR AN and its corresponding variance are
bR AN =
∑n
i=1 w
?
i bi∑n
i=1 w
?
i
, var
(
bR AN
)
= 1∑n
i=1 w
?
i
.
Bayesian methods
Meta-analysis can also be performed in a Bayesian way. The model usually depends on the
context but hierarchical models (to be defined in Section 2.3.1) are very useful. Taking the
setting of the random effects model, one could construct the Bayesian model
bi | θi ,σ2i ∼N (θi ,σ2i ), θi ∼pi(θi ), σ2i ∼pi(σ2i ),
where pi(x) is the prior distribution of x. MCMC methods (see Section 2.3) are then used to
sample from the posterior densities of the parameters. Priors are chosen either to reflect prior
knowledge, or to give the largest flexibility in case of non-informative priors . Bayesian meta-
analysis borrows strength from all studies to update estimates of single studies, which leads to
precise point estimates and shrinks the confidence intervals by reducing variability. Moreover,
it is highly flexible and is therefore easily modified to include other types of information or
covariates, while taking parameter uncertainty into account. However, this method is usually
computationally intensive, which makes it often less attractive than frequentist approaches.
There is also the recurrent problem of the choice of the prior.
Combining different types of data
When the results provided by the different studies are not of the same type, they need to
be made comparable. Transformation to binary outcomes (for example whether a gene is
differential expressed or not) prior to combination usually leads to uninteresting results, as
the intersection is likely to be empty or to contain very few genes. Chang et al. (2013) describe
several methods to convert study results to the same scale. For example if study results consist
of summary statistics not arising from the same distribution, they can be transformed to
normal z-scores. To this end, we obtain the p-values, pg i , i = 1, . . . ,n, for each summary
statistic and then transform them to z-scores, Zg i =Φ−1
(
pg i
)
, for variable g in study i , where
Φ denotes the standard normal distribution. The z-scores, Zg 1, . . . , Zg n , Zg i ∼N (0,1), are
then combined by the inverse normal method, also known as Stouffer’s method (Stouffer et al.,
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1949),
Z g = 1p
n
n∑
i=1
Zg i ∼
H0
N (0,1),
where ∼
H0
means that, under the null hypothesis H0 that variable g has no effect across studies,
the test statistic follows a standard normal distribution. Rejection of the null hypothesis
indicates an effect from variable g across studies.
Another possibility is to directly combine the p-values. They can be obtained from any test
statistics, and are therefore easily combined. Several methods exist for combining p-values:
• Fisher’s method (Fisher, 1932),
X 2g =−2
n∑
i=1
log(pg i ) ∼
H0
χ22n ;
• the logit method developed by George (1977),
T = −
∑n
i=1 log
{
pi /(1−pi )
}√
npi2(5n+2)/{3(5n+4)}
∼
H0
t5n+4,
where td is the Student distribution with d degrees of freedom;
• the minimum p-value, which takes the minimum p-value among all studies as test
statistic,
T =min
i
pg i ∼
H0
Beta(1,n);
• the maximum p-value, which takes the maximum p-value among all studies as test
statistic,
T =max
i
pg i ∼
H0
Beta(n,1);
• the r th ordered p-value, which takes the r th ordered p-value as a test statistic,
T = pg ,(r ) ∼
H0
Beta(r,n− r +1);
where ∼
H0
F means “follows the distribution F under the null hypothesis”. If none of the previous
methods is applicable, study results may be transformed to ranks. This will be studied in
Section 2.2.
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2.1.2 Meta-analysis of genomics data
Microarray data are good candidates for meta-analysis, as the number of variables (genes)
is much larger than the number of samples (patients), and results from single studies tend
to be highly variable. Meta-analysis, by combining results from several studies looking at
the same question, may increase power in detecting differentially expressed genes between
groups of tissues. However, care should be taken, as microarray data need special treatment in
order to perform good meta-analyses. Guerra and Goldstein (2009, Chapters 1 and 9) provide
information and guidelines to combine data from genomic studies, while Ramasamy et al.
(2008) give seven steps for meta-analysis for gene expression data, and likewise Stevens and
Doerge (2005) for Affymetrix data. Because microarrays can be built on different platforms, or
analyzed using very different techniques, one needs to ensure that the studies to be included in
the meta-analysis are comparable. It is first important to identify suitable microarray datasets,
which should of course address the same scientific question. Then data need to be extracted
from the studies, and can be of different types, including image files, also called raw data,
already preprocessed matrices of gene expression values, final lists of summary statistics, or
ranks. Suppose that raw data, or at least gene expression matrices, have been collected for each
of the selected studies. The datasets need to be prepared in order to be comparable. Covariates
of the clinical data must be consistently named and encoded (same binary variable indicating
cancer or control for example). The probes need to be matched to their corresponding gene,
and when several probes match to the same gene, a common procedure should be applied, e.g.,
averaging or selecting the most variable probe. Gene annotation is also a recurrent problem,
especially if the datasets are built on different platforms. In this case one has to make sure
that the annotation is the same for every dataset. Once the datasets have been prepared, a
suitable method for meta-analysis is selected.
Tseng et al. (2012) performed a literature review recording all meta-analyses performed on
genomics data. They identified the methods, the type of data and the question of interest
for each study. Most of the papers used genome-wide data in order to discover differentially
expressed genes between two groups of tissues. The authors identified five methods, or classes
of methods, used to combine results from genomics data. The first consists in combining
p-values, which is the method used in the very first meta-analysis of microarray data (Rhodes
et al., 2002). p-values are easy to combine as they are on the same scale, and can be easily
obtained from all studies. Methods for combining p-values were described in Section 2.1.1.
However, using p-values loses the information on the direction of the differential expressions,
i.e., over- or under-expression. Second possibility is to combine effect size changes, as in Choi
et al. (2003). These can be combined through fixed or random effects models (see Section 2.1.1
for more details) or by Bayesian analysis, which Choi et al. (2003) were the first to apply. This
method, unlike to p-value or decision combinations, does not lose information regarding the
magnitude or the direction of the differential expressions. However, it usually requires access
to raw data, or less preferably to the gene expression matrix, which we saw in Section 1.4
can be a problem in practice. The third method identified was the combination of ranks,
which we will present in more detail in Section 2.2 and which was used in a meta-analysis of
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gene expression data by DeConde et al. (2006). Ranks are interesting, because they are not
driven by outliers and tend to be more robust and therefore more reliable than effect sizes
or p-values. However, using ranks loses information on the magnitude and direction of the
differential expressions. Some studies merge the data, in what is called a mega-analysis, and
as stated previously this can be dangerous if not performed carefully, because of Simpson’s
paradox. In the case of gene expression data, one could merge all the raw data (CEL files for
example) and normalize them all together. This procedure is very restrictive as it requires all
the data to be built on the same or very similar platforms. However, even with normalization,
it may not remove cross-study discrepancies or batch effects, as demonstrated in Goldstein
et al. (2009). Meta-analysis, by considering studies to be different, and therefore taking
into account their possible heterogeneity, deals with Simpson’s paradox. The last group of
methods identified by Tseng et al. (2012) concerns the latent variable approach, including
hierarchical Bayesian models. These models are more complex than the others described in
this section and usually use Markov chain Monte Carlo, which can be quite computationally
demanding, which may be the reason why they have not been much used. Conlon et al.
(2007) combine probabilities of differential expression, without combining expression values,
through a hierarchical Bayesian model. By eliminating the need to model between-study
variability, they claim to be able to increase the number of integration-driven discoveries, i.e.,
genes that are found to be differentially expressed by the combination of studies but not in
single study analyses. Their model can combine several studies providing full information.
Hierarchical models for microarray data were also used by Ishwaran and Rao (2003) for a single
study. Shen et al. (2004) used them to obtain the probability of expression for each gene and
each study prior to combination, and finally Chen et al. (2013) propose to model gene sets and
gene expression data from multiple studies using hierarchical Bayesian framework. In this
last paper, raw data along with pathway information have to be available. Bayesian methods
allow the fitting of complicated models, while being very flexible, as described in Section 2.1.1.
However, up to now, they were only designed to combine the same type of information from
different studies.
2.2 List aggregation
Analysis of microarray data often aims at finding differentially expressed genes, in which case
the published results consist of a list of ordered genes, from the most to the least differentially
expressed. It may therefore be interesting to combine ranks, which are usually easy to find
as published study results in articles or supplementary material. Ranks can also be obtained
by ordering the absolute values of z-scores or the p-values for example. Therefore, even if a
study provides more information about its data, it is always possible to extract an ordered list
of genes. Transformation to ranks avoids discarding studies, which commonly arises when
restricting the analysis to those providing raw data. Ranks also have the valuable property
of being robust to outliers, invariant under normalization or transformation, and scale free.
However, as stated in the previous section, they lose information about the magnitude and
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the direction of the differential expressions. In this section, we present a brief review of the
methods used for list aggregation. We consider either full or partial lists, composed of the top
k most interesting genes, with k much smaller than the number of genes G . We assume that
top k lists are subsets of the same common set of genes G . Thus if an element does not appear
in a partial list, it means it was included in the analysis, but ranked lower than k, and therefore
not observed in the top k list. This section is mainly inspired by Lin (2010) and DeConde et al.
(2006).
Let G be a discrete space of size G , with elements G = {1, . . . ,G}. The rank of an element g of
G is denoted R(g ). The complete ranking of the elements of G is τ(G )= (g1, . . . , gG), gi ∈G ,
such that R(gi )<R(g j ), for i < j , obtained by applying the permutation τ to all the elements
of G . A partial list is based on a subsetS ⊂G ,S = (s1, . . . , sS), and is supposed to be already
ranked, i.e., R(s1)<R(sS), and a particularly interesting case is whenS consists of the top k
list,S = (g1, . . . , gk), the k first elements of τ(G ).
We are interested in aggregating L lists, S1, . . . ,SL , where list Sl is of length nl , either full or
partial (top nl ), obtained from applying a permutation τl to the elements of interest. We aim
to find the resulting aggregated list of elements inS =∪Ll=1Sl . If an element is in the union of
all lists but not in Sl , i.e., i ∈S ∩Scl , we set Rτl (i )= nl +1. Methods for list aggregation can
be classified into three categories, according to Lin (2010): distribution-based, heuristic and
based on stochastic optimization.
2.2.1 Distribution-based methods
Distribution-based methods were first developed for aggregating many short lists, such as
consumer rankings of products, or internet search results (Lin, 2010).
Thurstone’s model
This model was first used in the context of marketing, where the interest is in combining
many short lists. For full ranked lists, it assumes that the underlying vector of values X =
(X1, . . . , XG ) follows a multivariate normal distribution with mean vector µ= (µ1, . . . ,µG ) and
G×G covariance matrix Σ. Each pair is distributed as a bivariate normal
(Xu , Xv )=N
[(
µu
µv
)
,
(
σ2u σuσvρuv
σuσvρuv σ
2
v
)]
.
It is therefore possible to compute the probability that an element Xu of X is ranked above
another, Xv ,
P (Xu > Xv )=Φ
 µu −µv√
σ2u +σ2v −2ρuvσuσv
 , (2.1)
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where Φ is the standard normal distribution function.
If τ1, . . . ,τL are the full rankings of each of the L lists that we want to aggregate, Thurstone’s
score for two elements u and v of a ranked list l is
Hτl (u, v)= I{Rτl (u)<Rτl (v)}.
We estimate the probability (2.1) by
P (Xu > Xv )= 1
L
L∑
l=1
Hτl (u, v).
The final aggregated list is obtained by ranking the entries of the estimated mean parameters
µ. In practice, the elements of the covariance matrix are hard to estimate if we consider all
pairs. To simplify the problem and reduce the number of unknown parameters, the variances
σ2u can be fixed to 1, while the correlations are set to ρuv = 0 (DeConde et al., 2006). The mean
parameters are estimated by least squares.
For partial lists, we want to aggregate S1, . . . ,SL , lists containing the top nl rankings of the
elements of G , with underlying ranking functions τ1, . . . ,τL . If u ∈ Scl , then Rτl (u)= nl +1. For
u, v ∈S =∪Ll=1Sl , Thurstone’s score is
Hτl (u, v)=
 p, Rτl (u)=Rτl (v)= nl +1,I{Rτl (u)<Rτl (v)}, otherwise,
where p is a parameter to be set between 0 and 1, and which represents the probability that u
is ranked before v when their rankings are unknown. Usually we choose p = 0.5, indicating an
equal chance for u to be ranked higher than v .
This method is quite simple, under the assumption of normality. However, as pointed out pre-
viously, the parameters are hard to estimate due to the large number of pairwise comparisons,
and setting σ2u = 1 and ρuv = 0 may be unrealistic. Thurstone’s method is more appropriate
for many short lists for two reasons. The first concerns the number of pairwise comparisons,
which is much smaller if the lists are small, and the second concerns the estimation of the
probabilities (2.1), which are well estimated if L is large.
2.2.2 Heuristic algorithms
In this section, we describe two types of algorithms, Borda’s method and some other related
rank combination methods, as well as several Markov chain-based methods.
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Borda’s method
This method is simple and quite intuitive. It consists in attributing a score to each element of
each list and aggregate them through a function. Suppose we have L full lists S1, . . . ,SL , and let
S =∪Li=1Si . For an element g having rank Rτl (g ) in list Sl , Borda’s score is
Bl (g )= f
{
Rτ1 (g ), . . . ,RτL (g )
}
,
where f can be one of the following functions:
• the median, f
{
Rτ1 (g ), . . . ,RτL (g )
}=median{Rτ1 (g ), . . . ,RτL (g )};
• the arithmetic mean, f
{
Rτ1 (g ), . . . ,RτL (g )
}= L−1∑Ll=1 Rτl (g );
• the geometric mean, f
{
Rτ1 (g ), . . . ,RτL (g )
}= (∏Ll=1 Rτl (g ))1/L ;
• the p-norm, f
{
Rτ1 (g ), . . . ,RτL (g )
}= L−1∑Ll=1 Rτl (g )p .
For partial lists, one can either use Rτl (g )= nl+1 or ignore the lists that do not include element
g . The final list is then based on the Borda scores, where a small score corresponds to a small
rank.
The product of ranks (PR) and sum of ranks(SR) methods (Chang et al., 2013) are both based
on similar ideas to Borda’s method, as they attribute a score to each rank, defined as:
PRg =
n∏
i=1
Rτi ,g , SRg =
n∑
i=1
Rτi ,g ,
respectively. p-values for these methods may be obtained by permutation of the variable
labels.
Markov Chain methods
These methods only use pairwise ranking information and consist in constructing an ergodic
Markov chain, whose transition matrix converges to a stationary distribution that will assign
a larger probability to the elements/states that are ranked higher. Details about Markov
chains and their construction are presented in Section 2.3. There exist several methods for
constructing the transition matrixP , with elementsPuv being the probability of going from
state u to state v , with u, v ∈S . Dwork et al. (2001) introduced the method in the context of
spam fighting, Lin (2010) present three algorithms, which we will denote MC1, MC2 and MC3.
The MC1 and MC2 algorithms are slight variations of the algorithms developed by Dwork et al.
(2001), while MC3 is inspired by the algorithm developed by DeConde et al. (2006), which is
more appropriate for combining lists of genes from microarray data analysis (Lin, 2010).
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• MC1: the transition probability matrix is
Puv =

1/S, if Rτl (u)>Rτl (v) for at least one of the input lists,
0.5/S, if u and v are not compared,
0, otherwise,
Puu = 1−
∑
v 6=u
Puv .
• MC2: in this case, the probability transition matrix is
Puv =

1/S, if Rτl (u)>Rτl (v) for a majority of the input lists,
0.5/S, if u and v are not compared,
0, otherwise,
Puu = 1−
∑
v 6=u
Puv .
This algorithm is also called the MC4 algorithm in DeConde et al. (2006).
• MC3: for u, v ∈S ,
Puv =
 (LS)
−1∑L
l=1 I
{
Rτl (u)>Rτl (v)
},
0.5/S, if u and v are not compared in any list,
Puu = 1−
∑
v 6=u
Puv .
This algorithm is also called the MCT algorithm in DeConde et al. (2006).
In order to make the transition matrix ergodic, we apply the following transformation
P ′ =P (1−²)+ ²
S
,
where ² is a small number (we choose ²= 0.05 when using these methods). Once the transition
matrix is defined, we can find the stationary distribution of the Markov chain, which will
determine the aggregate ranking, by attributing a higher probability to the states (the genes)
that are ranked higher.
2.2.3 Stochastic optimization methods
Stochastic optimization methods optimize a criterion based on a dissimilarity measure be-
tween the ranked list and the aggregated list. Here we define two distance measures, the
Kendall’s tau and Spearman’s footrule distances.
Kendall’s tau
Let S1 and S2 be two lists of elements ofS , with ranking functions τ1 and τ2 respectively. We
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define
B = {(u, v) : Rτ1 (u)=Rτ1 (v)= n1+1, or Rτ2 (u)=Rτ2 (v)= n2+1} ,
i.e., the set of pairs of elements that do not appear in at least one of the two lists. The Kendall’s
tau measure between τ1 and τ2 is defined as
K (τ1,τ2)=
{ ∑
u,v∈S I{(Rτ1 (u)−Rτ1 (v))(Rτ2 (u)−Rτ2 (v))<0}, (u, v) ∈B c ,
Sp, otherwise,
where p is a parameter between 0 and 1, usually set to 0.5.
Spearman’s footrule distance
Spearman’s footrule distance is defined as
S(τ1,τ2)=
∑
u∈S
|Rτ1 (u)−Rτ2 (u)|.
In the stochastic optimization setting one wants to minimize a criterion following the gen-
eralized Kemeny guidelines (Lin, 2010), which, in the case of full ranked lists of elements of
G , assumes that the observed τl are some noisy realizations of the true list τ and that they
differ from τ by swapping two elements with a given probability p < 0.5. The Kemeny optimal
aggregation is the maximum likelihood estimate of τ,
τ̂= argmin
τ
1
L
L∑
l=1
K (τ,τl ),
where K (τ,τl ) is Kendall’s tau distance.
The assumption that each observed list differs from the true one by simply swapping two
elements is not realistic but the idea can be extended to any ranked list, also partial, of the
elements of G , under the generalized Kemeny guidelines. If S1, . . . ,SL are partial lists with
underlying ranking functions τ1, . . . ,τL and common element spaceS =∪Ll=1Sl , we want to
find τ, a list of elements inS , which minimizes the distance with each of the observed lists.
This is equivalent to minimizing the function f , defined as the weighted sum of distances
between τ and each of the Sl ,
τ̂= argmin
τ
{
f (τ),τ⊂ S}= argmin
τ
{
L∑
l=1
wl d(τ,Sl )
}
, (2.2)
where wl represents the confidence we put on the list Sl and d(·, ·) is either Kendall’s tau or
Spearman’s footrule.
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Cross-Entropy Monte Carlo method
In order to optimize criterion (2.2), one could try every possible list τ and take the one that gives
the lowest value of the objective function. However, since the setS can contain thousands of
elements, such a method is not tractable. The Cross-Entropy Monte Carlo (CEMC) method
searches for the optimal list that minimizes (2.2), by using an iterative method (Lin and Ding,
2009). Suppose we have L partial lists S1, . . . ,SL of different lengths, but truncated to have
length k. As previously, we denote by S =∪Ll=1Sl of size S the list of all elements. We wish
to find τ⊂S of length k, which satisfies (2.2). First, we define a matrix X of size S×k with
elements taking values 0 or 1, Xi j = 1 meaning that Rτl (i )= j , and satisfying
n∑
i=1
Xi j = 1,
k∑
j=1
Xi j ≤ 1.
A probability matrix v = (vi j ), of size S×k, with columns summing to 1, is associated to the
matrix X . Therefore, each column X j of X follows a multinomial distribution with sample
size 1 and probability vector v j = (v1 j , . . . , vn j ). Then, the probability mass function can be
computed as
Pv
(
X = x = (xi j )S×k
)∝ k∏
j=1
S∏
i=1
(vi j )
xi j I{∑S
i=1 xi j=1, i=1,...,k;
∑k
j=1 xi j≤1, j=1,...S
}.
In CEMC, the candidate top k list is τ = {xi j : xi j = 1; i = 1, . . . ,n ; j = 1, . . . ,k}, so finding the
optimal τ is equivalent to finding the optimal x, x̂, by iteratively updating the parameter matrix
v , such that Pv (x) places more and more probability mass on the x’s in the neighborhood of x̂.
We describe the order explicit algorithm (OEA), as presented in Lin and Ding (2009):
1. set v0, with each v0i j = 1/S for example, if no prior information is available;
2. draw a sample Xr = (xr i j ) from Pv t (x), r =N1+1, . . . , N . The N1 first values, X1, . . . , XN1 ,
are the realizations from Pv t−1 leading to the smallest values of the objective function;
3. we obtain a sample of size N , (X1, . . . , XN1 , XN1+1, . . . , XN ), from which we find the corre-
sponding top k list candidates, τ1, . . . ,τN , and their objective values, y1 = f (τ1), . . . , yN =
f (τN );
4. sort the objective values in increasing order f(1) ≤ ·· · ≤ f(N ) and define y t = fbρNc, 0<
ρ < 1;
5. using the same sample, update the parameter vector v t+1 as follows
v t+1 = (1−pi)v t +pivnew, (vnew)i j =
∑N
r=1 I{ f (τi )≤y t }xr i j∑N
r=1 I{ f (τi )≤y t }
,
where pi is the weight parameter;
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6. if ||v t+1− v t || < ², 0< ²< 0.01, go to step 7, otherwise, set t = t +1 and go back to step 2;
7. set y = f(1) and the corresponding ordered subset is the aggregated list.
Rank aggregation methods have been used in several studies to combine results from microar-
ray studies. DeConde et al. (2006) combine five prostate cancer studies using two Markov
chain algorithms and compare the results with Thurstone’s method. Pihur et al. (2009) devel-
opped an R package to compute the CEMC algorithm and applied it to the meta-analysis of
five prostate cancer studies. Lin (2010) reviews existing methods and compares the results
of all methods presented above based on three long fictional lists and five prostate cancer
gene expression studies. She found that the CEMC usually performs slightly better than other
methods. However, it needs quite a lot of tuning and results are sensitive to the choice of the
tuning parameters, which was also found by Pihur et al. (2009). Borda’s method, despite its
simplicity and absence of tuning parameters, performs surprisingly well, giving results similar
to the more complicated algorithms.
2.3 Bayesian approaches
2.3.1 Hierarchical models
Our model, presented in Chapter 3, is a hierarchical Bayesian model. We here review the
definition and motivation for using such models. Material on Bayesian hierarchical models
mainly comes from Gelman et al. (2013, Chapter 5), Congdon (2010, Chapter 1) and Davison
(2003, Chapter 11). Hierarchical models allow the fitting of complex models to data in a
relatively straightforward way. They are particularly suited for data having several levels
of variation, or that depend on parameters connected in some way by the structure of the
problem. In the context of microarray data, for example, studying the differential expression
of a gene g across several patients from different studies, we may assume that the differential
expression parameters of gene g , in each study l , β(l )g , are related. We can see different β
(l )
g
as coming from the same underlying distribution. The expression value of a gene g , for the
j th patient, in the l th study, Y (l )g j , can be used to estimate aspects of the unobserved β
(l )
g . A
hierarchical structure in this case seems natural: the observations are modeled conditioned
on the parameter β(l )g , which comes from a common population distribution, which may also
depend on another set of parameters, called hyperparameters. Hierarchical models help to
understand the dependence structure among multiple parameters. They rely on using the
observations to update knowledge about unknown parameters, obtained by revised knowledge
through the posterior density of the parameter given the data. The prior density of a parameter
represents knowledge collected before observing the data, while the posterior density uses the
information collected in the observations to update the parameter.
A crucial assumption in this context is infinite exchangeability.
Definition 2.3.1. (Davison, 2003, p. 619) The random variables X1, . . . , Xn are called finitely
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exchangeable if their density f (x1, . . . , xn) can be written as f (x1, . . . , xn) = f
(
xξ(1), . . . , xξ(n)
)
,
for any permutation ξ : {1, . . . ,n}→ {1, . . . ,n}.
An infinite sequence X1, X2, . . . is infinitely exchangeable if any finite sequence of it is finitely
exchangeable.
Infinite exchangeability may be assumed if there is no way to identify the studies in the
microarray data example presented previously, i.e., the joint distribution of β(1)g , . . . ,β
(L)
g would
be exactly the same if we permute the indices 1, . . . ,L. Assuming exchangeability of the random
variables, hierarchical models are motivated by the following theorem.
Theorem 2.3.2. De Finetti’s theorem: (Davison, 2003, p. 619) If X1, X2, . . . is an infinitely
exchangeable sequence of binary variables, taking values 0 or 1, then for any n, there is a
distribution G such that
f (x1, . . . , xn)=
∫ 1
0
n∏
i=1
θxi (1−θ)1−xi dG(θ),
where
G(θ)= lim
m→∞P
(
1
m
m∑
i=1
Xi ≤ θ
)
, θ = lim
m→∞
1
m
m∑
i=1
Xi .
For the proof, we refer to Davison (2003) (Section 11.4). This theorem implies that any set of
exchangeable binary variables may be modeled as independent Bernoulli variables, condi-
tional on success probability θ, which has a distribution G . Even if the theorem is stated for
binary variables for simplicity, it also holds for continuous variables.
As the parameters on which the observations rely are not observed (β(l )g in our example) we
put a prior distribution on them, to reflect prior knowledge, which may depend on hyperpa-
rameters, ϕ. The joint posterior distribution is given by
pi(β,ϕ | y)∝ f (y |β)pi(β |ϕ)pi(ϕ),
using the dependence structure to simplify the calculations (y only depends on β and not on
ϕ). To obtain a sample from the posterior distribution, one can follow the algorithm described
in Gelman et al. (2013, p. 126), assuming that the posterior pi(β | ϕ) is conjugate with the
likelihood f (y | β). To simplify the notation and following the arguments of the authors,
we denote the observations by y , which depend on a parameter β, itself depending on a
hyperparameter ϕ. Then the algorithm is
• write the joint posterior density pi(β,ϕ | y) = f (y | β)pi(β | ϕ)pi(ϕ)/ f (y). The marginal
likelihood appearing in the denominator f (y) does not depend on β nor ϕ, so can be
treated as a constant, in which case we could write pi(β,ϕ | y)∝ f (y |β)pi(β |ϕ)pi(ϕ), or
it could be computed by integrating the likelihood over β: f (y |ϕ)= ∫ f (y |β)pi(β |ϕ)dβ;
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• for a fixed observation y , obtain the explicit form of the conditional posterior density
pi(β |ϕ, y);
• use the marginal posterior density of ϕ, pi(ϕ | y) to estimate ϕ, by integrating over β,
pi(ϕ | y)= ∫βpi(ϕ,β | y)dβ, or using the conditional probability formulapi(ϕ | y)= f (β,ϕ |
y)/pi(β |ϕ, y).
In the last step, to simulate from the posterior distribution pi(β,ϕ | y), one can use another
algorithm from Gelman et al. (2013, Chapter 5, page 127):
• simulate ϕ∼pi(ϕ | y);
• simulate β from its conditional posterior distribution pi(β |ϕ, y), given the value of ϕ
generated in the previous step;
• if necessary, draw y˜ from its posterior predictive distribution given the value of θ gener-
ated in the previous step.
These steps are performed until a sample of acceptable size is reached. This allows the
estimation or prediction of any quantity of interest.
To better visualize and represent hierarchical models, directed acyclic graphs allow the identi-
fication of the different levels of the hierarchy and the relation between the different variables
and parameters. A directed acyclic graph is a graph having oriented edges and no loop. Fixed
hyperparameters can be represented by squares, and parameters by circles. The relation
between two variables is represented by an arrow going from the parameter (the parent) to
the variable (the descendent). The directed acyclic graph gives a representation of the decom-
position of the joint distribution into conditional distributions, implying that variables are
conditionally independent from the non-descendents given the parents (Green, 2001). As an
illustration, we give here a very simple example, inspired by Green (2001, p. 5), for modeling
a normal random sample Y1, . . . ,Yn , having mean β, with a normal prior depending on two
hyperparameters, and variance σ2, with an inverse gamma distribution also depending on
two hyperparameters, a and b. The model is
Yi |β,σ2 iid∼ N (β,σ2), β | θ,τ2 ∼N (θ,τ2), σ−2 | a,b ∼Gamma(a,b), (2.3)
and is represented as a directed acyclic graph in Figure 2.1.
Meta-analysis, being a method for combining results from several indistinguishable sources
(i.e., exchangeable), has a natural hierarchical structure and is therefore a perfect candidate for
hierarchical modeling. We need to assume that the studies are exchangeable, i.e., we do not
assume that they are identical replications, they may show differences, but these differences
are not expected to have any impact on the outcome of interest a priori. In other words, even if
study results vary, no study is favored and variation is at random. We also need to assume that
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θ τ2 a b
β σ2
Y
Figure 2.1 – Directed acyclic graph (DAG) of the example model (2.3)
the individuals enrolled in each study are independent samples from a common population,
conditional on model parameters. The idea, as already mentioned in the illustration at the
beginning of this section, is to attribute a parameter to each study, assuming that it comes from
the same underlying population. A combined estimate is obtained through the estimation of
the population distribution parameters.
An important type of hierarchical model, which we will use in Chapter 3, is the latent hierar-
chical Bayesian model. It assumes that the observed data rely on unobserved latent variables,
intermediate between the data and the parameters. We let y denote the observed data, u
the latent variables and β the parameter. This structure defines a three-stage hierarchical
Bayesian model whose joint density may be written
f (y,u,β)=pi(y | u,β)pi(u |β)pi(β).
Using Bayes’ theorem, one can write the joint posterior density for β and u and the marginal
posterior density for β as
pi(β,u | y)= pi(y | u,β)pi(u |β)pi(β)
f (y)
, pi(β | y)= pi(y |β)pi(β)
f (y)
= pi(β)
∫
f (y | u,β)pi(u |β)du
f (y)
,
where f (y |β) is called the observed data likelihood or the integrated likelihood. Often, this
quantity is not explicitly available and classical likelihood estimation relies on numerical
approximations. MCMC methods circumvent this by sampling directly from the posterior
distribution pi(β,u | y), which only requires pi(β | u, y) and pi(u | β, y) (see Congdon, 2010,
p. 8, for more details). If the latent data exist for each observation, there is a parameter βu
corresponding to each latent variable. This model was applied by Albert and Chib (1993) for
modeling latent variables u1, . . . ,un underlying binary observations y1, . . . , yn .
Hierarchical Bayesian models have become increasingly used due to the development of
Markov chain Monte Carlo (MCMC), a computing tool for parameter estimation, which draws
multiple parameter samples from the posterior distributions of interest (Congdon, 2010, p.
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2). MCMC methods can handle models of increased complexity, and ease inference by not
requiring any normality assumption to compute confidence intervals for example. We describe
Markov chains in the next sections, MCMC methods in Section 2.3.4, and the best-known
algorithms in Sections 2.3.5 and 2.3.6.
2.3.2 Markov chains
This section is mainly inspired by Brooks et al. (2011) and Gilks et al. (1996).
Definition 2.3.3. A sequence of random variables X1, X2, . . . is a Markov chain, if the con-
ditional probability of the next value given the present and the past only depends on the
present:
P (Xn+1 | Xn , Xn−1, . . . X1)= P (Xn+1 | Xn) , n ∈N.
We denote the chain by {Xn}. If the conditional probability of Xn+1 given Xn does not depend
on n, the chain is time-homogeneous. In this work we only consider time-homogeneous
Markov chains.
The set of possible values for {Xn} is called the state space and is denoted byS . If the state
space is discrete and finite, the stationary transition probability may be written as a matrix
indicating the probability of going from xi to x j in one step, xi , x j ∈S ,
P (1)i j = P
(
Xn = x j | Xn−1 = xi
)
.
The probability of going from xi to x j in k steps is P
(k)
i j . The marginal distribution of the
nth stage, pi(n), takes values in S , and pi(1), the marginal distribution of X1, gives the initial
distribution of the chain.
When the state space is uncountable, which is generally the case in applications, the transition
probability matrix becomes a conditional probability distribution. For simplicity, we will
present results for countable state spaces, keeping in mind that they can be generalized. A
Markov chain is stationary when the distribution of consecutive variables at different time lags
does not depend on the lag, i.e., for any positive integer k, the distribution of (Xn+1, . . . , Xn+k ),
does not depend on n.
Our goal in the next sections will be to construct a homogeneous Markov chain that converges
to a given stationary distribution. To obtain this property, the chain must satisfy three criteria:
irreducibility, aperiodicity and positive recurrence. An aperiodic and positive recurrent Markov
chain is called ergodic. We give the definitions of each of the terms, as stated by Gilks et al.
(1996, Chapter 3, p.46-47).
Definition 2.3.4. A Markov chain {Xn} is irreducible if for all i , j there exists a k such that
P (k)i j > 0.
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Definition 2.3.5. An irreducible Markov chain {Xn} is recurrent if P (τi i <∞) = 1 for any i ,
where τi i is the return time to state xi ∈S . Otherwise the chain is transient.
Definition 2.3.6. An irreducible and recurrent Markov chain
{
X (n)
}
is positive recurrent if the
expected return time is finite for all i , E (τi i )<∞. Otherwise, it is called null-recurrent.
Definition 2.3.7. An irreducible Markov chain is aperiodic if the greatest common divisor of
the number of steps to return to state xi from xi is 1,
gcd
(
n > 0 : P (n)i i > 0
)
= 1.
An irreducible and positive-recurrent Markov chain admits the existence of a stationary or
invariant distribution pi(·), which satisfies∑
i
pi(xi )P i j =pi(x j ), xi , x j ∈S . (2.4)
In matrix notation, equation (2.4) can be written piP = pi. The stationary distribution of an
irreducible, aperiodic and positive definite Markov chain is the limiting distribution, whatever
the starting value, in the sense that, if there exists a stationary distribution pi, then lim
n→∞P
(n)
i j =
pi(x j ). It can also be shown that if pi(n) is the marginal distribution at stage n, then pi(n) →
n→∞pi.
This is stated more formally by the following theorem (Gilks et al., 1996, Chapter 3, p.47),
Theorem 2.3.8. If {X (n)} is ergodic, its stationary distribution pi(·) is the unique stationary
probability distribution. The chain also satisfies the following properties,
• P (n)i j →pi(x j ), n →∞, for all i , j .
• Ergodic theorem: If Epi
(| f (X )|)<∞, then P[ f N → Epi { f (X )}]= 1,
where Epi
[
f (X )
] = ∑i f (xi )pi(xi ) is the expectation of f (X ) with respect to pi(·), and f N =
N−1
∑N
i=1 f (Xi ).
The last part of Theorem 2.3.8 is the Markov equivalent of the law of large numbers and ensures
consistency of the estimators of the parameters of the limiting distribution (Gamerman, 1997,
p.105). There exists a version of the central limit theorem for ergodic Markov chains which
satisfies a property called geometric ergodicity. Having an equivalent of the central limit
theorem will be very useful in the next section, and especially in Section 2.3.7 for inference.
Definition 2.3.9. An ergodic Markov chain is geometrically ergodic if there exist 0≤λ< 1 and
a real integrable function V (x) such that∑
j
|P (n)i j −pi(x j )| ≤V (xi )λn , i = 1, . . . ,n.
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The value λ? = inf
{
λ : ∃V such that ∑ j |P (n)i j −pi(x j )| ≤V (xi )λn} is called the rate of conver-
gence.
If
{
X (n)
}
is geometrically ergodic, then we can give a version of the central limit theorem for
Markov chains:
1p
n
[
f n −Epi
{
f (X )
}] d→N (0,τ2),
where
d→means convergence in distribution, and τ2 is the limiting sampling variance ofpn f n ,
which is obtained as the limit of the sampling variance varpi
(
f n
)
= τ2n
τ2n
n
= →
n→∞ τ
2,
Another property that is useful for construction is reversibility, which holds when the detailed
balance equation
pi(xi )P i j =pi(x j )P j i , (2.5)
is satisfied. Detailed balance is a sufficient condition for invariance (Gamerman, 1997, Sec-
tion 4.7).
2.3.3 Empirical Bayes and Bayes models
In Bayesian settings, all parameters are attributed prior distributions, which may themselves
depend on hyperparameters, on which we may put second stage priors, either parametric
or non-parametric. Priors for hyperparameters are often difficult to estimate and their effect
on subsequent inferences is hard to assess (Davison, 2003, Section 11.5). Empirical Bayes
methods solve these issues by using the information contained in the data to estimate the
hyperparameters. The Bayesian model is then applied using the estimated value of the
hyperparameters rather than a prior distribution. The name empirical Bayes comes from
the fact that we are using the data to estimate the hyperparameters (Carlin and Louis, 2000,
Chapter 3). If an explicit expression can be obtained for the likelihood, we can estimate the
hyperparameters of the model by maximum likelihood. We consider a simple example, which
will be the basis of our empirical Bayes model from Chapter 6. Suppose we observe data Y
which are a mixture of two normals with different means, a priori
Y | θ,σ∼N (θ,σ2),
θ | p,τ∼ (1−p)δ0(θ)+pN (0,τ2),
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where δ0(θ) puts mass 1 at θ = 0. The likelihood based on observations y1, . . . , yn is
L(p,σ,τ)=
n∏
i=1
f (yi )=
n∏
i=1
∫
θ
1
σ
ϕ
(
yi −θi
σ
){
(1−p)δθ+p
1
τ
ϕ
(
θi
τ
)}
dθ,
=
n∏
i=1
{
(1−p) 1
σ
ϕ
( yi
σ
)
+ pp
σ2+τ2
ϕ
(
yip
σ2+τ2
)}
,
where ϕ is the standard normal density. Thus, we can estimate parameters p, σ and τ by
maximizing the log likelihood, and use Bayesian methods to obtain an estimate for θi , with
the hyperparameters replaced by their estimate. Inference is based on the estimated posterior
distribution pi(θ | y, σ̂, τ̂, p̂), and with φ̂= (σ̂, τ̂, p̂),
pi(θi | yi , φ̂)= f (yi | θi )pi(θ | φ̂)
f (yi )
.
In our previous example, the parameter θ depends on a parametric distribution and there-
fore the approach is called parametric empirical Bayes (Carlin and Louis, 2000, Chapter 3).
Nonparametric empirical Bayes methods offer more flexibility, and are applied when pi(θ) has
an unknown form. Returning to the previous example, and following Carlin and Louis (2000,
Chapter 3, Section 2.1), we now consider the model
Yi | θi ∼ f (yi | θi ), i = 1, . . . ,n,
θi ∼G(·).
Robbins (1985) developed a non-parametric estimate for θ using empirical frequencies to
estimate the marginal probabilities, in the case where yi | θi ∼ Poisson(θi ). However, Carlin
and Louis (2000, Section 3.2.3) show that this estimator performs poorly, and they prefer the
approach which consists in estimating G , before using the method of Robbins.
2.3.4 Markov Chain Monte Carlo
As seen in Section 2.3.1, posterior distributions from hierarchical Bayesian models may be
quite complicated to sample from. In simpler nonhierarchical models, especially when
conjugate prior distributions are assumed, the sampling process may be done directly (Gelman
et al., 2013, chapter 11). For hierarchical Bayesian or other complicated models, one may
factor the posterior distribution of interest and sample by parts. For example, one may sample
from the marginal posterior distribution of the hyperparameters, and then sample from the
conditional posterior distribution of the other parameters given the value generated for the
hyperparameters and the data. This procedure is usually simple as it involves sampling from
known distributions. Obtaining a sample from a distribution f without sampling directly from
it is the goal of Markov chain Monte Carlo methods. As their name suggests, these methods
aim at constructing Markov chains, defined in Section 2.3.2, which are ergodic and whose
stationary distribution is the posterior distribution of interest. As defined by Robert and
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Casella (2005, Chapter7, p. 268) “a Markov chain Monte Carlo method for the simulation of
a distribution f is any method producing an ergodic Markov chain
{
X (n)
}
whose stationary
distribution is f ”. The samples are drawn successively with the sampled draws depending on
the last value drawn, which defines a Markov chain. Starting from an initial value x(0), at each
t , we draw x(t ) from the transition distribution pi
(
x(t ) | x(t−1)), which depends on the previous
draw, and the transition distribution must be constructed so that the Markov chain converges
to the stationary distribution, which is the posterior distribution of interest (Gelman et al.,
2013, Chapter 11, p. 286). The chain must therefore be run for long enough to generate samples
from the target distribution. There exist several algorithms to construct such a Markov chain.
We present the two best-known and most-used algorithms in Sections 2.3.5 and 2.3.6.
We must distinguish Markov chain Monte Carlo (MCMC) methods from general Monte Carlo
methods to generate independent simulations from a target density. Indeed MCMC methods
lead to successive sampled parameters that are not independent (Congdon, 2010, p. 4).
2.3.5 Gibbs sampling
In this section and the next, we present two widely used methods for stochastic simulation
using Markov chains. As said in the previous section, we would like to generate draws from the
posterior distribution. To this end, we construct a Markov chain whose stationary distribution
is the target distribution. We denote the target distribution by pi(x), with x = (x1, . . . , xn), and
we suppose that the full conditional distributions pii (xi | x−i ), i = 1, . . . ,n, and x−i = {xg , g 6= i },
are available and easy to sample from. Gibbs sampling was named by Geman and Geman
(1984), but the algorithm was known much earlier. It is based on successive draws from the
full conditional distributions (Green, 2001, p.15). As a first step, initial values are arbitrarily
chosen, x(0) =
(
x(0)1 , . . . , x
(0)
n
)
, and at each step of the Gibbs sampler, each element is updated by
sampling from the full conditional distributions. At step r of the Gibbs sampler, we generate
x(r )1 ∼pi
(
x1 | x(r−1)2 , . . . , x(r−1)n
)
,
x(r )2 ∼pi
(
x2 | x(r )1 , x(r−1)3 , . . . , x(r−1)n
)
,
...
x(r )n ∼pi
(
xn | x(r )1 , . . . x(r )n−1
)
.
The process is repeated until convergence, i.e., when x(R) =
(
x(R)1 , . . . , x
(R)
n
)
is a sample from the
target distribution. In more details, the algorithm constructs a Markov chain, with transition
kernel
P (x, y)=pi(yi | x−i ) I{x−i=y−i },
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where I A is the indicator function, and equals 1 if condition A is satisfied and 0 otherwise. We
can easily verify that detailed balance (2.5) holds for the Gibbs sampler, since
pi(x)P (x, y)=pi(xi , x−i )pi(yi | x−i )I{x−i=y−i }
=pi(xi | x−i )pi(x−i )pi(yi | x−i )I{x−i=y−i }
=pi(xi | y−i )pi(y−i )pi(yi | y−i )I{x−i=y−i }
=pi(yi , y−i )P (y, x)
=pi(y)P (y, x).
Parts of the Gibbs sampler can be done several times without changing the convergence of
the chain, the effect of multiple updates being the same as the effect of just one (Brooks
et al., 2011, Chapter 1, p.25). We can easily check the detailed balance equation (2.5) for
going from x to y in two steps, and it generalizes to n steps similarly. We want to show that
pi(x)P 2(x, y) = pi(y)P 2(y, x), by applying the detailed balance equation (2.5) for one step,
twice,
pi(x)P 2(x, y)=pi(x)P (x, x˜)︸ ︷︷ ︸
=pi(x˜)P (x˜,x)
P (x˜, y)
=P (x˜, x)pi(x˜)P (x˜, y)︸ ︷︷ ︸
=pi(y)P (y,x˜)
=pi(y)P 2(y, x),
we obtain the desired results, for any intermediate state x˜. This remark will be useful when
applying our model in Chapter 3. Indeed, part of our model involves a group of highly
correlated latent variables. Running this part of the chain more than the rest will help reduce
the correlation between the draws, without changing the target distribution pi(x).
2.3.6 Metropolis–Hastings algorithm
In this Section, we present two algorithms, which consist in proposing a new candidate from
a proposal distribution qi to update the current value, and accept it with some probability
a(x, y). The first algorithm, called the Metropolis algorithm, was introduced by Metropolis et al.
(1953). It consists in constructing a candidate y by drawing yi from a proposal distribution
q(yi | x), parametrized by x, and setting y−i = x−i . We write qi (yi | x) = qi (x, y) and we
require symmetry, q(x, y) = q(y, x). The proposal is accepted, and therefore xi is updated,
with probability
a(x, y)=min
{
1,
pi(y)
pi(x)
}
=min
{
1,
pi(yi | x−i )
pi(xi | x−i )
}
.
The Metropolis algorithm was generalized by Hastings (1970) to the case where qi is not
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symmetric. The acceptance probability is
a(x, y)=min
{
1,
pi(y)qi (y, x)
pi(x)qi (x, y)
}
=min
{
1,
pi(yi | y−i )qi (xi | y)
pi(xi | x−i )qi (yi | x)
}
.
The Metropolis–Hastings algorithm constructs a Markov chain with kernel
P (x, y)= qi (yi | x)a(x, y)+ I{y=x}r (x), r (x)= 1−
∫
qi (y | x)a(x, y)d y,
where r (x) is the probability of rejecting the proposal.
Detailed balance (2.5) for the Metropolis–Hastings algorithm is also true, since
pi(x)P (x, y)=pi(x)[qi (yi | x)a(x, y)+ I{y=x}r (x)]
=pi(x)qi (yi | x)min
{
1,
pi(y)qi (x | y)
pi(x)qi (y | x)
}
+pi(x)r (x)I{y=x}
=min{pi(x)qi (y | x),pi(y)qi (x | y)}+pi(y)r (y)I{y=x}
=pi(y)qi (x | y)min
{
1,
pi(x)qi (y | x)
pi(y)qi (x | y)
}
+pi(y)r (y)I{y=x}
=pi(y)[qi (x | y)a(y, x)+ r (y)I{y=x}]
=pi(y)P (y, x).
The Metropolis–Hastings algorithm reduces to the Metropolis algorithm by imposing sym-
metry on q and to the Gibbs sampler when qi (yi | x)=pi(yi | x−i )=pi(yi | y−i ), leading to an
acceptance probability of 1. The main difference between the Gibbs and Metropolis–Hastings
algorithms lies in the fact that for the first, one needs to generate from the full conditionals,
whereas for the latter, one simply needs to evaluate the ratio pi(y)/pi(x).
Concerning the proposal distribution, there are several possibilities. The best choice usually
depends on the context. Here, we give some examples (Green, 2001, p.18):
• the independence proposal, whereby q(y) is unrelated to x;
• the random walk, whereby qi (x, y)= qi (yi − xi ) is symmetric about 0 and can also be
written yi = xi +², with ²∼ qi ;
• the random walk on the log scale, when xi > 0, the random walk is applied to log(xi ).
Finally, the Metropolis–Hastings algorithm needs some tuning, aiming for an acceptance
probability rate of about 25% (Roberts et al., 1997; Robert and Casella, 2005, Chapter 7).
When a Metropolis–Hastings step is included within a Gibbs framework, it is possible to
perform the sampling several times before moving on to sampling from the posterior density
of another parameter. The important fact here is that the number of times that we perform
the Metropolis–Hastings step should be independent of the rejection or acceptance of the
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proposal. We show the detailed balance equation for going from x to y in two steps, which is
enough to generalize to n steps. Starting from x there are three solutions for the first move
before heading to state y . We either stay at x, and therefore we reject the proposal, say x˜, only
moving to y on the second step. We can move to an intermediate proposed state x˜ 6= y and
then accept the second move from x˜ to y , or we can directly move to y and reject the proposal
the second time. We want to show that pi(x)P 2(x, y) = pi(y)P 2(y, x), keeping in mind that
detailed balance (2.5) is already satisfied for one step.
pi(x)P 2(x, y)=pi(x)P (x, x˜)P (x˜, y)+pi(x)P (x, x)P (x, y)+pi(x)P (x, y)P (y, y)
=pi(x˜)P (x˜, x)P (x˜, y)+pi(y)P (y, x)P (x, x)+pi(y)P (y, x)P (y, y)
=pi(y)P (y, x˜)P (x˜, x)+pi(y)P (y, x)P (x, x)+pi(y)P (y, y)P (y, x)
=pi(y)P 2(y, x),
where we apply the detailed balance equation (2.5) for one step each time and for any proposal
x˜. This remark will be useful in Section 3.3 for the model under the normal-gamma prior, as
one parameter requires a Metropolis–Hastings update, and tends to have high correlation and
move slowly if only one step is performed at each stage of the Gibbs sampler. Increasing the
number of times we perform this part of the algorithm gives better convergence and reduces
correlation.
2.3.7 MCMC in practice
Now that we know how to construct a Markov chain whose stationary distribution is the
distribution of interest, we want to assess the convergence of the chain and identify what
kind of information is useful for further analyses from the output. Convergence of MCMC
algorithms has been widely studied (see Gilks et al., 1996; Robert and Casella, 2005, Chapter
8, and Chapter 12 respectively, for instance). It can be based on rigorous statistical tests or
on graphical output. We will follow Brooks et al. (2011, Chapter 6) to give some ideas on
monitoring convergence and performing inference with MCMC output. One of the simplest
ways to see whether the constructed Markov chain has converged is to generate multiple
parallel chains, with very different starting values, and see whether they converge to the same
distribution. Indeed, as stated in Section 2.3.2, the stationary distribution of the Markov
chain does not depend on the starting value. From parallel chains, one can also compare
convergence within and between chains by analysing the variance. The idea is to detect when
the variance between the different runs is larger than the variance within each chain, which
would indicate a lack of convergence. Suppose that I chains were run in parallel and that
we have output information about f = f (x). We denote each chain i of length M by fi , with
elements f (m)i (i = 1, . . . , I ; m = 1, . . . , M). The between- and within-sequence variances are
defined respectively by (Gilks et al., 1996, p.137)
B = M
I −1
I∑
i=1
(
f i − f
)2
, W = 1
I
I∑
i=1
1
M −1
M∑
m=1
(
f (m)i − f i
)2
,
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where f i =M−1
∑M
m=1 f
(m)
i and f = I−1
∑I
i=1 f i . The quantity of interest, R̂, defined by
R̂ =
√
v̂ar
(
f
)
W
, v̂ar
(
f
)= M −1
M
W + 1
M
B ,
is the ratio between the estimates of the variance of f and the within-chain variance. The
estimate of the variance of f tends to be an overestimate, and the estimate of the within-chain
variance tends to be an underestimate, because the individual chains probably did not explore
the entire target distributions, thus reducing the variance. In case of convergence, we therefore
expect R̂ to tend to 1. We usually reject convergence for values of R̂ larger than 1.1 or 1.2. Other
tests of convergence exist, such as the Geweke, Raftery and Lewis, and Heidelberg and Welch
diagnostics, all available in the coda package in R (see also Chapter 6 of Brooks et al., 2011).
We often discard the early iterations of the chain, as they may be too strongly influenced by
starting values, or not probable under the target distribution. Time series tools are useful to
check whether the sequence obtained is a quasi-independent sample from the target distribu-
tion. Autocorrelation and partial autocorrelation plots help to check the correlation within
the chain, while traceplots give information about convergence. In case of correlation or slow
mixing, a common method consists in performing thinning, where one only keeps observa-
tions separated by a lag of length k, where the choice of k is based on the autocorrelation plot
for example.
Finally, one could also generate data from the model and use MCMC to re-estimate the
parameters. The chains should converge to distributions that represent the true distribution
of the parameters.
Once the output of the chain is satisfactory, the required quantities can be estimated from the
simulations. We suppose we have a chain
{
X (R)
}
of length R, with appropriate burn-in and
thinning already performed. Then we can estimate several quantities from the output chain:
• the expectation Epi{ f (X )}, where f is a real-valued function on the state space, is es-
timated by the sample average, as justified by the ergodic theorem (Theorem 2.3.8),
i.e.,
f R =
1
R
R∑
r=1
f
(
x(r )
)
;
• the posterior variance is estimated by
varpi
(
f
)= 1
R−1
R∑
r=1
(
f
(
x(r )
)− f R)2 ;
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• the qth quantile φq can be estimated by the inverse empirical distribution,
φ̂q = X(r+1), r
R
≤ q ≤ r +1
R
,
where X(1) < ·· · < X(R) are the order statistics of
{
X (R)
}
. Using the quantiles, one can
construct posterior credible intervals for the quantity of interest;
• the Monte Carlo standard errors are obtained through
var
(
f R
)
= 1
R2
R−1∑
t=−R+1
(R−|t |)γt ≈ 1
R
∞∑
t=−∞
γt ,
where γt is the autocovariance, defined as
Definition 2.3.10. The autocovariance of lag k ≥ 0 of the chain { f (n)}= { f (X (n))} is
γk = covpi
(
f (n), f (n+k)
)
,
and the variance is varpi
{
f (X )
}=σ2 = γ0.
Several methods are available to estimate var
(
f R
)
, we refer to Green (2001) for more
details;
• the marginal density of X1 can be estimated by one of
R∑
r=1
1
h
K
(
X1−X (r )1
h
)
,
1
R
R∑
r=1
pi
(
X1 | X (r )−1
)
,
where h is the bandwidth and K is a kernel function.
2.4 Conclusion
Data combination is relatively straightforward when similar studies provide data of the same
type. We saw in this section that there exist many data combination methods in this case,
depending on the type of data available. Meta-analysis of gene expression microarray data
requires particular attention in order for studies to be comparable. To perform meta-analysis,
one can combine summary statistics (p-values, z-scores), or perform list aggregation, using
frequentist or Bayesian methods. Bayesian and empirical Bayesian methods are the most
flexible ways to incorporate several levels of variation. Hierarchical Bayesian models provide a
simple way to model complex data. Moreover the fitting of such models is made easier with
the use of MCMC methods, consisting in sampling from full conditional distributions, which
are usually easier to obtain and to sample from.
When the set of studies is heterogeneous, one needs to transform the study results to meet
the requirements for combination. As study results need to be of the same type in order
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to be combined, the best solution usually consists in transforming everything to the least
informative support, which does not fully exploit all the information at hand.
In the next chapter, we present a model to combine datasets of different types without requir-
ing all the data to be transformed before combination. To this end, we develop a hierarchical
Bayesian model for differential expression of a gene in each study. The parameters of each
study are assumed to be samples from a common underlying distribution, whose mean
parameter aids in detecting differentially expressed genes across all studies.
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3 Hierarchical Bayesian modeling for
incomplete microarray studies
We saw in Section 1.4 that finding studies that provide raw data for meta-analysis is not an
easy task. We then saw in Section 2.1 that up to now, there does not exist a meta-analysis
method to combine heterogeneous types of data. Existing methods either select only those
studies providing the same type of information, discarding possibly many others, or they
transform all studies to the least informative support, usually ranks, not benefiting from all
the extra information at hand. The purpose of this thesis is to combine results from studies
providing different levels of information, which are described in Section 3.1. We describe
a hierarchical Bayesian model, under which each type of data is modeled using a single
parameter to measure the effect of each gene. A prior on this parameter is then chosen to aid
the detection of differentially expressed genes.
3.1 Data types
We aim to detect genes differentially expressed between two groups of samples, say cancer
and normal for concreteness, among L studies. We assume that each gene g included in the
analysis has a parameter γg representing its differential expression, but that γg is not directly
observed; instead, a noisy realization, β(l )g influences study l (l = 1, . . . ,L), where β(l )g follows a
normal distribution centered at γg ,
β(l )g ∼N (γg ,σ2β), l = 1, . . . ,L. (3.1)
We discuss some possible priors for the parameter γg in Section 3.3, but first, we describe the
four types of data that we consider:
1. Raw data: the most complete data one can obtain from a study, usually consisting of a
matrix of gene expression values along with some clinical information about the study
patients. If values are missing for technical reasons, we consider them to be missing
completely at random, as the missing values depend neither on the observed nor the
missing data. The patients are assumed to be independent.
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2. Full lists of z-scores or other statistics: a list recording a value of a statistic for each gene.
The statistic can be any result of a statistical analysis based on a gene expression matrix,
most often a t-statistic or a p-value. Without loss of generality, we assume that the
values are standardized and can be therefore considered to be z-scores.
3. Partial z-scores: the value of some statistic for each of the top k genes. Here missingness
is not at random, as only the most significant genes are observed. As for Type 2, we
assume that the values can be transformed to z-scores.
4. Partial list of ranks: a list, often incomplete, of the “best” genes detected by a statistical
analysis based on a gene expression matrix. This list usually gives the top k most
significant genes, with k usually between 20 and 100.
We develop a hierarchical model that can handle each of the previously defined data types.
In the development of the model, we consider one study of each type to simplify the repre-
sentation. However, note that we can model any reasonable number of studies of each data
type.
A Type 1 study consists of a G ×N data matrix Y , containing the gene expressions for the G
genes, for n1 cancer samples and N −n1 normal control samples. We suppose that the first n1
columns of the matrix contain the cancer samples. The intensities for each gene are denoted
by Yg j and are modeled using a parameter µg representing the baseline mean and a parameter
β(1)g which represents the differential expression of gene g in the Type 1 study,
Yg j ∼N
(
µg +β(1)g I{ j≤n1},σ2g
)
, σ−2g ∼Gamma(b1,b2) , g = 1, . . . ,G , j = 1, . . . , N .
Type 2 provides a vector of z-scores, Z = (Z1, . . . , ZG ), which results from performing gene-by-
gene two-sample t-tests, or other similar tests, on a full data matrix, in order to compare the
gene expression of cancer and control samples. In what follows the calculations are the same
for each gene, so we omit the index g . The setting is the same as for the full data, i.e., a full
data matrix Y of size G×N , containing the gene intensities for the G genes and the n1 cancer
and n2 =N −n1 control samples, is available. Let, Y 1, S21 and Y 2, S22 denote the sample mean
and sample variance of the cancer and control groups, respectively,
Y i = 1
ni
ni∑
j=1
Y j , S
2
i =
1
ni −1
ni∑
j=1
(
Y j −Y i
)2
, i = 1,2.
We can easily find the distribution of the sample variance,
ni −1
σ2
S2i ∼χ2ni−1, i = 1,2,
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where σ2 is the variance of a gene in a Type 1 study. The two-sample t-statistic is given by
Tobs =
Y 1−Y 2√(
1
n1
+ 1N−n1
)
S2p
, S2p =
(n1−1)S21+ (N −n1−1)S22
N −2 .
Defining X = (N −2)S2pδ2, we note that X ∼ χ2N−2, with δ2 = σ−2 and ν= (N −n1)n1/N . We
first notice that, if N is large enough, X /(N −2)≈ 1, and then we obtain
Tobs ∼β(2)
√
νδ2+ tN−2 .∼N
(
β(2)
√
νδ2,1
)
,
where β(2) represents differential expression of a gene in a Type 2 study. The z-statistic for a
gene g in the Type 2 study can thus be modeled as
Zg |β(2)g ,δ2g ∼N
(
β(2)g
√
δ2gν,1
)
, δ2g ∼Gamma
(
f1, f2
)
.
Notice that we use a two sample t-test, which assumes equality of the variances of the two
groups, though this is untrue in real datasets. However, this assumption greatly simplifies
the calculations, allowing the derivation of a closed form prior, and hence simplifies the
expression for the posterior distribution. As this assumption is only made for the prior, we
believe it will only have a minor impact on the posterior results because information from the
data should counterweight this assumption, and using a more complicated statistic would
not make a huge difference. Usually, assumptions on variances are of secondary importance
compared to those on means.
A Type 3 study consists of a partial lists of z-scores, for which only the k largest absolute
values are observed. For observed genes, we use the same model as for the Type 2 data, and
we impute data for missing genes, using information from the other studies. The z-scores
decompose into Z = (Z o, Z m), for the observed genes and for the missing ones. We know
that the observed Z o are the largest k in absolute value of the entire vector. Let |zref| be the
smallest observed score. Then, for any missing gene g belonging to the set {Z m}, we have
−|zref| < Zg < |zref|, and
Zg |β(3)g ,δg ∼N |zref|−|zref|
(
β(3)g
√
δ2gν,1
)
, δ2g ∼Gamma( f1, f2),
whereN ba is the truncated normal distribution on the interval [a,b], and β
(3)
g is the differential
expression parameter for a gene g in the Type 3 study.
A Type 4 study consists of a partial list of ranks. For each gene g , a rank Rg is attributed by
sorting some unobserved statistics, such as z-scores. We introduce a latent variable ug to
model the summary statistic that leads to Rg , i.e., Rg = rank(|ug |). Using the parameter β(4)g to
represent the differential expression of gene g in the Type 4 study, we have
ug ∼N
(
β(4)g
p
ν,σ2u,g
)
,
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with ν= (N −n1)n1/N . The variance σ2u,g is gene-dependent, taking into account uncertainty
about the methods used to obtain the ranks. Since the ranks are incompletely observed,
missing ranks are imputed by borrowing information from the other studies, as done for the
Type 3 data. We write R = (Ro,Rm), with corresponding u = (uo,um), where the superscripts o
and m represent observed and missing genes respectively. To impute the missing ranks, we
first impute the missing ug ∈ {um}. Let Rref be the smallest rank observed and let |uref| denote
the corresponding latent variable. Any missing gene g would have a higher rank than Rref, if it
were observed, or said differently, |ug | ≤ |uref|. Thus ug is imputed according to
ug ∼N |uref|−|uref|
(
β(4)g
p
ν,σ2u,g
)
,
and the missing ranks are then imputed by ordering the vector |u|.
3.2 Combining all data types
Now that we have modeled each type of data separately we can combine them using rela-
tion (3.1), where each differential expression parameter for each gene g in each study l , βlg , is
assumed to be a noisy realization of a common normal distribution centered at γg . The full
model combining one study of each type of information is, for gene g = 1, . . . ,G , and sample
j = 1, . . . , N ,
Yg j |µg ,β(1)g ,σ2g ∼N
(
µg +β(1)g I j≤n1 ,σ2g
)
, σ−2g | b1,b2 ∼Gamma(b1,b2),
Z (l )g |β(l )g ,δ2g ∼N
(
β(l )g
√
νlδ
2
g ,1
)
, l = 2,3, δ2g ∼Gamma( f1, f2),
ug |β(4)g ,σ2u,g ∼N
(
β(4)g
p
ν4,σ
2
u,g
)
, σ−2u,g | d1,d2 ∼Gamma(d1,d2),
β(l )g | γg ,σ2β ∼N (γg ,σ2β), l = 1, . . . ,4, σ−2β | e1,e2 ∼Gamma(e1,e2).
(3.2)
The model is also represented as a directed acyclic graph in Figure 3.1, where the part con-
cerning the Type 3 study, being identical to that for the Type 2 study, was omitted for better
readability. Full conditional densities of all parameters of model (3.2), along with detailed
calculations, are available in Section A.1 of the Appendix. Most of the posterior densities
are conjugate. A summary of the parameters used for the model and their meaning is also
presented in Section A.5 of the Appendix.
3.3 Priors for the parameter of interest, γ
The parameter of interest γg indicates differential expression of the corresponding gene. A
value close to zero indicates no differential expression, while a value far from zero indicates
that the gene is differentially expressed between the two groups of samples, among all studies.
As this parameter is of central importance, we need to choose its prior carefully. Most of the
genes included in the analysis are not significant, and therefore a large proportion of the γ’s
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Figure 3.1 – Directed acyclic graph of the hierarchical model representing one study of each of
Types 1, 2 and 4. Type 3 studies are omitted as they are modeled and represented as Type 2
studies. Red dashed circles are data; Y denotes a full data matrix (Type 1), Z , a z-score (Type 2
or Type 3) and R, a list of ranks (Type 4). The variables u, in the orange dotted circles, are
latent. Blue circles represent parameters, while green squares denote hyperparameters.
should be null. On the other hand, some of the genes are differentially expressed, and in order
to be able to detect them easily, the corresponding γ should be large. Three different priors
for the parameter γ are considered, all based on the idea of shrinking the parameters of the
uninteresting genes towards zero, while leaving the parameters of the differentially expressed
genes large enough to be easily detected. The first is the spike and slab prior (Mitchell and
Beauchamp, 1988; George and McCulloch, 1993), which has been used in the context of the
detection of differentially expressed genes in microarrays by Ishwaran and Rao (2003, 2005),
and of multiple hypothesis testing by Pang and Gill (2011). The second is the horseshoe prior,
introduced by Carvalho et al. (2010), and used in several contexts (Carvalho et al., 2009; Polson
and Scott, 2010; Datta and Ghosh, 2012). The third is the normal-gamma prior (Griffin and
Brown, 2010). Computations of the posterior densities for each of the models can be found in
Section A.1 of the Appendix.
The spike and slab prior (Mitchell and Beauchamp, 1988) uses a mixture of two normal
distributions centered at zero, one with very small variance for the non-differentially expressed
genes, and the other with possibly large variance for differentially expressed genes,
γg | cg ,τ2g ∼N
(
0,cgτ
2
g
)
, τ2g | a1, a2 ∼Gamma(a1, a2),
cg |α∼ (1−α)δc? +αδ1, α∼U (0,1),
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Figure 3.2 – Spike and slab prior. (a): Directed acyclic graph. Blue circles represent parameters,
while green squares are hyperparameters. (b): Density of the variance of γ for the spike and
slab prior. (c): Density of the mean parameter γ for the spike and slab prior.
where δa is the Dirac function putting all mass at a. The parameter c is binary and can either
take the value of the hyperparameter c? = 0.005, which describes the spike of the distribution,
and shrinks most of the γ’s to zero; or 1, leading to possibly large values of the variance of
γg through the parameter τ. A graphical representation of this part of the model is shown in
Figure 3.2a. Figure 3.2b presents the bimodal density of the variance of γg ; it is clear that a
lot of weight is attributed to very small values, and a small weight to large values. Figure 3.2c,
which presents the prior distribution of γg , illustrates the “spike and slab” shape of this density.
All posterior densities are obtained by conjugacy of the priors, as detailed in Section A.1.8 of
the Appendix.
The horseshoe prior (Carvalho et al., 2010) uses half-Cauchy distributions, C+, as follows:
γg |λg ∼N (0,λ2gτ2), λg ∼C+(0,1), τ∼C+(0,1).
It is represented as a directed acyclic graph in Figure 3.3a. The name of the prior stems from
the shape of the distribution of the parameter κg = (1+λ2gτ2)−1, which follows a Beta(1/2,1/2)
distribution when λg ∼C+(0,1), as illustrated in Figure 3.3b. The global shrinkage parameter τ
gives a measure of the underlying sparsity of the data: a small τ indicates large shrinkage. The
parameter λg is gene-dependent, yielding a highly adaptive prior. From Figure 3.3c, we see
that the density of γg under the horseshoe has a huge spike at 0, but can also take very large
values. The posterior density of γg is obtained by conjugacy of the prior. However, sampling
from the posterior densities of λg and τ is not straightforward and we use the algorithm
described in Scott (2011) to avoid a Metropolis–Hastings step (see details in Section A.1.9 of
the Appendix).
The normal-gamma prior, introduced by Griffin and Brown (2010) and represented as a
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Figure 3.3 – Hierarchical model for the horseshoe prior. (a) Directed acyclic graph. (b): Density
of the parameter κg . (c) Density of the mean parameter γg .
directed acyclic graph in Figure 3.4a, is defined as follows:
γg |ψg ∼N (0,ψg ), ψg |λ,τ∼Gamma
(
λ,
1
2τ2
)
, λ∼ E (1),
τ−2 |λ∼Gamma
(
2,
M
2λ
)
, M = 1
p
p∑
g=1
γ̂2g , γ̂g =
1
L
L∑
i=1
β(i )g .
Large shrinkage is obtained for small values of the parameter λ, whose prior is motivated
by the fact that λ = 1 corresponds to the Bayesian lasso; the exponential prior gives more
variability and flexibility around this value. The prior for τ2 is chosen by noticing that the
variance of ψg is vψ = 2λτ2, for which we choose an inverse gamma prior. The distribution
of ψ, is very concentrated at zero, while also allowing for large values (Figure 3.4b), which
leads to a prior distribution for γ as desired (Figure 3.4c). Posterior densities are obtained by
conjugacy of the priors for all parameters, except λ, which requires a Metropolis–Hastings
step (see Section A.1.10 for detailed calculations).
Figure 3.5 compares the three priors presented previously. While all three achieve the goal of
shrinking the non differentially expressed genes to zero, the figure shows how different they
are, by comparing the prior density of the parameter γg under each of them.
3.4 Finding differentially expressed genes
Once values have been sampled from the posterior densities, we need a cutoff or a posterior
quantity from which to decide if a gene is differentially expressed. This problem was discussed
in Carvalho et al. (2010) and Scott (2009) for the horseshoe prior in the context of linear
regression. Their simulations suggest that a simple weight-based thresholding rule leads
to strong control of the false positives by automatically penalizing for multiple hypothesis
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Figure 3.4 – The normal-gamma prior (a): directed acyclic graph for the normal-gamma prior
for γ. (b): Density of the variance of γg under the normal-gamma prior. (c): Density of the
mean parameter γ under the normal-gamma prior.
-10 -5 0 5 10
0.
0
0.
5
1.
0
1.
5
density of gamma
γ
D
en
si
ty
spike and slab
horseshoe
normal-gamma
Figure 3.5 – Densities of the three priors considered for the parameter γ: the plain blue line is
the spike and slab prior, the dashed red line is the horseshoe prior, and the dotted black line is
the normal-gamma prior.
3.4. Finding differentially expressed genes
testing (Scott, 2009), while maintaining high power. They make a parallel between the signal
selection in the simple two-group discrete model and the horseshoe prior. Suppose we have
data yi ∼N (θi ,1) and we put a two-group discrete prior on θi , θi ∼ (1−w)δ0+wN (0,τ2),
i.e., θi will be non zero with some probability w . Then,
E
(
θi | yi
)= E(θi | θi 6= 0, yi )P(θi 6= 0 | yi ) . (3.3)
The quantity wi = P
(
θi 6= 0 | yi
)
is the posterior probability of inclusion. If instead of choosing
a discrete prior for θi , we choose a horseshoe prior,
yi | θi ∼N (θi ,1) , θi |λi ,τ∼N
(
0,λ2i τ
2) , λi ∼C+(0,1),
and denoting κi =
(
1+λ2i τ2
)−1
, we can obtain, similarly to (3.3), a link between the posterior
mean and the data,
E
(
θi | yi ,κi
)= (1−κi ) yi .
The quantity wi = (1−κi ), even if not formally a probability of inclusion, can be interpreted
as such. The shrinkage parameter, κi , gives an indication of how much observation i was
shrunk to 0. Indeed, κi ≈ 0 indicates almost no shrinkage and identifies signals whereas κi ≈ 1
indicates almost complete shrinkage and identifies noise. Carvalho et al. (2010) proposed
to call i a signal if the corresponding weight wi is larger than 0.5. Datta and Ghosh (2012)
show that this simple thresholding rule has the same risk as the Bayes oracle, i.e., the decision
rule under the discrete mixture model, when using an additive loss, where the total loss is the
number of incorrect decisions (0-1 loss function). In our context, we can use these results
to construct a thresholding rule for our priors. In each case, our parameter of interest is γg ,
whose posterior mean is
γ̂g = E
(
γg |λ2g ,τ2,σ2β,βg
)
=
λ2gτ
2
σ2
β
+Lgλ2gτ2
Lg∑
l=1
β(l )g =
(
Lgλ2gτ
2
σ2
β
+Lgλ2gτ2
)
1
Lg
Lg∑
l=1
β(l )g .
where Lg is the number of studies that contain gene g . The quantity wg ,HS = Lgλ2gτ2/
(
σ2
β
+Lgλ2gτ2
)
is a signal to noise variance ratio, λ2gτ
2 being the prior variance of γg and σ2β/Lg being the vari-
ance of the average signal. The thresholding rule, inspired by Carvalho et al. (2010), consists in
calling gene g differentially expressed if wg ,HS > 0.5 and noise otherwise.
This rule can be applied for the other priors, using the appropriate form of the posterior
weights, wg ,NG = Lgψg /
(
Lgψg +σ2β
)
, for the normal-gamma prior, and wg ,S AS = Lg cgτ2g /
(
Lg cgτ2g +σ2β
)
,
for the spike and slab prior.
For the spike and slab prior, the posterior probability of inclusion is readily available via
the parameter cg , which indicates whether the gene is differentially expressed or not, by
calculating P(cg = 1). This last quantity can be roughly estimated as the number of times
cg = 1 over the total number of replications. Therefore, if the number of realizations in
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which cg = 1 is larger than the number of realizations where cg = c?, we can call the gene
differentially expressed, which is equivalent to taking a threshold of 0.5 for the posterior
probability of inclusion.
3.5 Practical considerations
The model presented in the previous sections is fully Bayesian. However, some adjustments
are needed for practical or computational reasons. First, the parameter µg representing the
baseline mean in the Type 1 data, is directly estimated from the data for each gene. Indeed,
Type 1 data are usually quite precise and they bring a lot of information, so we assume that
this parameter can be quite well estimated by
µ̂g = 1
N −n1
N∑
j=n1+1
Yg j .
This empirical step also reduces the computational cost. The second parameter that is empiri-
cally estimated is δ2g , which appears in Type 2 and 3 data. Taking δ
2
g ∼Gamma( f1, f2) leads
to identifiability issues and considerably increases the computational cost, as it requires a
Metropolis–Hastings step to sample from the posterior distribution. The parameter δ2g is
therefore estimated from the L1 full data (L1 ≥ 2), as the inverse of the average gene variance
over all Type 1 studies:
δ̂2g =
(
1
L1
L1∑
l=1
σ̂2,(l )g
)−1
.
A version of the model, where a single δ2 was sampled for all genes through a Metropolis–
Hastings step, was also tried, but, it appears to be less efficient than the version where δ2g is
estimated from the Type 1 studies for each gene, while also increasing the computational cost,
which is why we prefer to estimate δ2g from the data.
Values of the hyperparameters for the spike and slab prior (Section 3.3) are taken to be a1 = 5
and a2 = 50 as suggested by Ishwaran and Rao (2003). The values of the other hyperparameters
are b1 = d1 = e1 = 5 and b2 = d2 = e2 = 50. Different values of the hyperparameters were tried
but they did not affect the results.
The model was coded in R using C code for the Gibbs sampler part to decrease computational
time. We performed 31500 iterations, discarding the 1500 first iterations and using a thinning
of 10 to reduce correlation. The part concerning Type 4 data (ranks) is run 40 times more at
each step to reduce the correlation between the draws. Indeed, for this particular type of data,
each gene depends on its neighbors, making consecutive draws highly correlated. We thus
obtain 3000 roughly independent realizations from the posterior density of the parameters.
Computational time for G = 200 genes, N = 50 samples, is of the order of 900 seconds for the
spike and slab prior and the horseshoe prior and 1200 seconds for the normal-gamma prior.
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This last prior requires a larger computational time as one of its parameters is updated using a
Metropolis–Hastings step.
Running the code without the extra lagging for the ranks does not change the results con-
cerning the variables of interest. However the hidden variables tend to be highly correlated,
especially when the number of genes is high, as the number of latent variables is larger in this
case. Only looking at the variable of interest, lagging is not required and the computational
time is reduced to 45 seconds instead of 900 seconds for G = 200. We believe the variables of
interest are not affected by the lack of convergence of the latent variables because the magni-
tude of the parameter β(4)g does not depend on the latent variables but this information rather
comes from the other study parameters, through the parameter γ. Indeed, this information is
not present in the ranks and therefore not present in the latent variables. The latent variables
u influence the order of the β(4), so we just require order stability of the latent variable, which
seems to appear quite early in our simulations, in order to have proper convergence for the
variables of interest.
However, for the calculations presented in this thesis, we chose to obtain roughly independent
realizations for the latent variables, i.e., we perform the extra lagging of 40, which increases
the computational time.
3.6 Conclusion
We developed a hierarchical Bayesian model to combine different types of microarray data.
The detection of differentially expressed genes is aided by choosing an appropriate prior for
the parameter of interest, which puts most of its mass at zero, but allowing large values for
interesting genes. We also developed a thresholding-based criterion, which can be interpreted
almost as a posterior probability of differential expression, to identify genes of interest.
In the next Chapter, we assess the performance of this model through simulation. We compare
our model with existing meta-analysis methods in terms of the number of true differentially
expressed genes identified, and power. We also show how much we gain from integrating all
information, compared to reducing everything to ranks, or combining only full information
data. To this end, we develop a simulation design which is intended to mimic true gene
expression data.
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4 Simulations
4.1 Numerical examples
In this chapter, model (3.2) is applied to simulated microarray data. Several studies are
generated according to the simulation design presented in Section 4.1.1. We consider five
studies, two of Type 1 and one each of the other types. Each study consists of a set of G = 200
genes, of which the first 10 are differentially expressed, and N = 50 patients, of which n1 = 40
are cancer samples. The ratio 10/40 for the two groups of patients was chosen to mimic real
data. Indeed, it is often difficult to obtain control samples in ovarian cancer, as the procedure
is quite invasive (see Chapter 5 for examples of real data). The gene ratio 10/200 was chosen in
order to have only a small proportion of genes differentially expressed, as is often the case in
real data. One could argue that 200 genes is a very small number compared to what is usually
encountered in real data. However, as simulations require to run our MCMC algorithm many
times, the number of genes had to be kept small for computational reasons. A summary of the
parameters used for simulations with their usual value is available in Table A.5 of the Appendix.
We compare the performance of our model using the three priors presented in Section 3.3
with several meta-analysis and rank combination methods in Section 4.2.1, and assess the
power of different combination schemes in Section 4.2.2.
4.1.1 Simulation design for microarray data
The simulation design we use comes from DeConde et al. (2006), who took the idea from Kooper-
berg et al. (2005). The authors wanted to confirm the results obtained from a real dataset
on some simulated data, and their design seemed more realistic than other existing designs.
We further modify the design to make it even more realistic, as we will explain later. We
consider G genes, of which k are differentially expressed, with N samples belonging to M = 2
groups (cancer or normal) and L such studies. Let xi j ml denote the expression level of the i th
gene for the j th sample belonging to the mth group (either cancer or control) and for study l
(i = 1, . . . ,G , j = 1, . . . , N , m = 1,2 and l = 1, . . . ,L). The expression level xi j ml is generated by
decomposition into a mean expression parameter µi , a differential expression parameter δi m
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and noise Zi j ml ,
xi j ml =µi +δi m +Zi j ml , µi ∼U (0,1),
δi m =
{
a(2Bi −1)Gi , m = 1, i = 1, . . . ,k,
0, otherwise.
Bi ∼Be(p), Gi ∼ Γ(5,1), Z j l ∼N (0,Σl ),
(4.1)
where a is a differential expression parameter, usually chosen equal to 0.5, and Σl is a G×G
block matrix with B blocks (in the simulations, we take B = 1), diagonal elements σ2i l and
off-diagonal elementsσiσ jρb , where ρb ∼U (0.5,1), b = 1, . . . ,B . The varianceσ2i l is generated
as σ2i l = (0.3−0.02µi )Gi l , where Gi l ∼ Γ(5,0.1). In DeConde et al. (2006), the authors defined
Gi l ∼ Γ(5,1), which we modified to Gi l ∼ Γ(5,0.1) to better mimic real datasets. The variance
parameter of a gene thus depends on the mean in such a way that genes with smaller mean
expression have a larger variance, as is often encountered in real data (Kooperberg et al.,
2005), and the variance varies across studies. We also modify the design from Kooperberg
et al. (2005) by including a block diagonal covariance matrix. This modification makes the
simulation design more realistic by introducing correlated genes. Indeed, even if we model
genes independently in model (3.2), the independence assumption is not satisfied for real
data, as genes tend to have correlated expression in groups (see Chapter 6 for more details), as
may also be seen from Figure 4.1.
The data matrix obtained for study l is:
X =

µ1+δ1,1+Z1,1,1,l . . . µ1+δ1,1+Z1,n1,1,l µ1+Z1,n1+1,2,l . . . µ1+Z1,N ,2,l
... . . .
...
... · · · ...
µk +δk,1+Zk,1,1,l · · · µk +δk,1+Zk,n1,1,l µk +Zk,n1+1,2,l · · · µk +Zk,N ,2,l
µk+1+Zk+1,1,1,l · · · µk+1+Zk+1,n1,1,l µk+1+Zk+1,n1+1,2,l · · · µk+1+Zk+1,N ,2,l
... · · · ... ... · · · ...
µG +ZG ,1,1,l · · · µG +ZG ,n1,1,l µG +ZG ,n1+1,2,l · · · µG +ZG ,N ,2,l

.
We illustrate the simulation design in the heatmaps of Figure 4.1, where four studies were
generated under the design presented previously, with a ten-block diagonal covariance ma-
trix, either with no correlation, or with large correlations (ρ ∼U (0.5,1)). We also show the
heatmaps of four real datasets, which will be presented in detail in Chapter 5, and from which
we conclude that assuming gene independence does not seem realistic. Our simulation design
mimics the behaviour of real microarray data and is more realistic than other simulation
designs, which consist in generating from independent normal distributions. To illustrate
this, we present some plots in Figure 4.2 that compare a simulated dataset from our design
and a real dataset, labelled YOS (Yoshihara et al., 2009, presented in Chapter 5). Figure 4.2
suggests that a = 0.5 is a sensible value for the differential expression parameter, if we want to
mimic real data. This choice is also motivated by looking at the gene mean and variance for
a simulated data and for YOS. Mean gene expression for YOS is around 8, while it is smaller,
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(a) Real datasets (b) without correlation (c) with correlation
Figure 4.1 – Heatmaps of the four Type 1 real datasets presented in Chapter 5 (left), and
four simulated studies under a design with no correlation (center) and with correlation,
ρ ∼U (0.5,1) (right). The trees on the y axis are hierarchical clustering trees for the individuals,
while the tree on the x axis is a hierarchical clustering tree for the genes. We clearly identify
the block structure in the right-hand panel.
around 6, for simulated data with a = 0.5. Genes are however more variable in our simulated
dataset, making differentially expressed genes a little easier to detect than in YOS, which is
why we don’t increase a further to obtain the same range of mean gene expression values. On
the one hand, our simulation design is different from our model in many ways, as it generates
dependent genes with variance depending on the mean expression, for example. On the other
hand, we assume normality of gene expression, suppose that there are no subgroups other
than the two main cancer and control groups, and assume that the same genes are differen-
tially expressed across studies. In that sense, it may be easier to detect differentially expressed
genes in our simulated data than in real data. However, we believe that our design does not
favour any particular model, so that it should provide a fair way to compare our method with
the other meta-analysis and rank aggregation procedures presented in Section 4.2.1. In the
next sections, the simulation design can be used as such to obtain a Type 1 study. For Type 2
and 3 studies, a matrix X is generated and z-scores are obtained by applying limma (Smyth,
2005) from the bioconductor package in R. For Type 4 data, after generating another matrix X
and applying limma, the absolute values of the z-scores are ordered to obtain the ranks.
To make the simulations even more realistic, missingness at random is also introduced. In
Type 1 studies, some genes are completely missing while some only have missing values for a
few patients. In Type 2 studies, missingness is introduced by randomly selecting genes with
missing information at random. In Types 3 and 4, missingness is present as only the tops of
the lists are observed.
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(a) Boxplot, a = 0.5 (b) Density, a = 0.5 (c) QQ plot, a = 0.5
(d) boxplot of YOS (e) density of YOS (f) QQ plot of YOS
(g) boxplot, a = 5 (h) density, a = 5 (i) QQ plot, a = 5
Figure 4.2 – Comparison of a simulated dataset with different values of a and a real dataset.
Rows: Top: plots for simulated data with a = 0.5; center: plots for real data; bottom: plots for
simulated data with a = 5. Columns: Left: boxplots for each sample, with red indicating cancer
samples and green indicating normal controls; center: density plot of each sample, where red
is for cancer and orange for controls; Right: QQ plots of gene expressions for each dataset.
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Figure 4.3 – 95% posterior credible intervals for the parameter γ for each of the three priors.
The first 10 genes (at the bottom of each plot) were set to be differentially expressed with a
large value of the differential expression parameter.
4.1.2 Basic simulations for each prior
In this section, we are interested in seeing whether our method, using each of the three priors,
can properly detect the 10 first genes as being differentially expressed, when the differential
expression parameter is as large as a = 2. We also present the kind of output one can obtain
from the model.
In Figure 4.3, the 95% confidence intervals for the parameter γg are presented for each of
the three priors. If R is the number of iterations recorded for each parameter, then a 95%
confidence interval for a parameter β, say, is given by
β ∈
[
β̂± z0.975
√
var(β̂)
]
, β̂= 1
R
R∑
r=1
β(r ), var(β̂)= 1
R−1
R∑
r=1
(
β(r )− β̂)2 ,
where z0.975 is the 97.5% quantile of the standard normal distribution.
The true differentially expressed genes are clearly correctly identified by all three priors, as
expected under such a large value of the differential expression parameter (a = 2). The
main difference concerns the width of the posterior confidence intervals, indicating that the
estimation is less precise when using the horseshoe than the spike and slab or the normal-
gamma prior, whose intervals both have about the same width.
In the previous simulations, and in the following, we choose to discard some of the early
iterations and perform thinning to reduce correlations between the draws. Figure 4.4 shows di-
agnostic plots for the parameter γ, before and after adjusting for convergence and correlation.
Each time, 31500 iterations are performed. Data are simulated using the simulation design
presented in Section 4.1.1, for a = 0.5. The model is fitted with the spike and slab prior, but the
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same results apply for the other priors. Based on these plots, we chose to discard the 1500 first
draws to ensure convergence and to use a thinning of 10 to reduce correlation between the
draws. Therefore we obtain 3000 quasi-independent draws for each parameter. In both plots
the extra lagging of 40 for the latent variables was already applied.
4.2 Simulations for model assessment
4.2.1 Comparison with other methods
We saw in Section 4.1.2 that the model with any of the priors seems to detect differentially
expressed genes quite well when they are easy to detect. We want to assess the performance
of the different models in terms of detection of differentially expressed genes, for different
degrees of differential expression. We compare the performance of the models with Borda’s
method (de Borda, 1781), the Markov chain methods MC4 and MCT (DeConde et al., 2006),
product and sum of ranks (Chang et al., 2013), which reduce all information to lists of ranks
prior to combining (see Section 2.2 for details), and some classical meta-analysis methods
for combining p-values— Fisher, Stouffer, minimum p-values (MinP), maximum p-values
(MaxP), r th ordered p-values (rOP, with r =0.7) (see Section 2.1.1 for details)— as described
in Chang et al. (2013) and coded in the R package MetaDE (Wang et al., 2012). We apply Borda’s
method with the arithmetic mean; the median was also used to combine the scores but it did
not change the results. We also considered paired comparisons, using the Bradley and Terry
(1952) model, but as its performance was worse than Borda’s method, these results are not
presented.
For values of the parameter a from 0.2 to 2, we generated 100 datasets using the simulation
design presented in Section 4.1.1. For each dataset, we fitted our model using each of the
three priors, and applied the other methods just mentioned. We recorded the values of the
parameters γ̂g and ŵg for each prior and each gene g , along with scores corresponding to
the other methods. Figure 4.5 compares all methods based on the detection of differentially
expressed genes; the absolute values of the posterior means of γ are ranked for each of the
three priors and the number of true differentially expressed genes present in the top 10 is
recorded. The same thing is done for the other methods, using the appropriate score. Our
method detects the differentially expressed genes more easily than any other method, no
matter which prior is chosen, and for all values of the differential expression parameter a.
It is also interesting to see how the priors perform in terms of false positives. For this analysis,
we obtain permutation p-values for the Borda and Markov chain methods based on 1000
random permutations. This step is computationally intensive, especially in very large datasets.
The p-values for all the methods were then corrected by the Benjamini and Hochberg (1995)
correction to account for multiple testing. Figure 4.6 shows the receiver operating characteris-
tic (ROC) curves, which plot the false positive rate against the true positive rate, for the three
priors and the other methods, for different values of a and for 500 simulations. Our models
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Figure 4.4 – Diagnostic plots (trace plot, ACF and PACF) for one parameter γ in one of the
simulations, with a = 0.5 for the spike and slab prior. left column: 31500 iterations were
performed without any thinning or burn-in. Right column: 31500 iterations were performed
with a burn-in of 1500 and a thinning of 10.
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Figure 4.5 – Comparison of the model with the three different priors: horseshoe (HS), spike
and slab (SAS) and normal gamma (NG) priors (all superimposed under the plain red curve),
and several other meta-analysis and aggregation methods: Fisher, Stouffer, Borda, product
of ranks (PR), minimum p-value (minP), sum of ranks (SR), maximum p-values (maxP), r th
ordered p-value (rOP with r =0.7), MC4 and MCT which are the two Markov chains methods
described in Section 2.2.2. Here we compare the number of true differentially expressed genes
in the top 10 genes based on the value of γ̂ for our model, or the corresponding scores for
other methods. In the simulation design, 10 genes out of 200 were differentially expressed. We
therefore provide the number of truly differentially expressed genes to the methods and count
how many they can identify by looking at their top 10.
4.2. Simulations for model assessment
perform well in terms of ROC for values of a ≥ 0.3, which corresponds to a realistic setting for
real microarray data; see Figure 4.2.
All priors detect differentially expressed genes equally well in Figure 4.6, especially for small
values of a, and they all perform almost perfectly for larger values. The spike and slab prior
seems to be best in each panel of Figure 4.6, closely followed by the normal-gamma prior,
particularly when a = 0.5. The horseshoe prior performs less well, but it remains competitive
and has high power. Since the normal-gamma prior requires a Metropolis–Hastings step to
sample one of its parameters, we prefer the spike and slab prior, which performs at least
as well, and is much faster to run. All these priors give more power to detect differentially
expressed genes than any other methods with which they were compared.
4.2.2 What do we gain from including all studies?
In order to highlight the gain of power from the inclusion of several types of data rather than
only considering full raw datasets, we perform 500 simulations, generating two Type 1 datasets,
and one dataset of each of the other types, and include the different studies as follows:
1. only the two Type 1 studies (full raw data);
2. the two Type 1 studies and the full list of z-scores;
3. the two Type 1 studies and the partial list of ranks;
4. the two Type 1 studies and the partial list of z-scores;
5. the two Type 1 studies, the full list of z-scores and the partial list of ranks; and
6. all the studies.
We fit the model using the spike and slab prior to these data and plot the ROC curves for
several values of the differential expression parameter a in Figure 4.7. Using all the information
available results in a clear increase of power compared to when only Type 1 data are combined.
More formally, we test whether the differences between the black (full studies only) and
the pink (all data included) ROC curves are significantly different, using a non-parametric
test introduced by DeLong et al. (1988). It is based on the comparison of the AUCs (Area
Under the Curve) corresponding to the ROC curves. The authors notice that estimating the
AUC by the trapezoidal rule corresponds to the Mann–Whitney U -statistic. They then use
a jacknife estimator for the variance to test the null hypothesis that the two areas are equal.
Suppose that we have G genes on which a test was conducted to decide whether they are
differentially expressed. We also assume that higher values of the test statistic are associated
with disease. In our case the quantity to decide from corresponds to ŵi for each gene i
averaged over all simulations, as defined in Section 3.4. We know that k genes are truly
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Figure 4.6 – ROC curves for prior comparisons with other meta-analysis and rank aggregation
methods. Power of the model for each of the three priors: spike and slab (SAS), horseshoe (HS)
and normal-gamma (NG) priors, for several values of the differential expression parameter a
along with corresponding power for other meta-analysis methods: Fisher, Stouffer, minimum
p-value (minP), maximum p-value (maxP), r th ordered p-value (rOP), product of ranks (PR),
sum of ranks (SR), Borda and the two Markov chain methods described in DeConde et al.
(2006), MC4 and MCT. The vertical dashed grey lines indicate 5% and 10% false positive rate
and the horizontal dashed grey lines indicates the corresponding true positive rate for our
best method.
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Figure 4.7 – Comparison of the power of several data combinations among two full studies,
a full list of z-scores, a partial list of ranks and a partial list of z-scores. The different combi-
nations are as follow (in the same order as the legend): black: only full studies, red: the full
studies and the full list of z-scores, green: the full studies and the partial list of ranks, blue:
the full studies and the partial list of z-scores, cyan: the full studies, the full z-scores and the
partial list of ranks, pink: all the studies. The ROC curves are plotted for several values of the
differential expression parameter a. The vertical dashed grey lines indicate 5% and 10% false
positive rate and the horizontal dashed grey lines indicates the corresponding true positive
rate for our best method.
Chapter 4. Simulations
differentially expressed while the other G −k are not. The group of differentially expressed
genes, C1 contains the variables Xi , i = 1, . . . ,k, of the test variable in this group, whereas
the group of non-differentially expressed genes, C2, contains the variables Y j , j = 1, . . . ,G −
k, which denotes the values of the test variable for this other group. In this notation, the
ROC curve can be obtained by plotting the sensitivity (the true positive rate) against 1− the
specificity (the false positive rate) at different values of a threshold t ,
sens(t )= 1
k
k∑
i=1
I{wi≥t }, spec(t )=
1
G−k
G−k∑
j=1
I{Y j<t }.
The estimated AUC is equal to the Mann–Whitney statistic, which estimates the probability θ
that a randomly selected observation from the non-differentially expressed genes will be less
than or equal to a randomly selected observation from the differentially expressed population.
An estimator of θ can be computed as:
θ̂ = 1
k(G−k)
G−k∑
j=1
k∑
i=1
Ψ(Xi ,Y j ), Ψ(X ,Y )=

1, Y < X ,
1/2, Y = X ,
0, Y > X .
Suppose we want to compare two ROC curves. We thus have a vector θ̂ = (θ̂1, θ̂2) representing
the areas related to the ROC curves, and the measures
{
X ri
}
,
{
Y rj
}
(r = 1,2). The elements of
the variance covariance matrix are obtained by using jackknife estimator,
V r10(Xi )=
1
G−k
G−k∑
j=1
Ψ(X ri ,Y
r
j ), V
r
01(Y j )=
1
k
k∑
i=1
Ψ(X ri ,Y
r
j ).
Then, the 2×2 matrices S10 and S01 are defined using
sr s10 =
1
k−1
k∑
i=1
[
V r10(Xi )− θ̂r
][
V s10(Xi )− θ̂s
]
, sr s01 =
1
(G−k)−1
G−k∑
j=1
[
V r01(Y j )− θ̂r
][
V s01(Y j )− θ̂s
]
.
Finally, the covariance matrix of the parameter estimates θ̂ is
S = S10
k
+ S01
G−k .
Assuming asymptotic normality, a test statistic of the null hypothesis H0 : θ1 = θ2, can be easily
constructed, and is
Z = L
(
θ̂−θ)(
LSLT
)1/2 ∼H0N (0,1),
where L = (1,−1) is the contrast matrix. There exist other tests for comparing two ROC curves,
but they require permutation to find the null distribution (Venkatraman, 2000; Bandos et al.,
2004; Braun and Alonzo, 2008) or bootstrapping (Pepe et al., 2009), and are computationally
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4.3. Conclusion
Table 4.1 – Comparison of the area under the ROC curves of Figure 4.7 for different values of
the parameter a. We compare the combination of all datasets and the one including only full
studies.
AUC Z p-value
a=0.2 design 1 0.54 −13.23 < 2.2.10−16
design 6 0.62
a=0.3 design1 0.59 −26.36 < 2.2.10−16
design 6 0.75
a=0.4 design 1 0.64 −33.97 < 2.2.10−16
design 6 0.84
a=0.5 design 1 0.71 −32.97 < 2.2.10−16
design 6 0.90
a=1 design 1 0.92 −22.28 < 2.2.10−16
design 6 0.98
intensive, especially when dealing with high-dimensional data. We therefore apply the test
developed by DeLong et al. (1988) and implemented in the pROC R package (Robin et al., 2011),
through the roc.test function. Only two ROC curves are compared: the one corresponding
to full studies only (design 1, in black in Figure 4.7) and the one corresponding to the analysis
with all data included (design 6, in magenta in Figure 4.7).
All tests are strongly rejected, as presented in Table 4.1 for different values of a. This indicates
a significant improvement of the power of the method when all studies are included.
4.3 Conclusion
In this chapter, we assessed the performance of our method. By developing a simulation design
independent of our model, and which attempts to mimic real microarray gene expression
data, we saw that we can detect true differentially expressed genes quite well, no matter which
prior is used. Moreover, we attain high power, which suggests that our procedure has a high
true positive rate associated with a low false positive rate. We also made comparisons with
other meta-analysis methods and show that our methods have more power than any of the
methods with which they were compared. The spike and slab prior being the fastest to fit and
obtaining slightly better results on simulated data, we apply it in the real data application of
the next chapter.
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5 Real data application
5.1 Selection of datasets
We now combine results from studies of the four types defined in Section 3.1, in order to find
genes differentially expressed between serous ovarian cancer and normal control samples.
Electronic search of the online databases PubMed, GEO and ArrayExpress identified 11 such
studies. They were selected based on previous work of Jacob et al. (2009), for studies before
2007, and from systematic search of online data and articles bases for studies published after
2007. In their paper, Jacob et al. (2009) identified 237 studies of ovarian cancer using different
-omics technologies. From these studies we extracted those using microarray gene expression
data to compare serous ovarian cancer and normal samples. Studies using cell lines were
removed, retaining only studies using human tissues. As ovarian cancer is very heterogeneous,
we focus our attention on the serous subtype, discarding all other subtypes. For the online
search, databases such as GEO, ArrayExpress and Pubmed were screened, looking for studies
with the characteristics detailed previously: microarrays, serous ovarian cancer, human tissues
and comparison between normal and cancer samples. We first selected 13 studies published
before 2007 and described by Jacob et al. (2009). Among these, three did not have free access to
the articles and were discarded, one did not provide the raw data and the analysis performed
in the article was not that of interest, and two provided a gene list in alphabetical order and
not ranked according to the differential expression of the genes, which was of little use for
our problem. This led to seven studies retained for further analysis, one of which provides
a full list of z-scores (Welsh et al., 2001), four provide partial ranks (Warrenfeltz et al., 2004;
Meinhold-Heerlein et al., 2007; Zhang et al., 2005; Bignotti et al., 2006), and two provide partial
z-scores (Martoglio et al., 2000; Donninger et al., 2004). We will denote these studies by the
three first letters of the first author’s name: WEL, WAR, MEI, ZHA, BIG, MAR and DON.
We then systematically searched the public repositories GEO, ArrayExpress and PubMed in
order to find relevant studies published after 2007. We identified three studies whose raw
datasets were all published on GEO (Mok et al., 2009; Yoshihara et al., 2009; Lili et al., 2013),
and denoted by the first three letters of the first author, MOK, YOS and LIL. The main difficulty
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when looking for microarray data comparing serous ovarian cancer and normal samples is to
find studies providing normal samples. Normal ovarian tissues are difficult to obtain, as the
surgery is quite invasive and is rarely performed on healthy women. This also explains why in
our datasets the number of normal samples is usually lower than the number of cancer cases.
Recently, Ganzfried et al. (2013) developed an R package grouping published microarray
datasets with available raw data on ovarian cancer. The R package curatedOvarianData,
provides the gene expression matrices of 21 published studies measuring gene expression of
primary ovarian tumors on human tissues. They obtained their data from GEO, ArrayExpress
or the supplementary material of publications. We screened their selection of studies and,
apart from studies already included in our analysis (MOK and YOS), only one dataset fulfilled
the requirements of our analysis, the TCGA dataset (Cancer Genome Atlas Research Network,
2011), which we thus downloaded directly from the package. Information about all the studies
is summarized in Table 5.1.
5.2 Preprocessing and normalization
In this section, we present the datasets selected for our analysis. We describe the main
preprocessing and normalization steps that were applied in order to have comparable data.
• MOK is an Affymetrix dataset with .CEL files available. We performed quality control
of the chips using the R package aroma.affymetrix (Bengtsson et al., 2008). Some
chips were detected with NUSE (Nomalized Unscaled Standard Error) larger than 1.05,
but analysis of the data with and without the unusual chips showing no significant
differences, and NUSE being really close to 1.05, we decided to keep all chips in the
analysis. We normalized the data using RMA (Irizarry et al., 2003), as described in
Section 1.2. We matched probes to gene symbols using the probe with the largest mean
absolute deviation (MAD) when several probes matched the same gene. This led to a
gene expression matrix containing 20 827 unique genes.
• YOS is built on an Agilent platform and raw data are not available. Instead we have a
gene expression matrix returned by the Agilent Feature extraction software. Following
the paper (Yoshihara et al., 2009), we removed intensities smaller than 0.01, treating
them as missing values, performed a per chip median normalization and took the log2
values. Probes were then matched to a unique gene name using the process described
for the MOK dataset.
• LIL: As .CEL files are available, the procedure is similar to that used for MOK dataset.
This dataset also comprises stroma samples which were discarted prior to normalization
and analysis. The dataset comprises 21 049 unique genes.
• TCGA: This dataset was loaded from the curatedOvarianData package, which provides
a gene expression matrix already normalized by RMA and where probes were also already
matched to the correct gene symbol.
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• WEL: A full list of z-scores is available as supplementary material from the authors’
website, and contains information about 5280 unique genes.
• WAR: The analysis described in the paper provides results that were of little use for us.
Therefore, we extracted the top 15 list of genes from the paper.
• MEI: We extracted the top 43 genes found differentially expressed between serous
ovarian cancer and control samples from the paper.
• ZHA: They provide intensity ratios for some genes, which we cannot use as such for an
analysis. We thus decided to transform the results to ranks, giving a top list of 39 genes.
• BIG: The fold changes are available for some genes, but are of little use for us. We used
rank information for 117 unique genes.
• DON: The authors provide a list of p-values along with a fold change sign, which allows
us to transform back to obtain z-scores for the 995 genes published.
• MAR: sign information and p-values were transformed into signed z-scores for the top
33 genes published in the paper.
We chose to use gene symbols in our analysis because they are often what is reported in Type
3 and 4 studies, even if we know that using them is not optimal because of the numerous
synonyms that may appear. Although dataset selection and preparation only represents a very
small written part of this thesis, it was long and tedious and required several months of work.
5.3 Gene selection
As seen in Table 5.1, the studies were conducted on different platforms, so they include very
different probes, and therefore genes. Moreover, as some studies only provide partial lists,
only a fraction of these genes are visible. The distribution of the genes is presented in Table 5.2,
where the number of genes belonging to k studies, k = 1, . . . ,11 is given. We see in the table
that no gene appears in all studies, and some genes appear in very few studies.
Since the union of all genes for all the studies includes 27063 unique genes, some gene selec-
tion is essential before fitting the hierarchical model. To have a better idea of the proportion
of differentially expressed genes in our data, we fit the hierarchical model using the spike and
slab prior to full data only (i.e., Types 1 and 2), selecting the 4343 genes common to the five
studies. The differential expression proportion is estimated to be α̂= 0.009, which indicates
that aiming to reduce the dataset to include more than 2000 genes seems reasonable, as it
will preserve many non-differentially expressed genes as well as those of interest, which is
needed for the priors to be valid. Gene selection is conducted in two steps, aiming to reduce
the gene set to about 5000 genes. The data are separated into full (Types 1 and 2) and partial
(Types 3 and 4) groups, and gene selection is performed on these two groups separately. Based
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Table 5.1 – Summary of the 11 studies included in the meta-analysis. SOC denotes serous
ovarian cancer.
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5.4. Hierarchical Bayesian model
Table 5.2 – Distribution of the genes by studies for the entire gene set and after gene selection.
The table shows the number of genes appearing in k studies, k = 1, . . . ,11, before and after
gene selection.
Number of studies 1 2 3 4 5 6 7 ≥ 8 Total
Number of genes (before) 7228 4655 4623 5936 4208 400 12 1 27063
Number of genes (after) 778 19 1 0 3940 390 12 1 5141
on the idea that the partial data include only genes that were found interesting at the study
level, it is important to include all the genes from these studies, as they provide good potential
candidates for differential expression. The union of all genes provided by partial studies
comprised 1201 genes. For the set of full data, we selected genes in the intersection (4343
genes). The final set of genes consisted of the union of the genes from the partial studies and
the full studies and comprised 5141 genes distributed as in Table 5.2.
5.4 Hierarchical Bayesian model
We fitted the hierarchical Bayesian model using the spike and slab prior to the 11 studies
on the reduced gene set, with 31500 iterations performed in order to obtain 3000 roughly
independent samples from the posterior distribution. This took 25 days, due to the large
number of iterations of the Gibbs sampler and the number of genes. Thinning by a factor 40
was used to reduce the correlation of the hidden variables ug to an acceptable level, but using
the unthinned chain does not affect the output for the parameters of interest and reduces the
running time to less than a day. We found a total of 296 differentially expressed genes (ŵ > 0.5),
presented in Figure 5.1a, 68 having values of ŵ , defined in Section 3.4, whose confidence
intervals do not contain w = 0.5. In Figure 5.1a, we notice a jump in the values of ŵ , which is
due to the fact that the first 1201 genes were included based on the selection performed on
the partial studies (types 3 and 4), and the rest are present or imputed in all studies, as shown
in Figure 5.1b. Table 5.3 presents the names of the top 100 genes, the corresponding values of
γ̂, which gives information about the direction of the differential expression, and ŵ . A more
complete list of differentially expressed genes is presented in Section A.2 of the Appendix. Bold
genes from Table 5.3 are known to be active in ovarian cancer (Jacob et al., 2009, for instance),
which shows that our model produces a credible list of differentially expressed genes.
5.4.1 Enrichment analysis
In order to further assess the credibility of the gene list found, we performed a gene set
enrichment analysis based on GO terms (The Gene Ontology Consortium, 2008). We started
by identifying the GO terms that are associated with the genes selected by our model. We
calculated the GO enrichment for our selected gene list, and present the 20 most enriched
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Table 5.3 – Top 100 list of differentially expressed genes. Genes are ordered according to the
value of ŵ , from the most to the least differentially expressed. The estimates ŵ are obtained
from the fit of our model to the 11 studies selected for the analysis. The estimate of γ̂ is also
given for each gene and indicates the direction of differential expression. Bold genes are
known to have a role in ovarian cancer.
Rank Genes ŵ sd(ŵ) γ̂ sd(γ̂)
1 CP 0.99 < 10−2 3.07 0.38
2 TOP2A 0.99 < 10−2 2.60 0.38
3 BCHE 0.99 0.01 -2.49 0.41
4 NEK2 0.99 0.01 2.48 0.38
5 TTK 0.99 0.01 2.48 0.38
6 CENPA 0.99 0.02 2.45 0.38
7 SPP1 0.99 0.02 2.31 0.39
8 MELK 0.99 0.02 2.35 0.39
9 PRAME 0.99 0.02 2.41 0.39
10 ADH1B 0.99 0.02 -2.33 0.41
11 KIAA0101 0.99 0.02 2.41 0.40
12 NMU 0.99 0.02 2.30 0.39
13 IGFBP6 0.99 0.03 -2.22 0.39
14 KLK6 0.99 0.02 2.24 0.39
15 EVI1 0.99 0.01 2.67 0.45
16 CLDN3 0.99 0.02 2.38 0.41
17 SST 0.99 0.02 2.27 0.41
18 FOLR1 0.99 0.03 2.22 0.39
19 WFDC2 0.99 0.03 2.30 0.40
20 UBE2C 0.99 0.03 2.22 0.38
21 CD24 0.99 0.03 2.47 0.45
22 HMGA2 0.99 0.04 2.21 0.43
23 SPARCL1 0.99 0.04 -2.00 0.38
24 KIF2C 0.99 0.04 2.08 0.40
25 ELF3 0.99 0.05 2.11 0.41
26 MAL 0.99 0.05 2.07 0.42
27 CDKN2A 0.98 0.05 2.09 0.41
28 PAX8 0.98 0.05 2.05 0.41
29 FOXM1 0.98 0.05 2.05 0.40
30 CENPF 0.98 0.06 2.02 0.40
31 TNNT1 0.98 0.06 2.01 0.42
32 CLDN4 0.98 0.06 2.05 0.42
33 HMMR 0.98 0.07 1.99 0.42
34 LCT 0.98 0.07 1.94 0.41
35 KIF11 0.98 0.07 1.92 0.41
36 TRIM31 0.98 0.08 1.92 0.43
37 CDC20 0.98 0.08 1.88 0.42
38 TACSTD1 0.98 0.08 2.61 0.63
39 CCNB1 0.97 0.09 1.87 0.44
40 PTTG1 0.97 0.10 1.93 0.48
41 PRSS8 0.97 0.10 1.87 0.46
42 CCNE1 0.97 0.11 1.80 0.45
43 RRM2 0.96 0.11 1.84 0.47
44 EHF 0.96 0.11 1.90 0.48
45 S100A1 0.96 0.11 1.82 0.47
46 ATP6V1B1 0.95 0.13 1.75 0.50
47 KLK7 0.95 0.13 1.72 0.48
48 ABCA8 0.95 0.13 -1.77 0.49
49 ALDH1A1 0.95 0.13 -1.70 0.47
50 SCNN1A 0.94 0.14 1.73 0.51
Rank Genes ŵ sd(ŵ) γ̂ sd(γ̂)
51 C7 0.94 0.14 -1.69 0.52
52 PDHA2 0.94 0.15 1.70 0.52
53 ANXA8 0.94 0.17 2.22 0.74
54 GLDC 0.94 0.15 1.66 0.49
55 LAMP3 0.94 0.16 1.72 0.54
56 KRT7 0.93 0.16 1.57 0.50
57 CKS2 0.93 0.16 1.61 0.50
58 AOX1 0.93 0.16 -1.63 0.53
59 EZH2 0.93 0.16 1.60 0.49
60 MYH11 0.93 0.16 -1.63 0.51
61 NY-REN-7 0.92 0.20 2.41 0.94
62 CCNA2 0.91 0.18 1.51 0.53
63 TK1 0.91 0.18 1.50 0.52
64 MAD2L1 0.91 0.18 1.51 0.54
65 ACTG2 0.91 0.18 -1.53 0.56
66 SCGB2A1 0.91 0.19 1.65 0.64
67 MUC1 0.90 0.19 1.52 0.57
68 SLC2A1 0.90 0.19 1.46 0.53
69 SULT1C2 0.89 0.20 1.47 0.57
70 MGP 0.87 0.21 -1.37 0.55
71 THBD 0.87 0.21 -1.38 0.57
72 IGF2BP3 0.86 0.22 1.36 0.58
73 SPINT2 0.86 0.22 1.36 0.58
74 ZIC1 0.86 0.22 1.38 0.60
75 CGN 0.85 0.24 1.44 0.66
76 RNASE4 0.85 0.22 -1.31 0.57
77 EFEMP1 0.85 0.22 -1.33 0.60
78 APOA1 0.85 0.23 1.31 0.59
79 DXYS155E 0.84 0.28 2.22 1.21
80 TFAP2A 0.83 0.23 1.25 0.57
81 NDP52 0.83 0.29 2.21 1.27
82 FRY 0.82 0.24 -1.25 0.62
83 DEFB1 0.79 0.25 1.12 0.59
84 TYMS 0.79 0.25 1.12 0.56
85 GRPR 0.79 0.25 1.15 0.60
86 MYBL2 0.79 0.25 1.13 0.58
87 MAOB 0.79 0.25 -1.11 0.56
88 CNN1 0.77 0.25 -1.08 0.57
89 CLDN7 0.77 0.26 1.14 0.64
90 BLM 0.77 0.25 1.09 0.59
91 CXCL10 0.76 0.25 1.07 0.61
92 KIF23 0.76 0.25 1.04 0.56
93 KLF4 0.76 0.25 -1.03 0.56
94 CDKN3 0.75 0.26 1.03 0.57
95 HTR3A 0.75 0.25 1.02 0.57
96 EPCAM 0.75 0.27 1.09 0.67
97 GNG11 0.75 0.26 -1.01 0.55
98 KIF14 0.74 0.25 1.00 0.55
99 NDN 0.74 0.25 -0.99 0.54
100 RAD54L 0.74 0.25 0.98 0.55
5.4. Hierarchical Bayesian model
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Figure 5.1 – Results for the real data analysis. Left: Posterior mean of w for all genes included
in the analysis, with the 0.5 threshold discriminating between differentially expressed and
non-differentially expressed genes in red. Right: number of studies each gene belongs to.
terms in Table 5.4.
Top entries from Table 5.4 suggest using cell-related GO terms as candidates for significant
enrichment. As we study differences between cancer and normal samples, which are very
different samples, it seems reasonable to use such terms. We used two reference GO terms “cell
cycle” and “cell proliferation”. We prepared two lists of genes containing the genes from the
two GO terms and their GO offspring and that were also present in our analysis. The two gene
lists have length 570 for cell cycle and 854 for cell proliferation. 281 out of our 296 selected
genes could be mapped to a gene ID and were included in the analysis. The enrichment for
our selected list of DE genes in these two GO terms was significant, with p-values of 1.6e−4 for
each GO term. The number of genes present in our data and in each GO category is presented
in Table 5.5.
We also compare the enrichment obtained by our method and by three other methods, MCT,
MC4 and Borda. To this end, we used the Molecular Signature database (MSig DB, Liberzon
et al., 2011), which provides pathways from several repositories. For our analysis, we kept the
pathways from KEGG, Biocarta, Reactome and GO available to download from MSig under
the c2 and c5 collections. After downloading all the pathways, we removed those too large
and too small, keeping only pathways containing between 5 and 200 genes, as suggested
in Tseng et al. (2012). We also only selected those having common genes with our gene set.
The enrichment analysis included 4024 genes and 2037 pathways. Enrichment of the top
k differentially expressed genes in each pathway, with k = 100, 500, 1500, was tested using
Fisher’s exact test, and the r tests with the smallest p-values, or the r most enriched terms,
were recorded for each module. Results are presented in Table 5.6, for the top 100 genes
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Table 5.4 – Top 20 GO enrichment of the genes selected by our model. p-values are corrected
using Bonferroni’s correction.
Rank p-value Fraction Ontology TermName
1 < 10−5 0.10 BP mitotic cell cycle phase transition
2 < 10−5 0.03 BP sister chromatid segregation
3 < 10−5 0.15 BP mitotic cell cycle
4 < 10−5 0.07 BP mitosis
5 < 10−5 0.09 BP cell division
6 < 10−5 0.02 BP mitotic sister chromatid segregation
7 < 10−5 0.03 CC condensed chromosome kinetochore
8 < 10−5 0.03 CC condensed chromosome, centromeric region
9 < 10−5 0.03 BP spindle organization
10 < 10−5 0.27 CC extracellular region
11 < 10−5 0.17 BP cell cycle process
12 < 10−5 0.05 BP digestion
13 < 10−5 0.17 CC extracellular space
14 < 10−5 0.03 BP mitotic spindle checkpoint
15 < 10−5 0.02 CC kinesin complex
16 < 10−5 0.04 BP chromosome segregation
17 < 10−5 0.03 BP metaphase/anaphase transition of mitotic cell cycle
18 < 10−5 0.03 BP regulation of mitotic metaphase/anaphase transition
19 < 10−5 0.03 BP spindle checkpoint
20 < 10−5 0.04 BP regulation of cyclin-dependent protein
serine/threonine kinase activity
Table 5.5 – Distribution of the genes from the GO term (in reference) and from the differentially
expressed gene list (selected); Left: GO term “cell cycle”. Right: GO term “cell proliferation”.
Both terms are enriched (p-value=10−4).
selected
FALSE TRUE
in Reference
FALSE 3905 227
TRUE 516 54
selected
FALSE TRUE
in Reference
FALSE 3642 206
TRUE 779 75
5.5. Conclusion
identified by four methods mentioned previously, and for r =25. We see that our method
generally has higher or equivalent enrichment than obtained from MCT and MC4. Borda’s
method on the other hand shows poor enrichment. The most enriched pathway is different
for each method, making it difficult to compare the results. We also present the results in
Figure 5.2, where we compare the enrichment of the top 100 enriched pathways for all methods
and for k = 100, 500 and 1500. In the left part of this figure, the 100 pathways may not be the
same for all methods, but in the right part of the figure, we compare the enrichment of the
same pathways for all methods. For the latter, we first select pathways in the union of the
top 100 enriched pathways for each method. Then we plot the corresponding enrichment
of each pathway for each method, which is the p-value on the log10 scale. In Figure 5.2, our
method has higher enrichment than competing methods for top 100 and top 1500 genes, but
the top 500 genes are slightly less enriched in our method compared to others. If we compare
the same pathways across all methods, we notice that our procedure identifies a list of genes
which is more or equally enriched than those detected by other methods. Once again, the
difference is larger for top 100 and 1500 genes than top 500 genes.
We saw in Figure 4.6 that our model tends to include few false positives compared to other
methods. To illustrate this, we studied the number of known housekeeping genes that are
not selected by our model. The list of housekeeping genes for human samples was obtained
from Eisenberg and Levanon (2013) and comprised 1059 genes that were included in our
analysis. Out of these genes, only one was found in our top list of 296 differentially expressed
genes, which is strong evidence that our model does not select housekeeping genes. The
significance was further assessed by permuting the list 106 times and the resulting p-value
was 10−6, which means that finding one or less housekeeping gene in a top list at random
never happened in any of the permutations performed. As a comparison, other meta-analysis
methods were applied to the set of real data, and the number of differentially expressed genes
identified by these methods is reported in Table 5.7. We took a threshold of 0.05 on the p-
values adjusted by the Benjamini and Hochberg (1995) correction method for multiple testing.
All these methods identify many genes and therefore, if real data behave similarly to simulated
data, this may imply that these other methods tend to include many false positives.
To our knowledge, there does not exist any list of ovarian cancer markers that we could use to
assess whether the 13 genes that were identified by biologists in our differentially expressed
gene list comprises a significant enrichment. Moreover, as, to our knowledge, we have included
all studies comparing serous ovarian cancer and normal samples, we cannot use another
study to validate the results.
5.5 Conclusion
Application of our model to a set of 11 microarray studies looking for genes differentially
expressed between serous ovarian cancer and normal control samples identified 296 poten-
tially interesting genes. Among those, 13 were recognized as being known to have a role in
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Figure 5.2 – Comparisons of the enrichments obtained for our method, MCT, MC4 and Borda.
The left column shows the enrichment of the first 100 most enriched pathways for each
method. The right column represents the enrichment of each method on the same pathways,
selected as the union of the top 100 most enriched pathways of each method.
Table 5.6 – 25 most enriched pathways for the top 100 differentially expressed genes for our
method (top left), MCT (top right), MC4 (bottom left) and Borda (bottom right).
Pathway p-value
cell cycle process 3.13e-08
cell cycle phase 7.98e-08
mitotic cell cycle 1.99e-07
mitosis 2.41e-06
M phase 3.61e-06
M phase of mitotic cell cycle 3.67e-06
Reactome apc CDC20 mediated degradation of nek2a 8.89e-06
microtubule cytoskeleton 1.16e-05
regulation of mitosis 1.29e-05
spindle 1.77e-05
microtubule cytoskeleton organization and biogenesis 1.16e-04
kinesin complex 1.37e-04
spindle organization and biogenesis 1.37e-04
KEGG cell cycle 1.68e-04
Reactome regulation of mitotic cell cycle 2.05e-04
Reactome inhibition of the proteolytic activity of apc c required 2.36e-04
for the onset of anaphase by mitotic spindle checkpoint components
Reactome apc c cdc20 mediated degradation of cyclin b 2.36e-04
calcium independent cell cell adhesion 2.36e-04
microtubule motor activity 2.36e-04
regulation of cell cycle 3.47e-04
Reactome tight junction interactions 3.73e-04
Reactome kinesins 3.73e-04
tight junction 3.73e-04
mitotic cell cycle checkpoint 3.73e-04
Pathway p-value
microtubule cytoskeleton 7.60e-09
mitosis 2.41e-06
m phase 3.61e-06
m phase of mitotic cell cycle 3.67e-06
cell cycle phase 5.69e-06
mitotic cell cycle 1.50e-05
cell cycle process 1.52e-05
spindle 1.77e-05
microtubule organizing center 5.10e-05
KEGG cell cycle 1.68e-04
Reactome apc cdc20 mediated degradation of nek2a 3.73e-04
spindle pole 3.73e-04
centrosome 4.17e-04
chromosome segregation 7.76e-04
KEGG oocyte meiosis 8.32e-04
Reactome mitotic prometaphase 1.45e-03
microtubule cytoskeleton organization and biogenesis 2.22e-03
regulation of mitosis 3.98e-03
chromosome 4.74e-03
regulation of protein kinase activity 5.25e-03
Reactome metal ion slc transporters 5.34e-03
Reactome conversion from apc c cdc20 to apc c cdh1 in late anaphase 5.34e-03
kinesin complex 5.34e-03
spindle organization and biogenesis 5.34e-03
regulation of kinase activity 5.90e-03
Pathway p-value
microtubule cytoskeleton 1.15e-06
m phase 3.61e-06
cell cycle phase 5.69e-06
cell cycle process 1.52e-05
mitosis 3.37e-05
m phase of mitotic cell cycle 4.79e-05
mitotic cell cycle 1.08e-04
KEGG cell cycle 1.68e-04
Reactome apc c cdc20 mediated degradation of cyclin b 2.36e-04
spindle 3.34e-04
Reactome kinesins 3.73e-04
Reactome apc cdc20 mediated degradation of nek2a 3.73e-04
microtubule organizing center 7.53e-04
chromosome segregation 7.76e-04
KEGG oocyte meiosis 8.32e-04
microtubule cytoskeleton organization and biogenesis 2.22e-03
protein c terminus binding 2.67e-03
Biocarta p53 pathway 2.74e-03
KEGG retinol metabolism 3.98e-03
regulation of mitosis 3.98e-03
chromosome 4.74e-03
Reactome metal ion slc transporters 5.34e-03
Reactome conversion from apc c cdc20 to apc c cdh1 in late anaphase 5.34e-03
kinesin complex 5.34e-03
spindle organization and biogenesis 5.34e-03
KEGG homologous recombination 5.52e-03
Pathway p-value
chromosomepericentric region 2.18e-02
gamete generation 3.94e-02
sexual reproduction 6.92e-02
Reactome mitotic prometaphase 9.00e-02
microtubule cytoskeleton 9.85e-02
Reactome sphingolipid de novo biosynthesis 1.11e-01
Reactome conversion from apc c cdc20 to apc c cdh1 in late anaphase 1.11e-01
kinesin complex 1.11e-01
voltage gated sodium channel activity 1.11e-01
Biocarta lectin pathway 1.29e-01
Reactome inhibition of the proteolytic activity of apc c required for 1.29e-01
the onset of anaphase by mitotic spindle checkpoint components
Reactome regulation of complement cascade 1.29e-01
Reactome glycoprotein hormones 1.29e-01
Reactome apc c cdc20 mediated degradation of cyclin b 1.29e-01
Reactome phosphorylation of the apc c 1.29e-01
establishment of organelle localization 1.29e-01
cytokine and chemokine mediated signaling pathway 1.29e-01
sodium channel activity 1.29e-01
microtubule motor activity 1.29e-01
kinase activator activity 1.29e-01
mitosis 1.34e-01
Biocarta ahsp pathway 1.46e-01
Reactome kinesins 1.46e-01
Reactome apc cdc20 mediated degradation of nek2a 1.46e-01
Table 5.7 – Number of differentially expressed genes identified by meta-analysis methods,
based on Benjamini and Hochberg (1995) corrected p-values, taking a threshold of 0.05.
Method Fisher Stouffer minP maxP Ours
Number of DE genes 3858 3510 3784 1548 296
Chapter 5. Real data application
ovarian cancer by our biologist, Dr. Viola Heinzelmann. Enrichment analysis of our gene set
showed strong enrichment in GO terms related to cell functions (cell cycle and cell prolifer-
ation). This last result was to be expected, as we are studying two sets of samples that are
biologically and genetically very different, so anything related to cells is likely to be enriched.
However it confirms that our model does not produce a random list of genes, but a biologically
meaningful list. Comparison of pathway enrichment of the top k differentially expressed
genes from our method, MCT, MC4 and Borda’s method also shows that we tend to detect
genes that are equally or more enriched than those of other methods, when k = 100 or 1500.
Again, as we are comparing such different tissues, we do expect other methods to also find
biologically enriched lists of differentially expressed genes. We also studied the robustness
of our model regarding false positives, by looking at the “non detection” of housekeeping
genes. Our results were highly significant, with only one housekeeping gene present in our
top list of differentially expressed genes, which is an evidence in favour of the robustness
of our model regarding false positives. This is also supported by comparing the number of
differentially expressed genes identified by other methods, which is much larger, indicating
that other methods, while finding many true differentially expressed genes, may also identify
many false positives. However, without the existence of a gold standard, we cannot know
whether we find many false negatives or whether we are robust against false positives. We can
only collect evidence to support the latter.
Even though our model seems to produce promising results, the computational time and the
necessity for gene selection are two drawbacks that we try to alleviate in the next chapter.
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6 Correlation matrix estimation
6.1 Introduction and motivation
One drawback of our model is its large computational requirements. It is infeasible to fit the
model to the union of all genes from all studies, so gene selection is essential. Even if our
selection of genes is not based on differential expression, which implies it is independent
of our model, we might discard important genes. Including only the best candidate genes
is unrealistic and is not appropriate for the chosen priors, which require the inclusion of
a large proportion of uninteresting genes. The real data example of Chapter 5 performs a
gene selection independent of the model, as we only select genes corresponding to unions or
intersections of groups of genes. However, it would be interesting to be able to fit the model to
the full set of genes.
We also assume that the genes are independent, which is not true, though it is a common
assumption in the literature even for single study analysis. Correlations between the genes
are included in the simulation design of Section 4.1.1, and do not seem to affect the efficiency
of the model, but we believe that our procedure should perform even better if the elements
on which it is applied are independent. One could define modules, sets of genes that are
correlated or related in some sense, and apply the model on these elements, to solve the
gene selection and dependence problems simultaneously. Indeed, using modules results in a
huge dimension reduction by grouping genes together, and also results in independence, as
genes that do not belong to the same module may be considered to be independent. With the
computational time thus reduced, our model would be even more competitive with others.
This idea was applied in Wirapati et al. (2008), who used coexpression modules in breast
cancer meta-analysis. They selected a few prototype genes having specific roles in the problem
under study, and grouped genes based on the correlation of their expression values with the
prototypes, thus defining coexpression modules and module scores to be used in a meta-
analysis. This method is particularly interesting in the context of microarray data for several
reasons:
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• it is biologically meaningful—genes do not act alone, but they are usually activated in
groups;
• it is statistically interesting—considering only a small group of coexpression modules
rather than 10000 genes reduces the number of hypotheses to be tested, thereby increas-
ing the power of the analysis;
• detecting interesting groups of genes is more reliable than identifying genes, since
differentially expressed genes can vary greatly from study to study while their common
modes of action may not (Ein-Dor et al., 2005, 2006). Therefore there is a better chance of
identifying a common differentially expressed module among studies than a particular
gene.
Up to now, identification of modules has been based on prior knowledge on specific genes, im-
plying collaboration with biologists on a case-by-case basis. This motivates the development
of an automatic prototype identification procedure that would not require prior knowledge
and could be applied to any dataset, with the goal of reducing its dimension.
In order to define modules, we base our approach on the correlation matrix. We define
modules to be groups of genes with high correlation. In this chapter, we discuss estimation
of large covariance matrices. We assume that the covariance matrix is sparse, as probably
many genes have no or weak correlation with the others, while only some of them are very
correlated, defining modules. Estimating a sparse covariance matrix will aid the detection of
modules by highlighting groups of genes that are highly correlated. We first review estimation
methods for a single high dimensional covariance matrix in Section 6.2, then present some
tests for assessing the equality of two large covariance matrices in Section 6.3. In the early
sections of this chapter, we focus on estimating a single covariance matrix. However, in the
meta-analysis context, we wish to define modules common to all studies, so in Section 6.4 we
investigate an empirical Bayes method for estimating a sparse high dimensional correlation
matrix common to several studies. Identification of modules based on clustering and this
common correlation matrix is described in Chapter 7.
6.2 Large covariance matrix estimation
When the number of individuals N is much smaller than the number of covariates G , N ¿G ,
the sample covariance matrix given by
ΣN = 1
N −1
N∑
k=1
(Xk −X )(Xk −X )T , X =
1
N
N∑
k=1
Xk ,
has rank at most N −1, is not a consistent estimator of the population covariance matrix,
and is often ill-conditioned. The elements of Σn are denoted by σ̂i j . Several methods exist
to estimate the covariance matrix of a population in the high-dimensional case, many of
78
6.2. Large covariance matrix estimation
which require extra assumptions, such as sparsity, in order to construct a consistent estimator.
Bai and Shi (2011) identify four classes of methods for covariance estimation when G À N
and in the context of asset returns: shrinkage, factor model, Bayesian approach and random
matrix theory methods. Pourahmadi (2011) presents a review of several methods to estimate
covariance matrices from two perspectives: generalized linear models and regularization. We
discuss some of these in the following sections.
6.2.1 Thresholding based methods
In the context of large covariance matrix estimation, thresholding methods are applied to the
sample covariance matrix in order to obtain a better estimate. Ledoit and Wolf (2004) were
among the first to use this technique. Their proposed estimator is both well-conditioned and
more accurate than the sample covariance matrix, with respect to a quadratic loss function.
They obtain a well-conditioned estimator by imposing a diagonal structure, which they average
with the sample covariance matrix, using appropriate weights, estimated to optimize a loss
function. Ledoit and Wolf (2012) state that shrinkage is one of the simplest ways to estimate
the covariance matrix, because it is distribution free, and usually has a simple and explicit
formula, which is easy to compute and interpret. They extend their previous linear shrinkage
estimator to nonlinear transformations of the sample eigenvalues.
Bickel and Levina (2008) developed the universal thresholding method, which fixes a com-
mon threshold for all the entries of the matrix and sets to zero any value that is below that
pre-determined threshold. Their hard thresholded estimator is shown to be consistent in
the operator norm, as long as the true covariance matrix is sparse in a suitable sense and
(logG)/N → 0 as G , N →∞. Cai and Liu (2011) extended this idea by defining an adaptive
threshold for each entry of the sample covariance matrix. By making an analogy with mean
estimation, and noticing that
1
N
N∑
k=1
(Xi k −µi )(X j k −µ j )=σi j +
√
θi j
N
zi j , zi j
iid∼ N (0,1), 1≤ i , j ≤G ,
they find that if the θi j were known, then a good estimator for σi j would be σ̂0i j = sλ0i j (σ̂i j ),
with sλ a thresholding function and λ
0
i j = 2
√
θi j logG/N . As θi j is generally unknown, they
estimate it, by θ̂i j =N−1∑Nk=1{(Xi k −X i )(X j k −X j )− σ̂i j}2.
Their final estimator of the covariance matrix is
σ̂?i j = sλi j (σ̂i j ), λi j = δ
√
θ̂i j logG
N
. (6.1)
The thresholding function sλ is any function satisfying the conditions
• |sλ(z)| ≤ c|y |, for all y, z satisfying |z− y | ≤λ;
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• sλ(z)= 0, for |z| ≤λ;
• |sλ(z)− z| ≤λ, z ∈R.
The soft thresholding function, sλ(z)= sign(z)(z−λ)+, and the adaptive lasso, sλ(z)= z(1−
|λ/z|)η+, η ≥ 1, satisfy these conditions. The authors also notice that the hard thresholding
function sλ(z)= zI{|z|>λ}, although not satisfying all the conditions, can be used anyway. The
parameter δ > 0 can be chosen equal to 2, as suggested by Cai and Liu (2011), or through
cross-validation. The adaptive thresholding estimator attains the optimal rate of convergence
in the spectral norm.
Thresholded matrices may have negative eigenvalues. This is avoided by lasso-type penalized
normal likelihood optimization, as detailed in Section 6.2.3.
6.2.2 Factor models to estimate large covariance matrices
A lot of methods such as Carvalho et al. (2008) and Fan et al. (2011, 2008), use factor modeling,
where the idea is to consider two types of variables: known variables and latent factors, to
represent known modules, defined by biologists, and unknown modules, that one wishes
to retrieve. Carvalho et al. (2008) base their method on sparsity modeling of multivariate
regression, ANOVA, and latent factor models to identify biological subpathway structure.
They assume that the matrix of factor loadings is sparse. However, they recognize that fitting
models with a very large number of variables and factors is computationally intensive, due to
the MCMC calculations involved. They aim to identify new genes and pathways linked to a
small number of known biological pathways. They recommend starting with genes of known
relevance, and then gradually including related genes. Runcie and Mukherjee (2013) develop a
Bayesian genetic sparse factor model for estimating the covariance matrix of high dimensional
traits in a mixed effects model. They only consider biologically plausible matrices, thus
imposing structure. They assume sparsity, and suppose that only a small number of factors
control the variation in the high dimensional phenotype, so that they are more interpretable.
Fan et al. (2008) develop a factor model for large covariance matrix estimation in economics,
where they assume that the factors are observable. Fan et al. (2011) relax the idiosyncratic and
independence assumptions often made on the components of a factor model. They assume a
sparse covariance matrix for the error term, which they estimate using the method of Cai and
Liu (2011). They then use factor models to estimate the covariance matrix of the observations.
6.2.3 Methods based on graphical models or penalized likelihood
In graphical models, conditional independence is assessed through the precision matrix,
which is the inverse of the covariance matrix. Zeros in the precision matrix correspond to
pairs of genes that are conditionally independent given the other variables, or certain subsets
80
6.2. Large covariance matrix estimation
of them. The precision matrix can be estimated by maximum likelihood. Maximizing
l (Σ−1)= N
2
{
log |Σ−1|− tr(SΣ−1)} ,
where S is the sample covariance matrix, leads to an estimate Σ̂−1 = S−1. However, when
G ÀN , S is singular and therefore not invertible. This problem can be circumvented by using
the graphical lasso (Friedman et al., 2008), which maximizes
log |θ|− tr(Sθ)−λ||θ||1,
with respect to θ. In order to estimate the precision matrix or the covariance matrix, one can
impose a penalty either on the entries of the matrix or on parts of some decomposition of
the matrix, like the Cholesky or the spectral decomposition (Pourahmadi, 2011). Stein (1975)
noticed that the sample covariance matrix distorts the eigenstructure of the covariance matrix.
By shrinking the eigenvalues to some central values, he obtains
Σ̂= P f (λ)P T ,
where λ represents the ordered eigenvalues and P the normalized eigenvectors of the sample
covariance matrix, and f is some shrinking function.
By imposing lasso-type constraints on the precision matrix, one can obtain sparse estima-
tors (Friedman et al., 2008; Rothman et al., 2008), while a logarithmic barrier function ensures
positive definiteness, as developed by Rothman (2012), who focuses on estimators invariant
under permutation. The fastest algorithm available to date is the glasso, proposed by Friedman
et al. (2008). Guo et al. (2011) describe a likelihood-based method for estimating precision
matrices across data from several graphical models that share the same variables and some of
the dependence structure. They employ a hierarchical penalty that forces similar patterns of
sparsity in the inverse covariance matrices across classes. This method is similar to the group
graphical lasso of Danaher et al. (2014). Banerjee and Ghosal (2013) use a Bayesian model to
estimate the precision matrix of a Gaussian graphical model. They impose a banding structure
on the matrix and require the user to set the order of the graph a priori. They show that their
estimator performs better than the maximum likelihood estimator in terms of the L2 operator
norm.
6.2.4 Bayesian, empirical Bayes and other methods
In Bayesian methods the covariance matrix is often modeled through either a Jeffreys non-
informative prior or an inverse Wishart prior. Pourahmadi (2011) identifies several methods in
Bayes and empirical Bayes covariance matrix estimation. First, one can model the logarithm
of the covariance matrix by using the log matrix prior, which introduces a multivariate normal
prior with many hyperparameters. While this is more flexible than an inverse Wishart prior, it
is not easily interpretable. The generalized inverse Wishart prior is obtained by partitioning a
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multivariate normal vector Y = (Z1, · · · , Zk )∼N (0,Σ) into k subsets, writing the joint density
as
f (y)= f (z1) f (z2 | z1) f (z3 | z2) · · · f (zk , zk−1 . . . z1),
then placing a normal prior on the regression coefficients and an inverse Wishart prior on
the prediction variances in each conditional distribution (Pourahmadi, 2011). Carvalho et al.
(2007) propose an efficient method for direct sampling from the hyper-Wishart distribution.
Conlon et al. (2012) developed a Bayesian model to incorporate information of co-regulated
genes, that are close on the chromosome and co-transcribed. They construct a hierarchical
Bayesian model to obtain the gene-specific posterior probability of differential expression in-
cluding co-regulation information. They show that this supplementary information improves
the independence model that they developed in a previous paper, which assumes genes to
be independent. Zhao et al. (2012) introduced a novel Bayesian model to integrate microar-
ray data with pathways obtained from KEGG. Corander et al. (2013) developed a predictive
supervised Bayesian classifier for several classes, assumed to be represented by multivariate
Gaussian distributions and known in advance, while a block diagonal structure is assumed on
the covariance matrix.
One can also model the correlation matrices, as done by Barnard et al. (2000), who use log
normal priors on variances independent of a prior on the whole matrix of correlations R.
Finally, Abadir et al. (2012) noticed that orthogonal matrices from the orthogonal decomposi-
tion of the sample covariance matrix are never ill-conditioned, and therefore they focus on
estimating the eigenvalues. Fan et al. (2013) apply the adaptive thresholding estimator of Cai
and Liu (2011) to principal orthogonal complements, in order to construct a sparse covariance
matrix.
Estimation of large covariance matrices is thus well-studied. Some methods focus on the
estimation of a covariance matrix common to several studies, either by estimating a single
covariance matrix for all groups, or by independently estimating the covariance matrices of
each group and identify their similarities (Gaskins and Daniels, 2013; Guo et al., 2011, for
example). Our model presented in Section 6.4 is of the former type and gives an empirical
Bayes procedure which estimates a sparse correlation matrix common to several studies.
Before presenting our model in Section 6.4, we describe some work on testing the equality of
several covariance matrices in Section 6.3.
6.3 Test for the equality of two covariance matrices
6.3.1 Likelihood ratio tests and other tests
To test the hypothesis H0 :Σ1 =Σ2 against H1 :Σ1 6=Σ2, one usually uses the modified likeli-
hood ratio test introduced by Bartlett (1937). Suppose there are two independent and normally
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distributed samples X1 and X2 of size n1 and n2 respectively, having measurements for G
variables. Denoting by S1 and S2 the sample covariance matrices of each sample respectively,
the likelihood ratio statistic is given by
L = |S1|
(n1−1)/2|S2|(n2−1)/2
|S|N /2 , S =
(n1−1)S1+ (n2−1)S2
n1+n2−2
, N = n1+n2,
where |S| is the determinant of S, and under the null hypothesis, −2logL ∼
H0
χ2G(G+1)/2, where
∼
H0
F means ‘follows the distribution F under the null hypothesis’. However, when G >N , the
sample covariance matrix is singular, and the statistic is not well defined.
Several tests have been developed to test the equality of covariance matrices when G À N .
Chaipitak and Chongcharoen (2013) review existing methods that can handle this case. The
test developed by Schott (2007) is based on an estimator of the square Frobenius norm of
Σ1−Σ2, and defines
TS = (n1−1)(n2−1)
2(n1+n2−2)
(
â21+ â22− 2
G
tr(S1S2)
)
,
â2i = (ni −1)
2
G(ni −2)(ni +1)
{
tr (S2i )−
1
ni −1
tr(Si )
2
}
, i = 1,2,
which, under the null hypothesis asymptotically follows a standard normal distribution,
TS
d→N (0,1), as (G ,n1,n2)→∞.
Srivastava et al. (2011) propose a test based on a lower bound of the Frobenius norm, given by
TSr = â21− â22√
η̂21+ η̂22
, η̂2i =
4
(ni −1)2
â22
(
1+ 2(ni −1)â4
Gâ22
)
,
â4 = 1
c0
(
1
G
tr(A4)−Gc1â1−G2c2â21 â2−Gc3â22−NG3â41
)
,
c0 =N (N 3+6N 2+21N +18), c1 = 2N (2N 2+6N +9), c2 = 2N (3N +2).
Under the null hypothesis, the test statistic, TSr , asymptotically follows a standard normal
distribution, TSr
d→N (0,1), (G , N )→∞.
Srivastava and Yanagihara (2010) compare the traces of the squared matrices,
TSY = γ̂1− γ̂2√
ξ̂21+ ξ̂22
∼
H0
N (0,1),
γ̂i = â2i
â21i
, ξ̂2i =
4
(ni −1)2
{
â22
â41
+ 2(ni −1)
G
(
â32
â61
− 2â2â3
â51
+ â4
â41
)}
,
â3 = 1
N (N 2+3N +4)
(
1
G
tr(A3)−3N (N +1)Gâ2â1−NG2â31
)
.
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Under the null hypothesis, TSY also follows a standard normal distribution asymptotically.
Finally, Chaipitak and Chongcharoen (2013) develop a test based on the ratio of the traces of
the squared matrices, b = tr(Σ21)/tr(Σ22), whose estimator, b̂ follows asymptotically (G , N →∞)
a normal distribution under the null hypothesis,
b̂−1
δ̂
d→
H0
N (0,1),
b̂ = â21
â22
, δ̂2 = 4
G
{
2â?4
â22
2∑
i=1
1
ni −1
+
1∑
i=1
G
(ni −1)2
}
,
â?4 =
τ
G
{
tr(S4)+β?tr(S3)tr(S)+ c?(tr(S2))2+dtr(S2)(tr(S))2+e(tr(S))4} ,
τ= N
5(N 2+N +2)
(N +1)(N +2)(N +4)(N +6)(N −1)(N −2)(N −3) ,
b? = −4
N
, c? = −(2N
2+3N −6)
N (N 2+N +2) , d =
2(5N +6)
N (N 2+N +2) , e =
−(5N +6)
N 2(N 2+N +2) .
Chaipitak and Chongcharoen (2013) performed simulations to assess the attained significance
level (ASL) of each of the above tests. The ASL is expected to be close to the nominal signifi-
cance level setting, usually 0.05. They also compare their test with others in terms of power
and found that overall, they attain the best power while keeping the ASL close to α= 0.05.
Motivated by the fact that the accuracy of the likelihood ratio test can be poor, Davison et al.
(2014) developed a method based on computing a p-value using a one-dimensional numerical
integration, conditioning on the direction. The authors use directional p-values to test the
hypothesis Λ=Λ0, where Λ is the inverse covariance matrix, and Λ0 is equal to Λ, apart from
some zero entries. We extend the theory to the comparison of two covariance matrices and
therefore test the hypothesisΛ1 =Λ2 =Λ0 against the alternativeΛ1 6=Λ2, in the hope that this
test is more accurate than the likelihood ratio test, and has potentially more power in settings
where the likelihood ratio test fails, i.e., when the number of samples is too small. Suppose
we have two independent populations, Y1 and Y2, of size respectively n1 and n2, having G
parameters and following a multivariate normal distribution with parameter µ1, Σ1 and µ2, Σ2
respectively. Then we can write the log likelihood of the parameter θ = (µ1,µ2,Λ1,Λ2), with
Λi =Σ−1i , i = 1,2, as
l (θ; y)=
2∑
i=1
ni
2
log |Λi |− 1
2
tr(Λi Y
T
i Yi )+1Tni YiΛiµi −
ni
2
µTi Λiµi .
The maximum likelihood estimator is θ̂ = (µ̂1, µ̂2,Λ̂1,Λ̂2), with µ̂i = Y Ti 1ni n−1i , and Λ̂−1 =
Y Ti Yi n
−1
i −Y Ti 1ni 1Tni Yi n−2i .
We can now compute the likelihood ratio test corresponding to the null hypothesis, using
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Λ̂−10 = (n1Σ̂1+n2Σ̂2)/(n1+n2),
w =−2(l0− l1)=2
(
2∑
i=1
ni
2
log(|Λ̂i |)− 1
2
tr(Λ̂i Y
T
i Yi )+1Tni Yi Λ̂i µ̂i
− ni
2
log(|Λ̂0|)+ 1
2
tr(Λ̂0Y
T
i Yi )+1Tni Yi Λ̂0µ̂i −
ni
2
µ̂Ti Λ̂0µ̂i
)
=−N log(|Λ̂0|)+n1 log(|Λ̂1|)+n2 log(|Λ̂2|)
=−n1 log(|Λ̂0Λ̂−11 |)−n2 log(|Λ̂0Λ̂−12 |).
We introduce ϕ= (ξ1,ξ2,Λ1,Λ2)= (Λ1µ1,Λ2µ2,Λ1,Λ2), and the log likelihood becomes
l (ϕ; y)=
2∑
i=1
ni
2
log |Λi |− 1
2
tr(Λi Y
T
i Yi )+1Tni Yiξi −
ni
2
ξTi Λ
−1
i ξi . (6.2)
Following Davison et al. (2014), we compute sψ, which is the value of s = −∂l 0(ϕ)/∂ϕ eval-
uated at ϕ = ϕ̂0ψ, the maximum likelihood estimate from (6.2). We can easily show that
ϕ̂= (Λ̂1µ̂1,Λ̂2µ̂2,Λ1,Λ2), and from the first order derivatives,
∂l (ϕ)
∂ξi
∣∣∣
ϕ=ϕ̂0 = Y
T
i 1ni −niΛ−1i ξi
∣∣∣
ϕ=ϕ̂0 = 0
∂l (ϕ)
∂Λi
∣∣∣
ϕ=ϕ̂0 =
ni
2
Λ−1i −
1
2
Y Ti Yi +
ni
2
Λ−1i ξξ
TΛ−1i
∣∣∣
ϕ=ϕ̂0
= ni
2
Λ̂−10 −
1
2
Y Ti Yi +
ni
2
µ̂i µ̂
T
i =
ni
2
(Λ̂−10 − Λ̂−1i ),
(6.3)
we obtain, sψ =
{
0,0,−(n1/2)
(
Λ̂−10 − Λ̂−11
)
,−(n2/2)
(
Λ̂−10 − Λ̂−12
)}
. The tilted log likelihood along
the line s(t )= (1− t )sψ is
l (ϕ; y)=
2∑
i=1
ni
2
log |Λi |− 1
2
tr(Λi Y
T
i Yi )+1Tni Yiξi−
ni
2
ξTi Λ
−1
i ξi−
ni
2
(1−t )Λi (Λ̂−10 −Λ̂−1i ). (6.4)
The maximization of (6.4) gives ϕ̂(s(t ))= {ξ̂1, ξ̂2,Λ̂1(t ),Λ̂2(t )}, where Λ̂−1i (t )= tΛ̂−1i +(1−t )Λ̂−10 .
The directional p-value is defined as
p(ψ)=
∫ tmax
1 t
d−1h(t ;ψ)dt∫ tmax
0 t
d−1h(t ;ψ)dt
, h(t ;ψ)=
c exp
[
l
{
ϕ̂0ψ(s(t )); s(t )
}
− l {ϕ̂(s(t )); s(t )}]√|Jϕϕ(ϕ̂(s(t )); s(t ))| .
We therefore need to compute the double derivatives of the tilted likelihood function, for
which we use the formulae in Fackler (2005). From the single derivatives (6.3), we see that
second order derivatives involving parameters from two different populations are 0, and we
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get the other second order derivatives, which evaluated at ϕ= ϕ̂ lead to
−∂2l
∂ξi∂ξ
T
i
∣∣∣
ϕ=ϕ̂ = ni Λ̂
−1
i ,
−∂2l
∂ξiΛi
∣∣∣
ϕ=ϕ̂ =−ni (Λ̂
−1⊗ µ̂T ),
−∂2l
∂Λiξi
∣∣∣
ϕ=ϕ̂ =
−ni
2
(µ̂i ⊗ Ip )− ni
2
(Ip ⊗ µ̂i ),
−∂2l
∂ΛiΛi
∣∣∣
ϕ=ϕ̂ =
ni
2
(Λ̂−1i ⊗ Λ̂−1i )+
ni
2
(µ̂iµ
T
i ⊗ Λ̂−1i )+
ni
2
(Λ̂−1i ⊗ µ̂i µ̂Ti ).
The determinant of Jϕϕ(ϕ̂), is |Jϕϕ(ϕ̂)| = |Λ̂−11 (t )|G+2|Λ̂−12 (t )|G+2. It is now possible to compute
h(t ;ψ), which leads to the directional p-value, after integration, given by
h(t ;ψ)=
(
|Λ̂−11 (t )|
|Λ̂−10 |
)(n1−G−2)/2 ( |Λ̂−12 (t )|
|Λ̂−10 |
)(n2−G−2)/2
,
p(ψ)=
∫ tmax
1 t
d−1h(t ;ψ)dt∫ tmax
0 t
d−1h(t ;ψ)dt
, d = G(G+1)
2
.
6.3.2 Simulations to compare tests of equality of large covariance matrices
As the likelihood ratio test is not well defined for G >N , we develop a new test for assessing
the equality of two covariance matrices, Σ1 and Σ2 of size G×G , with G ÀN . From our gene
set of size G , we first randomly select a subset of genes of size q < N . Then we extract the
corresponding q ×q covariance matrices, σ1 and σ2, from Σ1 and Σ2, and test the equality
of these two submatrices, H0 : σ1 = σ2, which results in a p-value. The likelihood ratio test
is valid in this case, as q < N . We repeat the process B times, resulting in a set of p-values
p(1), . . . , p(B), which we correct for multiple testing using the Benjamini and Hochberg (1995)
method. If any of the tests is rejected, we reject the null hypothesis that the two matrices are
equal.
Before assessing this method directly, we want to see how the different methods compare
in the case where the number of variables G is smaller than the number of samples N . This
would correspond to one test of the submatrices method described previously. We perform
simulations based on the five simulation designs presented in Chaipitak and Chongcharoen
(2013). Each design is based on the same structure; under H0, we generate Σ10 =Σ20 =M0 and
under H1, Σ11 =M0 and Σ21 =M1, where M0 and M1 are defined as follows:
• unstructured pattern (UN): for M0, mi j = 1 if i = j and mi j = (−1)i+ j 0.1i / j otherwise;
• compound symmetry pattern (CS): M0 = 0.99IG + (0.01)1G 1TG , M1 = 0.95IG + (0.05)1G 1TG ;
• heterogeneous compound symmetry pattern (CSH), mi i =m2i and mi j =mi m jρ, where
mi ∼U (5,6), ρ = 0.5 for H0, and mi ∼U (4,5), and ρ = 0.4 for H1;
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• simple pattern 1 (SIM1) M0 = 2IG , M1 = 1.5IG ;
• simple pattern 2 (SIM2) M0 = IG , M1 = diag(1,1,1,2, . . . ,1,1,1,2).
We compare three methods: the likelihood ratio test (LRT), the directional p-value (dirp) and
the Chaipitak and Chongcharoen (2013) method (chai), based on the attained significance
level (ASL), which gives the proportion of p-values that fall below the level α (α= 0.05 in our
case) under the null hypothesis, and power in rejecting the null, which counts the number of
rejected hypotheses when simulating under the alternative. Results of the comparisons are
presented in Tables 6.1 and 6.2 for N = 20 and 100 respectively, and for G =5, 10 and 15 genes,
based on 1000 simulations. In these tables, we give the ASL in the first row. This value should
be close to the nominal value of 0.05. When the ASL is larger than 0.05, the power of the test is
overestimated. We therefore computed the corrected αwhich is the significance level required
to test at a 5% level, and the corresponding power, computed using this corrected value of α.
For n1 = n2 = 20, we observe that the directional p-value has a value of the ASL which is almost
perfectly equal to 0.05, whereas the LRT and the method of Chaipitak and Chongcharoen
(2013) tend to overestimate it. However, the power of all three methods is very low. In the case
of the LRT for G = 15, we see how important it is to correct the significance level of the test.
Indeed, the power of LRT attains 99% without correcting the significance level, whereas it is
only 8% after correction. In general, all tests have low power when n1 = n2 = 20. Increasing the
sample sizes leads to better results in terms of power, even after correcting the significance
level for the SIM1 and SIM2 designs. However, the power under the other simulation designs
is still low. Moreover, recall we are in a favorable setting in these simulations, as the number of
variables is smaller than the number of samples.
Figures 6.1, 6.2, 6.3 and 6.4 present the sorted p-values obtained from the simulations under
the different tests, with a zoom on the smallest values. Under the null hypothesis, where the
two matrices are identical, we should obtain roughly uniformly distributed p-values. We notice
that this is always the case for directional p-values for all simulation designs, which indicates
that the ASL is well controlled. p-values obtained from the Chaipitak and Chongcharoen
(2013) test follow approximately a uniform distribution when N = 200, only departing a bit
from the theoretical uniform distribution for small p-values. However, for smaller N there is
a clear departure from the uniform distribution, indicating that the ASL is not as expected.
Indeed, in order to test at a 5% level, one would need to take a much smaller value for α. This
departure from the uniform distribution is even more pronounced for the likelihood ratio test,
for which observed p-values tend to be much smaller than they should, even for large sample
sizes.
The results of the simulations show that the significance level is often overestimated in the
LRT and the test from Chaipitak and Chongcharoen (2013), but is well controlled under the
directional p-value setting. However the power of the latter is lower than or comparable to the
corrected power of the other methods. We also noticed that when the sample sizes are small,
the power of all tests is very low. Therefore, the idea of splitting large covariance matrices into
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Figure 6.1 – p-values under H0 for the different simulation designs, for n1 = n2 = 20, and for
the likelihood ratio test (LRT), the directional p-value (dirp) and the test from Chaipitak and
Chongcharoen (2013)(chai). Under the null hypothesis, p-values are assumed to follow a
uniform distribution (grey line). The second and fourth rows are a zoom on the small p-values
(p<0.1).
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Figure 6.2 – p-values under H1 for the different simulation designs, for n1 = n2 = 20, com-
paring three tests: the likelihood ratio test (LRT), the directional p-value (dirp) and the test
from Chaipitak and Chongcharoen (2013)(chai). The second and fourth rows are is a zoom on
the small p-values (p<0.1)
Table 6.1 – Results from the simulations comparing three tests of equality of covariance
matrices of size G×G , for sample sizes n1 = n2 = 20, and for five simulation designs. The first
row of the table gives the ASL, which should be close to 5%. The second row is the power of
the test using a significance level of α= 5%. The third and fourth rows give the corrected α, a
corrected significance level required to test at a 5% level, and the corresponding power.
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Figure 6.3 – p-values under H0 for the different simulation designs, for n1 = n2 = 200, and
for the likelihood ratio test (LRT), the directional p-value (dirp) and the test from Chaipitak
and Chongcharoen (2013)(chai). Under the null hypothesis, p-values are assumed to follow a
uniform distribution (grey line). The second and fourth rows are a zoom on the small p-values
(p<0.1).
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Figure 6.4 – p-values under H1 for the different simulation designs, for n1 = n2 = 200, com-
paring three tests: the likelihood ratio test (LRT), the directional p-value (dirp) and the test
from Chaipitak and Chongcharoen (2013)(chai). The second and fourth rows are a zoom on
the small p-values (p<0.1)
Table 6.2 – Results from the simulations comparing three tests of equality of covariance
matrices of size G×G , for sample sizes n1 = n2 = 200, and for five simulation designs. The first
row of the table gives the ASL, which should be close to 5%. The second row is the power of
the test using a significance level of α= 5%. The third and fourth rows give the corrected α, a
corrected significance level required to test at a 5% level, and the corresponding power.
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Chapter 6. Correlation matrix estimation
many smaller submatrices to test equality is not promising: each individual test having low
power, combining them will certainly not be very powerful.
In the next section, we present a method to estimate a large sparse correlation matrix common
to several studies.
6.4 Empirical Bayes estimation of sparse correlation matrices
6.4.1 The model
As shown in Section 6.1, the estimation of large covariance or correlation matrices has been
well studied, and is eased by assuming that the matrix is sparse, which also makes sense
biologically. If several studies are available, estimation of common covariance features is
done either by estimating a single covariance matrix, or by independently estimating the
covariance matrices of each study and identifying their similarities afterwards. We use the
first approach. Starting from several studies, we estimate a common sparse correlation matrix,
which we can then analyze to discover modules. The idea is to use the Fisher transformation
on the pairwise correlation coefficients and assume that they are normally distributed. This
transformation was also used by Hafdahl (2007) to combine correlation matrices in a fixed
effects meta-analysis. The idea of the model comes from Johnstone and Silverman (2005),
who develop a Bayesian approach to wavelet regression, also used by Davison (2008) to model
nuclear magnetic resonance imaging.
We start from the sample correlation matrices of the studies providing a gene expression
matrix (Type 1 studies in Chapter 3), denoted by R(1), . . . ,R(L1), and we obtain the vectors
r (1), . . . ,r (L1), the vectorized upper diagonal part of the correlation matrices. Applying Fisher’s
transformation to these vectors leads to a set of vectors
{
Z (1), . . . , Z (L1)
}
, with elements
Z (l )g =
1
2
log
(
1+ r (l )g
1− r (l )g
)
, g = 1, . . . ,G(G−1)/2, l = 1, . . . ,L1.
We now assume the following model on Z , for each of the G(G − 1)/2 different pairwise
correlations:
Z (l )g ∼N (θg ,σ2l ), θg ∼ (1−p)δ0(θ)+pN (0,τ2), g = 1, . . . ,G(G−1)/2, (6.5)
where δθ is the Dirac function putting all mass at 0. The prior we choose for θ allows some
of the correlations to be exactly zero, making the resulting correlation matrix sparse. We can
easily obtain the posterior density for θg , and, the calculations being the same for all g , we
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omit the subscript in what follows:
pi
(
θ | Z (1), . . . , Z (L1))= pi(θ) f (Z (1), . . . , Z (L1) | θ)
f
(
Z (1), . . . , Z (L1)
)
= pi(θ) f
(
Z (1), . . . , Z (L1) | θ)∫
θ f
(
Z (1), . . . , Z (L1) | θ)pi(θ)dθ
= pz
p
bϕ
(
θ−b−1∑L1l=1 Z (l )/σ2l
b−1/2
)
+ (1−pz )δ0,
(6.6)
where
b = 1
τ2
+
L1∑
l=1
1
σ2l
, w1 = pp
bτ
exp
{
1
2b
(
L1∑
l=1
Z (l )
σ2l
)2} L1∏
l=1
1
σl
ϕ
(
Z (l )
σl
)
,
w2 = (1−p)
L1∏
l=1
1
σl
ϕ
(
z(l )
σl
)
, pz = w1
w1+w2
.
Detailed calculations are provided in Section A.3 with a summary of the parameters used
for model (6.5) in Table A.6 of the Appendix, and an illustration of the prior and posterior
distributions of θ is presented in Figure 6.5.
As it is possible to obtain an explicit expression for the likelihood, we adopt an empirical
Bayes approach, and estimate the parameters σ1, . . . ,σL1 , p, τ by maximum likelihood. The
log likelihood is given by
l (σ1, . . . ,σL1 , p,τ)=
G∑
g=1
log
(1−p)w˜2+ pw˜2
τ
p
b
exp
 12b
(
L1∑
l=1
Z (l )g
σ2l
)2
 , w˜2 = L1∏
l=1
1
σl
ϕ
(
Z (l )g
σl
)
,
which we optimize with respect to q = log{p/(1−p)}, σ1, . . . ,σL1 and τ.
A natural summary for θ is the posterior mean. However, as we seek a sparse correlation
matrix, we rather choose the posterior median θ˜ of θ, which performs a form of soft shrink-
age (Johnstone and Silverman, 2005; Davison, 2008). We denote by pz = w1/(w1+w2) the
posterior probability that θ is non-null. We also need to compute the posterior distribution of
θ, at θ = 0,
H˜(0)=
∫ 0
−∞
pi
(
θ | Z (1), . . . , Z (L1))dθ = ∫ 0
−∞
pz
p
bϕ
(
(θ−µθ)
p
b
)
dθ = pz
p
bΦ
(
−µθ
p
b
)
= pz H(0),
µθ =
1
b
L1∑
l=1
Z (l )
σ2l
.
The quantity H˜(0) identifies lower point of the jump in the posterior distribution of θ and is
useful to distinguish the different cases which can appear in the calculation of the median, as
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Figure 6.5 – Prior (left) and posterior (center and right) distributions for θ for one gene present
in three studies, with, center: z = (−1.5,−1.8,−1.2), right: z = (−0.5,−0.8,−0.2). The blue line
represents the median.
illustrated in Figure 6.6:
• if pz < 0.5, then 0.5 ∈
[
H(0)pz ; pz H(0)+ (1−pz )
]
and therefore the median θ˜ = 0;
• if pz > 0.5;
– if 0.5 ∈ [H(0)pz ; pz H(0)+ (1−pz )], θ˜ = 0;
– if H(0)pz > 0.5, we want to solve
pzΦ
(
θ˜−µ
σ
)
= 0.5⇒ θ˜ =Φ−1
(
1
2pz
)
1p
b
+µθ;
– if H(0)pz + (1−pz )< 0.5, then
pzΦ
(
(θ˜−µθ)
p
b
)
+ (1−pz )= 0.5⇒ θ˜ =Φ−1
(
2pz −1
2pz
)
1p
b
+µθ.
The common correlation matrix is then defined by applying the inverse of Fisher’s transfor-
mation to the matrix having entries θ˜ in the upper diagonal part, and filling the rest of the
estimated matrix to make it symmetric. We denote the estimated common correlation matrix
by R˜.
6.4.2 Simulations
We perform some simulations to ensure that the estimation of the hyperparameters is appro-
priate. To this end, we generate from model (6.5) with L = 2, G = 100, p = 0.06, σ= (0.5,1.5),
τ = 2.52, for 100 replications. The boxplots of the estimated parameters are presented in
Figure 6.7, where it can be observed that the estimation seems to be really good.
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(d) pz > 0.5, Φ(0)pz > 0.5
Figure 6.6 – Posterior distribution of θ and the corresponding median in blue, for different
situations.
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Figure 6.7 – Boxplots of the estimated parameters over 100 simulations from the model.
We now turn to more interesting simulations, and present results for two simulation designs.
The first generates a block diagonal correlation matrix R, using the model presented in Sec-
tion 4.1.1, which gives
R =

A1 0
. . .
0 AB
 , Ab =

1 ρb · · · ρb
ρb
...
...
. . . ρb
ρb · · · ρb 1
 , b = 1, . . . ,B , (6.7)
where the correlation ρb inside each block Ab , is generated according to a uniform distribution
between 0.5 and 1, b = 1, . . . ,B = 5. Then we transform R to the Fisher scale, add white noise
with varianceσ2² , and transform back to obtain several noisy correlation matrices as illustrated
by Figure 6.8. A summary of the parameters used for the simulations is presented in Table A.7
of the Appendix. We performed 100 replications for several values of the noise σ2² . Boxplots
of the estimated parameters can be found in Figure 6.9, while model performance is shown
in Table 6.3. The estimates of σl and τ tend to be very close to the predefined values, even
when the noise added is large. However, the probability of being non null, p, tends to be
overestimated, particularly when the noise is large, which is to be expected. Indeed, as the
noise becomes larger and larger, it becomes difficult to distinguish the noise from the signal.
We also performed other simulations generating sparser matrices. To this end, we randomly
set a proportion q = 0.01 of correlations to be non null, and distributed according toU (0.5,1)
in the matrix R. Then the simulations are conducted as presented in Figure 6.8. The resulting
R˜(i ) are not correlation matrices, because they are not positive definite, but the model does
not require positive definite matrices.
Results of the simulations for the sparse matrix are in Figure 6.10 and Table 6.4, where we see
that the estimators of p and σl are very accurate, except for p when the noise is very large, as
expected. The parameter τ is difficult to estimate when the noise is small. Concerning the
values of the Tables 6.3 and 6.4, we see that the true zero rate (TZR) is almost perfect while
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Z (1) = Z +²1 R(1)
R Z Z (2) = Z +²2 R(2)
Z (3) = Z +²3 R(3)
Figure 6.8 – Simulation design used to assess the model. R is the true block diagonal correlation
matrix and Z is the Fisher transformed matrix, ²i ∼N (0,σ2²). Genes in each block in R have
common correlation ρ.
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Figure 6.9 – Boxplots of the estimated parameters for non-sparse simulations with G = 100
(top) and G = 1000 (bottom). Red lines are the true values of the parameter for different values
of the noise σ² = 0.1, . . . ,1 (×10 of the x-axis the figures).
Table 6.3 – Simulations for G = 100, over Rsim = 100 simulations, for block diagonal matrices
with B = 5 blocks. The different quantities examined are the Frobenius, L1 and operator norms
of the difference between the estimated matrix and the truth; the true zero rate (TZR), false
zero rate (FZR), true positive rate (TPR) and false positive rate (FPR) in %; the average of the
differences of the true non zero entries; the average of all the differences; the proportion (%)
of the differences that are smaller than 5% and the estimates of the model parameters.
G = 100 σ² = 0.1 σ² = 0.2 σ² = 0.3 σ² = 0.4 σ² = 0.5
Frobenius norm 1.4(0.03) 3.34(0.06) 6.85(0.13) 10.81(0.16) 14.4(0.18)
L1 norm 0.89(0.01) 2.13(0.04) 4.66(0.11) 7.46(0.11) 9.68(0.09)
operator norm 0.34(0.004) 0.83(0.01) 1.99(0.08) 3.77(0.1) 5.30(0.1)
TZR (%) 99.0(0.2) 99.0(0.5) 98.0(1.0) 97.0(1.0) 96.0(2.0)
FZR (%) 0.0(0.0) 0.07(0.1) 3.0(3.0) 9.0(6.0) 18.0(10.0)
TPR (%) 1.0(0.0) 99.0(0.1) 97.0(3.0) 91.0(6.0) 82.0(10.0)
FPR (%) 30.0(20.0) 1.0(0.5) 2.0(1.0) 3.0(1.0) 4.0(2.0)
Mean 6= 0 0.02(0.004) 0.04(0.009) 0.07(0.02) 0.13(0.04) 0.19(0.05)
Mean of differences 0.004(0.0009) 0.009(0.002) 0.01(0.005) 0.03(0.008) 0.05(0.01)
prop (%) < 5% 98.0 94.0 90.0 87.0 84.0
p̂ (p = 0.2) 0.23(0.04) 0.25(0.04) 0.28(0.05) 0.30(0.05) 0.31(0.07)
σ̂ (σ=σ²) 0.11(0.02) 0.19(0.003) 0.30(0.0004) 0.40(0.005) 0.50(0.008)
τ̂ (τ= 1) 1.43(0.62) 1.08(0.32) 1.06(0.35) 1.00(0.31) 0.99(0.35)
σ² = 0.6 σ² = 0.7 σ² = 0.8 σ² = 0.9 σ² = 1
Frobenius norm 17.3(0.20) 19.7(0.17) 22.2(0.14) 23.8(0.15) 25.3(0.13)
L1 norm 11.34(0.12) 12.8(0.09) 13.77(0.08) 14.5(0.07) 15.4(0.09)
operator norm 6.67(0.1) 7.76(0.08) 8.53(0.07) 9.37(0.07) 10.23(0.08)
TZR (%) 96.0(2.0) 95.0(3.0) 93.0(4.0) 94.0(3.0) 94.0(4.0)
FZR (%) 26.0(10.0) 32.0(12.0) 39.0(12.0) 47.0(12.0) 52.0(12.0)
TPR (%) 74.0(10.0) 68.0(12.0) 61.0(12.0) 53.0(12.0) 48.0(12.0)
FPR (%) 4.0(2.0) 5.0(3.0) 7.0(4.0) 6.0(3.0) 6.0(4.0)
Mean 6= 0 0.25(0.06) 0.30(0.07) 0.36(0.06) 0.41(0.08) 0.45(0.06)
Mean of differences 0.06(0.01) 0.07(0.01) 0.09(0.01) 0.09(0.01) 0.10(0.01)
prop(%) < 5% 84.0 82.0 79.0 79.0 79.0
p̂ (p = 0.2) 0.31(0.08) 0.33(0.09) 0.37(0.09) 0.36(0.09) 0.35(0.1)
σ̂ (σ=σ²) 0.60(0.009) 0.70(0.008) 0.80(0.009) 0.90(0.012) 1(0.013)
τ̂ (τ= 1) 1.08(0.42) 1.03(0.38) 0.87(0.33) 0.91(0.33) 0.96(0.35)
Table 6.4 – Simulations for G = 100, over Rsim = 100 simulations, for sparse matrices (q = 0.01).
The different quantities examined are the Frobenius, L1 and operator norms of the difference
between the estimated matrix and the truth; The true zero rate (TZR), false zero rate (FZR),
true positive rate (TPR) and false positive rate (FPR); the average of the differences of the true
non zero entries; the average of all the differences; the proportion of the differences that are
smaller than 0.05 and the estimates of the model parameters.
G = 100 σ² = 0.1 σ² = 0.2 σ² = 0.3 σ² = 0.4 σ² = 0.5
Frobenius norm 0.29(0.009) 1.03(0.04) 2.47(0.04) 3.75(0.04) 4.79(0.03)
L1 norm 0.14(0.006) 0.55(0.02) 1.14(0.03) 1.75(0.04) 2.10(0.05)
operator norm 0.11(0.007) 0.47(0.02) 0.81(0.01) 1.12(0.01) 1.29(0.01)
TZR (%) 99.0(0.001) 99.0(0.01) 99.0(0.4) 99.0(0.01) 99.0(0.01)
FZR (%) 0.041(3.0) 2.0(4.0) 14.0(6.0) 30.0(6.0) 46.0(8.0)
TPR (%) 99.0(3.0) 98.0(4.0) 86.0(6.0) 70.0(6.0) 54.0(8.0)
FPR (%) 0.001(0.001) 0.01(0.01) 0.01(0.4) 0.01(0.01) 0.01(0.01)
Mean 6= 0 0.02(0.003) 0.05(0.02) 0.13(0.03) 0.23(0.04) 0.34(0.06)
Mean of differences 2.10−4(10−5) 6.10−4(10−4) 2.10−3(10−4) 2.10−3(10−4) 4.10−3(10−4)
prop (%) <5% 99.0 99.0 99.0 99.0 99.0
p̂ (p = 0.01) 0.04(0.04) 0.01(0.002) 0.018(0.03) 0.016(0.003) 0.016(0.005)
σ̂ (σ=σ²) 0.13(0.03) 0.20(0.02) 0.30(0.0003) 0.40(0.004) 0.50(0.005)
τ̂ (τ= 1) 2.87(0.91) 2.45(2.0) 1.44(1.26) 0.99(0.14) 1.02(0.16)
G = 100 σ² = 0.6 σ² = 0.7 σ² = 0.8 σ² = 0.9 σ² = 1
Frobenius norm 5.66(0.04) 6.16(0.04) 6.61(0.03) 6.88(0.03) 7.17(0.03)
L1 norm 2.42(0.05) 2.65(0.05) 2.83(0.05) 2.97(0.05) 2.99(0.04)
operator norm 1.48(0.01) 1.57(0.01) 1.66(0.01) 1.72(0.001) 1.77(0.01)
TZR (%) 99.0(0.01) 99.0(0.01) 99.0(0.01) 99.0(0.1) 99.0(1.0)
FZR (%) 62.0(9.0) 70.0(8.0) 78.0(8.0) 83.0(7.0) 88.0(9.0)
TPR (%) 38.0(9.0) 30.0(8.0) 22.0(8.0) 17.0(7.0) 12.0(9.0)
FPR (%) 0.01(0.01) 0.01(0.01) 0.01(0.01) 0.01(0.1) 0.01(1.0)
Mean 6= 0 0.44(0.05) 0.51(0.06) 0.57(0.05) 0.61(0.05) 0.67(0.05)
Mean of differences 0.005(10−4) 0.005(10−4) 0.006(10−4) 0.007(10−4) 0.007(10−4)
prop (%) < 5% 99.0 99.0 99.0 99.0 99.0
p̂ (p = 0.01) 0.015(0.006) 0.016(0.008) 0.017(0.01) 0.04(0.06) 0.11(0.16)
σ̂ (σ=σ²) 0.60(0.0006) 0.70(0.0007) 0.80(0.0008) 0.90(0.01) 1(0.01)
τ̂ (τ= 1) 1.16(0.64) 1.19(0.82) 1.27(0.90) 1.01(0.33) 0.92(0.66)
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Figure 6.10 – Boxplots of estimated parameters for sparse simulations with G = 100. Red lines
are the true values of the parameter for different values of the noise σ² = 0.1, . . . ,1 (×10 on the
x-axis of the figures).
Table 6.5 – Average computation time for the empirical Bayes model for different numbers of
genes G , with L = 3 studies.
G 100 200 500 1000 2000 5000 10000
time 1.91 5.3 10.4 12.9 18.4 70.5 394
the false zero rate (FZR) tends to be quite high. This means that many values that should
not be zero are fixed to zero anyway. However, the mean of the differences of the entries is
very small, which also indicates that the matrix is well estimated. The high rate of false zeros
may be due to very small entries in the true correlation matrix, which are estimated as being
null. However, in simulations performed in Section 7.2.1 we will see this is not a problem for
module detection.
6.5 Conclusion
We developed an empirical Bayes procedure for the estimation of a large and sparse correlation
matrix common to several studies. The estimated matrix is not a correlation matrix, as it is not
positive definite. However, we do not need our matrix to be positive definite, as we will only
use it to define modules in the next chapter. On top of being very simple, the method is also
fast, as shown in Table 6.5, and can therefore handle very large sets of genes. Computational
times may be larger than those presented in Table 6.5, depending on the maximum likelihood
estimation, which may require more iterations from time to time. This is due to the fact that
we do not use all observations to estimate the parameters, but only a subset, for two reasons:
first, it is faster to use fewer observations, and second, as the number of correlations is equal
to G(G−1)/2, which is very large for large G , taking a subset (usually 105, randomly selected),
will still give precise estimation.
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6.5. Conclusion
Simulations from the model and from independent designs show that the model works quite
well in estimating a common correlation matrix. In the next chapter, we focus on the detection
of gene modules based on this common correlation matrix. The fact that the matrix is sparse
aids the detection of modules. We also do not have to deal with one correlation matrix per
study in order to identify the common modules. In our case, we only have one matrix R˜ to
deal with, which simplifies module detection.
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7 Modules
7.1 Clustering
7.1.1 Overview
When one wants to partition a set of data into groups that are not known in advance, clus-
tering methods are very useful. Clustering, which is an unsupervised technique, must be
distinguished from classification, a supervised method where one wants to assign objects to
known classes. For a full review on clustering techniques, we refer to Gan et al. (2007) and
Hastie et al. (2009, Chapter 14). In the context of genomics data, Thalamuthu et al. (2006)
provide a good review of existing methods.
The first step for most clustering methods is to define a similarity or dissimilarity measure, such
that the more two data points are alike, the larger the similarity. This can be the Euclidean
distance, the correlation or any other distance measure. Hastie et al. (2009, Chapter 14)
distinguish three categories of clustering algorithms; combinatorial, which work directly
on the observed data, mode seeking, which are nonparametric approaches, and mixture
modeling, where the data are assumed to be independent and identically distributed samples
from a population described by a parametrized model.
Combinatorial algorithms are usually not feasible in high dimensions as they consist in
partitioning the data in all possible manners and identifying the one which seems to be the
most appropriate regarding the optimization of a given criterion.
Hierarchical algorithms divide the dataset into a sequence of nested clusters (Gan et al., 2007,
p. 109), and can be separated into two types: agglomerative and divisive. Agglomerative
algorithms start with each object clustered alone and then merge the clusters that are the
closest according to the similarity measure. Divisive algorithms start with all objects belonging
to the same big cluster, and recursively split the clusters into smaller ones, based on the largest
between-group dissimilarity. One of the main disadvantages of such methods is that once a
point has been attributed to a cluster, it cannot be changed, i.e., there is no correcting step if
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a point has been incorrectly assigned to a wrong cluster. Hierarchical clustering algorithms
also impose a hierarchical structure on the data, even if such a structure is inappropriate.
Hierarchical clustering does not require the number of clusters to be fixed or need a starting
configuration before running the algorithm. Agglomerative hierarchical methods can be
separated in two groups: those based on graph methods, which use links such as single
linkage, complete linkage, average linkage, weighted average linkage, and geometric methods
using links such as Ward’s, centroids and the median (Gan et al., 2007, p. 117). Geometric
distances require one to measure the center of two agglomerated clusters and obtain a measure
of dissimilarity between two centers. Divisive clustering is more appropriate if one wishes
to obtain a small number of clusters. It can be applied in different ways: either recursively
applying the k-means algorithm (to be presented later in this section) with k = 2, or splitting
the cluster with the largest diameter, or that with the largest average dissimilarity. Once the
tree is built, one needs to cut it at the appropriate height to obtain the desired number of
clusters. There exist several methods to select the optimal number of clusters, which are
described in more detail in Section 7.1.4.
A dendrogram is a useful graphical representation of the tree obtained from a hierarchical
clustering algorithm. It consists of a tree in which each node is associated with a height, such
that
h(A)≤ h(B)⇒ A ⊆B , A∩B 6= ;
for all subsets of data points A and B , and for each set of points (xi , x j ), hi j is the height of the
node specifying the smallest cluster to which both xi and x j belong (Gan et al., 2007, p.111).
The height is proportional to dissimilarity and is therefore highly interpretable.
Center-based clustering algorithms are usually very efficient for clustering large and high-
dimensional databases, and have their own objective functions. The k-means algorithm is
one of the most popular non-hierarchical clustering algorithm (Hastie et al., 2009, p. 509).
It allocates the remaining data to the nearest of the k clusters, for some fixed k, and then
changes the membership of the clusters according to some error loss function until there is
no improvement in the error loss function for any change in membership. Gan et al. (2007, p.
161) define the error loss function as E =∑ki=1∑x∈Ci d(x,µ(Ci )), where µ(Ci ) is the centroid
of Ci , and d is a distance measure. The algorithm proceeds from an initial partition of the
objects into k clusters, which may be determined randomly or by stepwise assignment (Hastie
et al., 2009, p. 518). It then computes the distance of each point to each cluster center and
reallocates the point to the closest cluster. Cluster centers are computed again for all modified
clusters until there is no further change. This algorithm is efficient in clustering large datasets,
but it may end at a local minimum of the loss function. Moreover, its performance is highly
dependent on the initialization of the centers, and it requires fixing the number of clusters in
advance. The k-means algorithm can be run for different values of k, and the best k is chosen
using methods described in Section 7.1.4. Self organizing maps (SOM) can be viewed as a
constrained version of the k-means algorithm. The k centers are constrained to lie in a one-
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or two-dimensional manifold in the feature (i.e., gene) space. The SOM procedure tries to
bend the plane so that the centers approximate the data points as well as possible (Hastie
et al., 2009, p. 528). The observations are processed one at a time and each neighboring center
is updated through a function which depends on a tuning parameter α. Neighbors are defined
as centers having distance smaller than some threshold r with the current center, where r
is also to be determined. The performance of the algorithm depends on the choice of the
parameters α and r . For more details about this algorithm, we refer to Hastie et al. (2009, p.
528-534)
The last clustering method we briefly present is model-based clustering, in which the data are
viewed as coming from a mixture of probability distributions, with one distribution per cluster.
Two approaches are considered in this case: classification likelihood or mixture likelihood.
For more details about this method, we refer to Gan et al. (2007, Chapter 14). Model-based
algorithms define the number of clusters by comparing different models, using BIC selection
for example.
In the next two sections, we present WGCNA (Langfelder and Horvath, 2007) and tight cluster-
ing (Tseng and Wong, 2005), which are competitors of our method for module detection, which
will use 1−the correlation matrix estimated as described in Section 6.4 as the distance matrix
in a hierarchical clustering algorithm (see Section 7.2 for more details). Both WGCNA and tight
clustering define modules common to several gene expression studies. In Section 7.2, we will
compare our empirical Bayes method with these two other methods, based on simulations.
7.1.2 Weighted correlation network analysis (WGCNA)
The first method is implemented in the R package WGCNA (Langfelder and Horvath, 2008).
The method, which is described in Langfelder and Horvath (2007), constructs co-expression
modules in each study under analysis and identifies the common modules. Consensus mod-
ules are defined as co-expression modules that are shared by at least two networks or studies.
Then the authors represent the gene expression profiles of each module by an eigengene, and
study differential expression of the eigengenes across studies. Langfelder and Horvath (2007)
start by constructing an adjacency matrix and attribute to each gene a scaled connectivity
measure. They transform the adjacency matrix using functions that are meant to make the
detection of modules easier, by performing soft thresholding, for example. To define the
consensus network they state that two nodes should be connected in a consensus network
if all, or only a proportion, of the input networks agree on this connection. The dissimilarity
matrix, defined as 1− the adjacency matrix, is then used as input for the clustering algorithm,
which identifies modules. Langfelder and Horvath (2007) use hierarchical clustering with
average linkage to construct the tree and cut it at either a fixed height or using their dynamic
tree cut approach (Langfelder et al., 2008), which, according to their simulations, is more
powerful in detecting modules. The eigengene for each module is defined as the first singular
vector, with the sign fixed to have positive correlation with the mean gene of the module.
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7.1.3 Tight clustering
Tight clustering is another method to detect modules common to several studies. It was
developed by Tseng and Wong (2005), and produces tight and stable clusters, which can be
thought of as being gene modules. Tight clustering has been developed to separate potentially
interesting genes, which can be clustered into modules, with what the authors call “scattered
genes”, which do not belong to any particular cluster. Scattered genes must be treated sepa-
rately, as, if clustered with other genes, they may make the determination of clusters and the
number of clusters difficult, by artificially distorting the clusters.
The method developed by Tseng and Wong (2005) uses a modified k-means algorithm, which
circumvents the local minimum problem by specifying starting values obtained from hier-
archical clustering. The algorithm proceeds in two parts. In the first part, called Algorithm
A, it selects the candidate genes, or, put differently, removes the scattered genes. It selects
a random subset of the data, usually 70%, on which k-means algorithm is applied. The re-
sulting cluster centers are used as classifiers for the rest of the data. The subsampling and
classification process is repeated several times, and the set of candidate genes is based on a
measure of co-membership. The second part of the algorithm defines the clusters. Starting
from an initial number of clusters k0, Algorithm A is applied to the candidate gene set and
the top q genes are clustered together. The cluster is formed by agglomerating genes until a
threshold on the distance with the previous included genes is reached. k0 is then decreased
by 1 and the process is repeated until the desired number of clusters is found. The algorithm
requires two tuning parameters, which control tightness and stability of the selected clusters.
The procedure is coded into the tightClust R package.
7.1.4 Choosing the number of modules
In clustering, where the goal is to find unknown groups of objects, the number of clusters
is unknown and needs to be determined, either as an input of the algorithm, like k-means,
or as the cutting height of the tree in hierarchical clustering. Dudoit and Fridlyand (2002)
present several methods for this task. The optimal number of clusters is usually not assessed
directly, results from a clustering algorithm for different numbers of clusters k are instead
compared, and the configuration optimizing some quantity is selected, thus defining the
optimal number of clusters. Methods to determine the number of clusters are either based on
internal or external indices. The former use statistics that are functions of between- or within-
cluster sums of squares, and that exploit the observations used to produce the clustering.
The silhouette plot and the GAP statistic (Tibshirani et al., 2001, to be described later in this
section) are examples of these internal indices. External indices are based on measures of
agreements between two clustering results. The Rand index (Rand, 1971), to be defined later in
this section, is one example of such an external index. Dudoit and Fridlyand (2002) developed
a method called Clest, which is a prediction-based resampling method, which uses ideas of
both internal and external indices. However, Clest seems more appropriate for selecting small
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numbers of clusters, as in cancer subtypes discoveries, rather than the case we are interested
in, namely gene clustering.
The GAP statistic
In many clustering methods the number of clusters has to be chosen a priori. However, in
real data applications, where we usually have no clue concerning the number of clusters, it
can be useful to have a criterion to help select this. Several methods have been developed to
tackle this problem, among which is the GAP statistic, developed by Tibshirani et al. (2001),
which uses resampling to define a reference distribution. We denote by C a partition which
attributes each gene to a cluster or a module, Ci , such that clusters are elements of the
partition, Ci ∈C . For a predefined number of clusters k from 1 to Kmax, we define the partition
Ck = (C1, . . . ,Ck ), where |Cl | = nl . Each cluster is summarized by the sum of the pairwise
distances of its elements,
Dl =
∑
i , j∈Cl
di j .
Each partition of k clusters is then characterized by the average pairwise distances of its
clusters,
Wk =
k∑
l=1
1
2nl
Dl .
The idea of the GAP statistic is to compare log(Wk ) with the expected value computed under a
reference distribution obtained from the data by resampling. The optimal number of clusters
k̂ is obtained as the value maximizing the GAP statistic, defined as
GAPB (k)= EB (logWk )− logWk , (7.1)
where B indicates the number of times data were resampled to estimate the reference dis-
tribution. Tibshirani et al. (2001) explain how to generate the reference distribution. We
present their method and a slightly different version which is more appropriate for our prob-
lem. Indeed, in the original paper, the authors use the data matrix to obtain the reference
distribution, whereas we want to compute the clusters based on the common correlation
matrix. Following Tibshirani et al. (2001), we can use two methods to obtain the null reference
distribution:
• the first consists in generating uniformly distributed gene expression values for the null
distribution over the range of the observed values for that gene;
• the second, a bit more complicated, takes the shape of the distribution into account
by generating uniformly distributed gene expression values over a box aligned with the
first principal component of the data.
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For both methods, the process is repeated B times, and W (b)k is calculated for each resample,
for b = 1, . . . ,B and k = 1, . . . ,Kmax, from which an estimate µ̂ of EB (logWk ) with corresponding
standard deviation sdk is obtained as,
µ̂= 1
B
B∑
b=1
log(W (b)k ), sdk =
√√√√ 1
B
B∑
b=1
(
logW (b)k − µ̂
)2
.
The optimal number of clusters is chosen to minimize the GAP statistic (7.1), but to take the
variance into account, we should rather choose the smallest k satisfying
GAP(k)≥GAP(k+1)− sdk+1
√
1+ 1
B
,
as suggested by Tibshirani et al. (2001)
In our case, we only have the common correlation matrix at hand, not the gene expression
matrix, so, the resampling method used in the GAP procedure is not directly applicable. The
idea in the construction of the reference distribution is to break the structure of the correlation
matrix, as, under the null hypothesis, the correlation matrix should not have any structure
(k = 1). We insert the elements of the upper triangular part of the common correlation matrix
R˜ in a vector and randomly permute it. This permuted vector corresponds to the upper
triangular part of the resampled matrix R˜(b), which we fill in by imposing 1 on the diagonal
and completing the lower triangular part so that the resulting matrix is symmetric. We then
apply the procedure explained previously to estimate the number of clusters.
In the original method, the resampling part is done for each value of k, which is very computa-
tionally intensive if we want to test many different values for k. Instead, if using a hierarchical
clustering algorithm, we construct a hierarchical tree for each resampled dataset, and cut
it in order to obtain k clusters, with k = 1, . . . ,Kmax. We also add the possibility of having a
lower bound , Kmin, for k, and therefore can have k =Kmin, . . . ,Kmax. These two modifications
makes the algorithm less computationally intensive, which is particularly interesting in high
dimensions.
Consensus clustering
Consensus clustering, developed by Monti et al. (2003), is an algorithm which aims to find a
consensus across multiple runs of a clustering algorithm. To assess stability of the discovered
clusters, and to determine the optimal number of clusters, they use gene resampling. Sup-
pose we want to cluster G genes {g1, . . . , gG } into k non-overlapping clusters {C1, . . . ,Ck }. The
consensus matrixM , which stores for each pair of items the proportion of clustering runs in
which two items are clustered together, is defined through the connectivity matrix M (b) and
the indicator matrix I (b), for each perturbed dataset D (b), obtained by resampling the original
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dataset D ,
M (b)(i , j )=
{
1, if items i and j belong to the same cluster,
0, otherwise,
I (b)(i , j )=
{
1, if i and j belong to dataset D (b),
0, otherwise,
M (i , j )=
∑B
b=1 M
(b)(i , j )∑B
b=1 I
(b)(i , j )
.
The consensus matrix with all entries set to either 0 or 1 gives the best clustering, with perfect
consensus. Therefore, to find the optimal number of clusters, one needs to identify the
consensus matrix having entries mostly 0 and 1. The idea is to construct a consensus matrix
M (k) for each partition containing k clusters, k = 2, . . . ,Kmax, and to choose the number
of clusters that corresponds to the best consensus matrix, i.e. the matrix having entries
mostly 0 and 1. To make the task easier, the authors define the consensus distribution and its
corresponding area as
CDF(c)=
∑
i< j I{M (i , j )≤c}
G(G−1)/2 , A(k)=
m∑
i=2
(xi −xi−1)CDF(xi ),
where G is the number of rows (the number of genes) inM , and (x1, . . . , xm) denotes the sorted
entries of the consensus matrix M (k), m = (G −1)G/2. The optimal number of clusters is
chosen as k̂opt = argmaxk ∆(k), where
∆(k)=
{
A(k), k = 2,
A(k+1)−A(k)
A(k) k > 2,
Although several methods exist to identify the optimal number of clusters, they are usually
very difficult to apply in practice due to their large computational requirements, or are not
efficient on real data. This fact was noticed by Thalamuthu et al. (2006), whose attempts to
estimate the number of clusters in real datasets were usually not successful, especially with
many scattered genes and large perturbations. We will also encounter this problem in our
real data application, and will therefore arbitrarily choose a number of clusters which seems
reasonable, i.e. which gives modules of sizes between 5 and approximately 100 genes.
7.1.5 Assessing a partition using the Rand index
The Rand index, first described by Rand (1971), is an objective criterion for comparing two
partitions of n objects based on their number of agreements in clustering a set of points. For
two partitions C = {C1, . . . ,CK } andP = {P1, . . . ,PL}, we define their K ×L agreement matrix A,
with (A)i j = ai j representing the number of elements that are found in both Ci and P j . In this
report, we use the adjusted Rand index, which corrects for classification by chance. We define
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the following quantities:
a·l =
K∑
k=1
akl , ak· =
L∑
l=1
akl .
The adjusted Rand index is then defined as
ARI=
{∑
k,l
(akl
2
)}−{∑Kk (ak·2 )∑Ll (a·l2 )/(N2 )}
1
2
{∑
k
(ak·
2
)+∑l (a·l2 )}+{∑k (ak·2 )∑Ll (a·l2 )/(N2 )} .
A value of ARI close to 1 indicates good agreement between the two partitions. Other measures
for evaluating partitions obtained from different clustering algorithms are described by Gan
et al. (2007, Chapter 17).
7.2 Simulations
In Section 6.4, we estimated a common correlation matrix using an empirical Bayes procedure.
We now want to define clusters or modules. To this end, we use some of the clustering
algorithms described in Section 7.1. We compare the GAP statistic and consensus clustering
(Section 7.1.4) combined with different clustering methods, and also compare our procedure’s
performance with other methods, WGCNA and tight clustering, described in Sections 7.1.2
and 7.1.3. To assess the performance of the different methods, we either use the Rand index
(Section 7.1.5), or
sensitivity= NTP
NTP+NFN , specificity=
NTN
NTN+NFP ,
where
• NTP, the number of true positives, counts the number of genes that are correctly at-
tributed to a module;
• NTN, the number of true negatives, those genes that are not in the module and that
should not be;
• NFN is the number of false negatives, genes that were not in the module but should
have been;
• NFP is the number of false positives, genes that are in the module but should not have
been.
The simulation design used to assess the performance of the different methods is either
that from Figure 6.8, or the following: from the gene expression matrix, generated according
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µ Σt Rt
X (1) = X t +²1 R(1)
X t X (2) = X t +²2 R(2)
X (3) = X t +²3 R(3)
Figure 7.1 – Simulation design used to assess the model. X t is the true gene expression matrix
to which we add noise ²i ∼N (0,σ2²) to obtain noisy realisations. Rt is the true correlation
matrix corresponding to X t , while R(i ) are the correlation matrices of the noisy gene expression
matrices.
to the procedure defined in Section 4.1.1, we extract the covariance matrix Σt , which we
transform to a correlation matrix Rt . We then add Gaussian noise to the gene expression
matrix, producing three noisy gene expression matrices. For each we compute the matrix of
pairwise correlations, which become the inputs of our model. The procedure is illustrated
in Figure 7.1, and will be particularly useful for comparing our method with WGCNA and
tight clustering, as these two last methods require gene expression matrices as input. Unless
otherwise specified, parameters for the simulation are taken as follows: the number of genes
is G = 100, the number of studies L = 3, the number of modules B = 5, and the number of
simulations Rsim = 100. The distance matrix used for a clustering algorithm is 1G 1TG − R˜ , where
R˜ is the matrix estimated from our procedure described in Section 6.4. Several clustering
algorithms will be compared in Section 7.3.
7.2.1 Simulations for module detection
We first want to assess the performance of our model combined with different clustering
techniques on module detection. Using the simulation design presented in Figure 6.8, which
adds noise to the correlation matrix generated according to equation (6.7), we use block
correlations ρb ∼ U (0.5,1), producing easy-to-detect modules, and ρb ∼ U (0,1), making
modules sightly more difficult to detect, for each block Ab of R, b = 1, . . . ,5. We also use ρ
as a tuning parameter, taking values between 0.1 and 0.9, by imposing all blocks to have the
same correlation, and using Gaussian noise with fixed variance σ² = 0.5. Results presented in
Tables 7.1 and 7.2 correspond to a hierarchical clustering algorithm with Ward’s link and the
number of clusters, B = 5, provided to the algorithm. A summary of the parameters used for
these simulations along with their values is presented in Table A.7 of the Appendix.
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Table 7.1 – Module detection by our method for the simulation design of Figure 6.8 adding
noise, ²∼N (0,σ²), to the correlation matrix generated according to (6.7). The table presents
the mean and standard deviation (%) for the Rand index, sensitivity, and specificity over 100
simulated data.
ρ ∼U (0.5,1) ρ ∼U (0,1)
σ² Rand index(%) Sensitivity(%) Specificity(%) Rand index(%) Sensitivity(%) Specificity(%)
0.1 100 (0.0) 100 (0.0) 100 (0.0) 95.7 (10.4) 96.0 (9.0) 99.5 (1.3)
0.2 100 (0.0) 100 (0.0) 100 (0.0) 91.0 (12.6) 90.5 (12.4) 98.9 (1.7)
0.3 100 (0.0) 100 (0.0) 100 (0.0) 88.0 (18.2) 88.6 (15.1) 98.5 (2.5)
0.4 100 (0.4) 99.9 (1.3) 100 (0.1) 78.1 (23.1) 82.2 (17.6) 97.4 (2.9)
0.5 98.8 (3.8) 98.1 (6.2) 99.9 (0.2) 66.2 (29.0) 73.4 (20.3) 95.9 (3.9)
0.6 96.6 (6.8) 95.4 (9.7) 99.8 (0.4) 64.1 (25.8) 71.1 (17.6) 95.7 (3.4)
0.7 94.9 (07.7) 94.0 (10.3) 99.5 (0.7) 52.2 (27.1) 64.4 (17.6) 94.2 (3.5)
0.8 91.2 (10.9) 91.7 (11.7) 99.1 (1.2) 48.0 (29.0) 60.0 (19.0) 93.5 (4.1)
0.9 89.2 (10.8) 90.5 (11.6) 98.9 (1.1) 45.8 (27.6) 59.3 (18.0) 93.3 (4.0)
1 80.5 (17.5) 83.0 (15.4) 98.0 (2.0) 37.5 (24.6) 54.6 (15.8) 92.1 (3.8)
Table 7.2 – Module detection using ρ, the intra-module correlation, as a tuning parameter.
The table presents the mean and standard deviation (%) of the Rand index, sensitivity and
specificity over 100 simulated datasets, with fixed noise variance σ² = 0.5.
ρ Rand index(%) Sensitivity(%) Specificity(%)
0.1 0.1(1.1) 28.2 (5.3) 85.2 (1.0)
0.2 6.1(11.2) 33.1 (9.8) 86.8 (2.5)
0.3 43.7 (20.3) 59.2 (14.9) 93.4 (2.7)
0.4 82.0 (8.6) 85.7 (11.5) 98.2 (0.9)
0.5 93.9 (6.8) 93.7 (10.3) 99.5 (0.4)
0.6 98.6 (3.5) 98.3 (5.6) 99.9 (0.2)
0.7 99.6 (2.1) 99.2 (4.1) 100 (0.1)
0.8 100 (0.0) 100 (0.0) 100 (0.0)
0.9 100 (0.0) 100 (0.0) 100 (0.0)
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In Table 7.1, the performance of our method in terms of detection of modules is almost perfect
if the correlation is large, i.e., ρ ∼U (0.5,1) for every noise level. When the correlations are
smaller, the performance decreases, especially when the noise level is big, as expected.
In Table 7.2, we see that our method detects the modules almost perfectly, as soon as the
correlation is large enough, ρ ≥ 0.4 inside a module, exactly as observed in Table 7.1. For
smaller correlations, the performance is less good but still reasonable for ρ ≥ 0.3. In these
simulations, the modules all have the same sizes and in Table 7.2 they all have the same
correlation ρ. We also performed simulations with varying module sizes and with varying
module correlations, ρb ∼N (ρ,σρ) for module b, with ρ and σρ fixed, but the results were
very similar to those presented in Tables 7.1 and 7.2.
7.2.2 Comparison of clustering methods
We saw in the previous section that our empirical Bayes model associated with hierarchical
clustering using the Ward’s link seems to perform quite well concerning module detection
when the number of modules is provided to the algorithm. However, we only used hierarchical
clustering and the number of modules was assumed to be known. In this section, we compare
hierarchical clustering with average, complete, single and Ward’s links, and k-means. We also
compare two methods for selecting the optimal number of clusters: the GAP statistic and
consensus clustering (CC). We use the simulation design of Figure 6.8, with a correlation ρ
inside each module varying from 0.1 to 0.9, a fixed noise level σ² = 0.5, and B = 5 clusters.
Table 7.3 compares these clustering techniques based on the average number of clusters
detected by the GAP statistic and the average Rand index over 100 simulations. The GAP
statistic only starts to be powerful when modules have large correlations. For values of ρ below
0.5, it systematically finds only one module, i.e., one cluster, as being the optimal number.
When the correlation is large, the GAP statistic can correctly identify that there are five modules.
It seems from this table that using a hierarchical clustering method with Ward’s link and the
GAP statistic is the best amongst all methods compared.
Figure 7.2 compares the Rand index obtained from several clustering methods using either
the GAP statistic or consensus clustering to determine the optimal number of clusters. From
the figure, it becomes clear that the GAP statistic with any method outperforms consensus
clustering. Once again, hierarchical clustering with Ward’s link and the GAP statistic to select
the number of modules seems to be the best choice in our simulations.
7.2.3 Comparison with WGCNA
In this section, we compare our method’s performance with that of WGCNA, described in
Section 7.1.2. Langfelder and Horvath (2007) provide in supplementary material a simulation
design that is supposed to mimic real gene expression data, and is coded in their package.
We first used their simulation design with the following settings: 3 studies, 100 simulations,
115
Table 7.3 – Comparison of different clustering methods. The first line for each method gives
the average number of clusters selected using the GAP statistic and the second line gives the
mean and standard deviation of the Rand index of the final partition compared to the truth.
The simulation design produces clusters of varying sizes, each having the same correlation ρ.
ρ 0.1 0.2 0.3 0.4 0.5
HC Ward clusters 1 (0) 1 (0) 1 (0) 1 (0) 1.64 (0.7)
Rand index 0 (0) 0 (0) 0 (0) 0 (0) 0.3 (0.3)
HC complete clusters 1 (0) 1(0) 1 (0) 1.08 (0.3) 1.81 (0.9)
Rand index 0 (0) 0 (0) 0 (0) 0.04 (0.16) 0.32 (0.35)
HC average clusters 1 (0) 1 (0) 1 (0) 1 (0) 1.27 (0.6)
Rand index 0 (0) 0 (0) 0 (0) 0 (0) 0.13 (0.27)
HC single clusters 1 (0) 1 (0) 1.02 (0.14) 1.05 (0.22) 1.10 (0.3)
Rand index 0 (0) 0 (0) 10−5(10−3) 0.001 (0.004) 0.004 (0.02)
k-means clusters 1 (0) 1 (0) 1 (0) 1 (0) 1.15 (0.39)
Rand index 0 (0) 0 (0) 0 (0) 0 (0) 0.09 (0.23)
ρ 0.6 0.7 0.8 0.9
HC Ward clusters 4.07 (0.6) 4.78 (0.4) 4.99 (0.1) 5 (0)
Rand index 0.95 (0.06) 0.99 (0.009) 0.99 (0.001) 1 (0)
HC complete clusters 3.48 (1.16) 4.43 (1.07) 4.85 (0.62) 5.06 (0.42)
Rand index 0.73 (0.33) 0.85 (0.24) 0.95 (0.12) 0.99 (0.04)
HC average clusters 2.93 (1.38) 4.42 (1.09) 4.79 (0.84) 4.96 (0.4)
Rand index 0.62 (0.40) 0.91 (0.25) 0.95 (0.20) 0.99 (0.10)
HC single clusters 1.66 (0.88) 3.62 (1.55) 4.92 (0.94) 5.05 (0.54)
Rand index 0.11 (0.20) 0.59 (0.38) 0.93 (0.23) 0.98 (0.11)
k-means clusters 2.56 (0.97) 3.26 (0.85) 3.17 (1.03) 3.29 (1.03)
Rand index 0.49 (0.32) 0.62 (0.22) 0.58 (0.23) 0.60 (0.24)
7.2. Simulations
0.2 0.4 0.6 0.8
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
ρ
R
an
d 
in
de
x
ward
average
complete
single
kmeans
GAP
CC
Figure 7.2 – Comparison of different clustering methods: hierarchical clustering with Ward’s,
average, complete or single linkage and k-means, and techniques to determine the optimal
number of clusters, GAP statistic and consensus clustering (CC).
Nmodules = 5, Npatients = 50, nGenes = 100, the eigengenes were generated according to a
standard normal distribution, with 20% of the genes in each module, and no grey genes (i.e.
scattered genes, see Section 7.2.4), the minimum correlation was taken to be 0.1 or 0.5, and
the maximum correlation was bounded by 1, background noise ranged between 0 and 0.3 with
six levels as stated in Langfelder and Horvath (2007), and no negative correlation was used.
In Table 7.4, we show the Rand index, sensitivity and specificity of module detection for
two versions of the design of Langfelder and Horvath (2007), and for our simulation design
(Figure 7.1), with varying ρ and constant noise variance σ² = 0.5. Our approach performs
better in detecting modules, even when applied to the design developed by Langfelder and
Horvath (2007). The difference between the methods is more striking for small correlations
(mincor= 0.1). However, the different levels of noise added to the design of Langfelder and
Horvath (2007) do not seem to make big differences in the results. For our simulation design,
where we add noise to the gene expression matrix (design illustrated in Figure 7.1), we also find
that our approach performs better in detecting modules. This simulation design leads to better
performance for our method than that where the noise is added directly to the correlation
matrix, as seen in Table 7.2.
To better see the difference in performance between the two methods in terms of the Rand
index, with respect to the intra-module correlation ρ, we present the results in Figure 7.3. It is
again clear that our empirical Bayes model performs better in terms of the Rand index. Note
that in these simulations, we use the fixed cut tree procedure, with the number of clusters
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Table 7.4 – Comparison between our empirical Bayes method (EB) and WGCNA, based on the
design of Langfelder and Horvath (2007) (WGCNA) and the design presented in Figure 7.1. We
present the mean and standard deviations (%) of the Rand index, sensitivity and specificity.
mincor=0.1, WGCNA design
EB WGCNA
Noise Rand index(%) Sensitivity(%) Specificity(%) Rand index(%) Sensitivity(%) Specificity(%)
0 36.2 (5.5) 73.0 (2.9) 93.7 (0.6) 1.8 (7.2) 25.5 (5.8) 84.3 (1.1)
0.06 35.4 (4.9) 72.6 (2.6) 93.6 (0.6) 6.3 (13.9) 29.1 (10.7) 85.0 (2.0)
0.12 35.5 (4.7) 72.6 (2.6) 93.6 (0.6) 4.8 (11.4) 28.3 (9.5) 84.8 (1.8)
0.18 34.4 (5.1) 72.0 (2.8) 93.5 (0.6) 2.8 (8.4) 26.5 (6.7) 84.5 (1.2)
0.24 34.4 (5.2) 72.0 (2.9) 93.5 (0.6) 2.3 (8.1) 26.0 (6.3) 84.4 (1.2)
0.3 33.5 (4.6) 71.5 (2.6) 93.4 (0.6) 4.1 (9.1) 27.9 (7.8) 84.7 (1.4)
mincor=0.5, WGCNA design
EB WGCNA
Noise Rand index(%) Sensitivity(%) Specificity(%) Rand index(%) Sensitivity(%) Specificity(%)
0 99.9 (0.5) 100 (0.2) 100 (0.0) 99.7 (2.4) 99.8 (2.0) 99.9 (0.5)
0.06 99.8 (0.8) 99.9 (0.3) 100 (0.1) 99.8 (2.4) 99.8 (2.0) 100 (0.5)
0.12 99.9 (0.4) 100 (0.2) 100 ( 0.0) 99.8 (2.4) 99.8 (2.0) 100 (0.5)
0.18 99.7 (0.9) 99.9 (0.3) 100 (0.1) 99.7 (2.4) 99.8 (2.0) 99.9 (0.5)
0.24 99.8 (0.8) 99.9 (0.3) 100 (0.1) 100 (0.0) 100 (0.0) 100 (0.0)
0.3 99.9 (0.6) 100 (0.2) 100 (0.1) 99.1 (4.5) 99.2 (3.7) 99.8 (0.9)
Simulation design of Figure 7.1
EB WGCNA
ρ Rand index(%) Sensitivity(%) Specificity(%) Rand index(%) Sensitivity(%) Specificity(%)
0.1 19.3 (10.0) 43.7 (8.3) 89.5 (1.7) 4.8 (5.9) 31.8 (6.2) 86.3 (1.4)
0.2 62.1 (13.1) 75.1 (12.7) 95.8 (1.5) 29.7 (18.7) 51.5 (13.8) 90.2 (2.9)
0.3 88.8 (7.4) 92.2 (9.2) 98.8 (0.7) 68.3 (19.7) 76.7 (15.3) 95.4 (3.1)
0.4 97.6 (3.3) 98.0 (4.9) 99.8 (0.3) 92.1 (11.3) 94.6 (8.4) 98.8 (1.8)
0.5 99.8 (0.7) 99.9 (0.5) 100 (0.1) 99.5 (2.2) 99.1 (4.0) 99.9 (0.3)
0.6 100 (0.2) 100 (0.1) 100 (0.0) 100 (0.3) 100 (0.1) 100 (0.0)
0.7 100 (0.0) 100 (0.0) 100 (0.0) 100 (0.0) 100 (0.0) 100 (0.0)
0.8 100 (0.0) 100 (0.0) 100 (0.0) 100 (0.0) 100 (0.0) 100 (0.0)
0.9 100 (0.0) 100 (0.0) 100 (0.0) 100 (0.0) 100 (0.0) 100 (0.0)
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Figure 7.3 – Rand index of module detection as a function of ρ for our procedure (EB) and for
WGCNA.
given to both methods, to define the clusters. Langfelder and Horvath (2007) suggest using
their dynamic approach, which may give different results, and which we will use in the next
section when introducing scattered genes.
7.2.4 Simulations with scattered genes
Scattered genes are genes that do not belong to any module and therefore are assumed to have
no or low correlation with other genes. This type of genes is also studied by Tseng and Wong
(2005) and Langfelder and Horvath (2007), who both developed methods to identify them.
Thalamuthu et al. (2006) compares six clustering methods based on their ability to detect
groups of genes in simulated microarray gene expression data. They conclude that in the
presence of scattered genes, tight clustering and model based clustering are the best methods
overall, while all methods except SOM recover the clusters accurately when no scattered
genes are present. Our approach follows this recommendation in the sense that, if we can
identify the scattered genes prior to clustering, and remove them from the correlation matrix,
most clustering methods will be appropriate in detecting modules. According to Figure 7.2,
we choose a hierarchical clustering approach with Ward’s link, which we apply after having
removed scattered genes.
In order to detect scattered genes, we tried several statistics, including the posterior probability
of being scattered, Tq , the sum and variance of absolute correlations, Tρ,sum and Tρ,var, and the
sum and variance of absolute Fisher transformed matrix, Tθ,sum Tθ,var. The posterior probabil-
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ity of being scattered is based on the Fisher transformed matrix, with entries corresponding to
the parameter θ, as defined in Section 6.4. Then for each gene g , the posterior probability of
being scattered corresponds to the probability that each entry of the g th row is null, except for
the diagonal,
Tq,g = P
(
θg ,1, · · · ,θg ,G = 0 | Z (1)g ,1, · · · , Z (L1)g ,1 , · · · , Z (1)g ,G , · · · , Z (L1)g ,G
)
=
∏
i 6=g f
(
Z (1)g i , · · · , Z (L1)g i | θg i = 0
)
P
(
θg i = 0
)
∏
i 6=g
∫
θg i
f
(
Z (1)g i , · · · , Z (L1)g i | θg i
)
pi(θg i )dθg i
= (1−p)
G−1∏
i 6=g ag i∏
i 6=g
[
(1−p)ag i + pag ipbτ2 exp
{(∑L1
l=1 Z
(l )
g i /σ
2
l
)2
(2b)−1
}] ,
where ag i =∏L1l=1σ−1l ϕ(Z (l )g i /σl ), and ϕ is the standard normal density. For numerical reasons,
we prefer to use the log posterior probability of being scattered. The sum and variance of the
Fisher transformed matrix are simply obtained as
Tg ,θ,sum =
∑
i 6=g
|θ˜g i |, Tg ,θ,var = var
(|θ˜g i |) , i 6= g , (7.2)
where θ˜ is the posterior median of θ, as defined in Section 6.4. The sum and variance of the
absolute correlations are obtained as the sum and variance for each row of the estimated
correlation matrix. For these last four quantities, we also work with − log(T ), to have a wider
scale, and scattered genes are identified as the genes with the largest values of − log(T ). We
study the power of each statistic in terms of detection of scattered genes, for different values
of ρ in Figure 7.4, where we simulated 100 datasets with G = 1000 genes of which 5% are
scattered, and ρb = 0.25, 0.5, 0.75 and 0.9, for all b = 1, . . . ,10, in (6.7). All statistics seem to have
high power of detection of scattered genes, with a slight advantage for the statistics based on
the variance of either the absolute correlations or the absolute Fisher values, Tθ,var and Tρ,var.
Looking at one particular simulation in Figure 7.5, we see that Tθ,var seems to discriminate
scattered genes the best. However, even if these statistics seem to have high power, meaning
that taking the genes with largest values most probably leads to a list of scattered genes, it
is hard to define a meaningful threshold, mainly because we do not know the distribution
of these statistics. We tried resampling to obtain a null distribution with which to compare
the observed value, but this is computationally intensive, especially since we work with high-
dimensional data. We are looking for a threshold in the tail of the distribution of our statistic,
from which we could decide whether a gene is scattered or not.
As we are working with the tail of a distribution, extreme value theory can be useful in helping
to determine a threshold. The mean residual life plot, defined as
E (X −u | X > u)= σ+ξu
1−ξ ,
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Figure 7.4 – Power of different statistics to detect scattered genes for some values of the
intra-module correlation, ρb = (0.25,0.5,0.75,0.9), b = 1, . . . ,10 in equation 6.7.
Chapter 7. Modules
0 200 400 600 800 1000
-1
e+
05
-6
e+
04
-2
e+
04
genes
lo
g 
po
st
 p
ro
ba
(a) Tq
0 200 400 600 800 1000
-5
.5
-5
.0
-4
.5
-4
.0
-3
.5
genes
-lo
g(
T)
(b) Tρ,sum
0 200 400 600 800 1000
2.
0
2.
5
3.
0
3.
5
4.
0
4.
5
5.
0
5.
5
genes
-lo
g(
T)
(c) Tρ,var
0 200 400 600 800 1000
-6
.0
-5
.5
-5
.0
-4
.5
-4
.0
-3
.5
genes
-lo
g(
T)
(d) Tθ,sum
0 200 400 600 800 1000
1
2
3
4
5
genes
-lo
g(
T)
(e) Tθ,var
Figure 7.5 – Detection of scattered genes (plain red points) for the different statistics, and
for ρ = 0.9 in (6.7) in one simulation. Tθ,var better discriminates between scattered and non-
scattered genes.
where σ and ξ are the parameters of the generalized Pareto distribution, is a useful tool to
help determine the threshold, as it should be linear in u for all values above the threshold
u. In Figure 7.6, where we present the mean residual life plot for − log(Tθ,var), we can clearly
identify linearity after u = 3, which seems to correspond to a reasonable value to discriminate
scattered genes from other genes, in the left panel of the same figure.
Threshold selection remains an open question in statistics of extreme values, although several
methods have been developed, e.g., by Wadsworth and Tawn (2012), who also provide a good
review of the topic. In our context, we need to find a method to identify scattered genes. We
know that the tail of the distribution of our statistic mostly contains scattered genes but can
have other genes mixed in too. However, we also know that very far in the tail, or put differently,
the most extreme values, are likely to be scattered genes. We decide to model the tail of the
distribution as a mixture of two generalized Pareto distributions (GPD), one for the scattered
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Figure 7.6 – Identification of scattered genes using − log(Tθ,var) as the statistic, for one simu-
lated dataset and ρ = 0.9. Left: values of − log(Tθ,var) with true scattered genes as red plain
dots; center: mean residual life plot; right: values of − log(Tθ,var) above the 90% quantile, with
scattered genes identified by our procedure (red plain dots) corresponding to all values of
− log(Tθ,var)> 2.9, true scattered genes (green crosses) and other genes (blue triangles). All
true scattered genes are correctly identified.
genes with parameters σ1 and ξ1 and the other with parameters σ2 and ξ2. To obtain more
accurate estimates, we assume that ξ1 = ξ2 = ξ, as suggested by Rootzén and Zholud (2014).
For an observed value of our statistic t above a threshold u, we have the following density,
f (t )= p f1(t ;σ1,ξ)+(1−p) f2(t ;σ2,ξ), t > u, fi (t ;σi ,ξ)= 1
σi
(
1+ξ x
σi
)−1/ξ−1
, i = 1,2.
(7.3)
In order to ensure that the observed values are a mixture of scattered and non-scattered genes
in the tail, we take u to be a large enough quantile of our observed statistic. The likelihood
can be easily obtained, and parameters are estimated by maximum likelihood. Identification
of scattered genes is done by computing the posterior probability of belonging to the first
mixture distribution for each gene g , based on the value of the corresponding statistic tg
defined in equation (7.2),
pg ,scattered =
p̂ f1(tg ; σ̂1, ξ̂)
p̂ f1(tg ; σ̂1, ξ̂)+ (1− p̂) f2(tg ; σ̂2, ξ̂)
.
We fitted this model to the simulated dataset of Figure 7.6. Estimates of the parameters with
corresponding standard errors are presented in Table 7.5. Using the estimated posterior
probability of belonging to the first distribution, detects all scattered genes properly and gives
a few false positives (50 true positives and 4 false positives, for this particular simulation), as
illustrated in the right pannel of Figure 7.6.
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Table 7.5 – Estimates of the parameters of the mixture of GPDs, with corresponding standard
errors, for one simulation and for ρb = 0.9, b = 1, . . . ,B = 10, in (6.7).
σ̂1 σ̂2 ξ̂ logit(p̂)
3.46 (1.33) 0.50 (0.16) −1.08(0.37) logit(0.43)=−0.28 (0.21)
We now compare our empirical Bayes approach using the GPD mixture to detect scattered
genes, with WGCNA and tight clustering, in terms of detection of scattered genes and accuracy
of the gene modules. To assess the performance of each method, we record the number of
true and false scattered genes, sensitivity and specificity regarding the detection of scattered
genes and the Rand index of the final partition compared to the truth. In all three methods the
detection of scattered genes is completely automatic, but the number of modules is provided
to the algorithms. For our method, scattered genes are detected by the extreme value method,
removed, and the resulting correlation matrix is used as input to the hierarchical clustering
algorithm with Ward’s linkage. Tight clustering and WGCNA have their own method to detect
scattered genes. We compute the Rand index on the entire set of genes by considering the
scattered genes to be a module.
In these simulations, we used G = 500 genes, of which 25 are scattered, B = 10 modules, and
performed 100 simulations for each value of the intra-module correlation ρb = 0.1, . . . ,0.9, for
all b = 1, . . . ,10, in (6.7). Results of these simulations are presented in Table 7.6 and Figure 7.7.
In both, the Rand index for our method is equivalent or better than for other methods, and the
difference is more striking for smaller correlations. We see that the scattered gene detection
using the GPD mixture tends to be quite conservative, with very few false positives. On the
other hand, the number of true positives is a little lower than with the other methods. The
plots of true positives and false positives, as well as specificity and sensitivity plots in Figure 7.7,
cannot be looked at separately. Indeed, one seeks to obtain many true positives associated
with very few false positives. Therefore, even if WGCNA seems to perform very well in detecting
scattered genes according to the plots of true positives, when looking at the false positives plot,
we see it actually selects all genes to be scattered, and therefore has many false positives too.
Therefore, looking at all plots of Figure 7.7 and at Table 7.6, we conclude that our approach is
a good compromise, as it has high Rand index, and tends to select scattered genes properly.
We would rather have low false positive rate for our method, eventually associated with low
true positive rate, as scattered genes are removed from the clustering process, and therefore
excluded from modules. So we prefer to have some scattered genes inside modules, rather
than correlated genes outside modules.
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Table 7.6 – Comparison of our empirical Bayes method with GPD mixture to detect scattered
genes, WGCNA and tight clustering. The Rand index is based on all clusters, with scattered
genes included as a cluster. Numbers of true positives (TP), which should equal 25, false
positives (FP), which is smaller than 475 and should equal 0 ideally, sensitivity and specificity
concern the detection of scattered genes only. The Rand index, sensitivity, specificity and their
corresponding standard deviations are in percent, whereas TP, FP and corresponding standard
deviations are in number of genes.
ρ 0.1 0.25 0.5 0.75 0.9
Rand index EB 13.9 (4.3) 69.0 (6.7) 94.3 (6.1) 94.1 (6.9) 91.5 (7.8)
(%) WGCNA 0.0 (0.0) 0.0 (0.7) 43.5 (9.0) 74.1 (8.2) 95.8 (1.9)
tight 1.2 (1.9) 28.9 (5.5) 40.2 (7.7) 40.8 (7.8) 41.4 (7.6)
TP EB 3.0 (2.5) 10.7 (6.3) 10.6 (9.9) 12.9 (11.3) 18.8 (10.1)
WGCNA 25.0 (0.0) 24.9 (0.1) 24.9 (0.3) 21.2 (2.0) 15.3 (2.5)
tight 21.7 (2.0) 20.6 (2.9) 16.2 (9.7) 8.7 (10.2) 3.0 (6.0)
FP EB 27.7 (19.5) 20.5 (15.5) 8.4 (11.8) 10.9 (12.1) 15.8 (11.5)
WGCNA 475.0 (0.0) 442.6 (19.7) 44.6 (21.5) 5.3 (3.8) 2.2 (2.4)
tight 350.3 (25.4) 187.6 (19.2) 171.2 (17.6) 184.2 (17.9) 178.9 (17.4)
sensitivity EB 12.1 (10.1) 42.9 (25.1) 42.6 (39.5) 51.8 (45.1) 75.1 (40.3)
(%) WGCNA 100.0 (0.0) 99.9 (0.4) 99.6 (1.2) 84.9 (8.0) 61.0 (10.0)
tight 86.9 (7.8) 82.3 (11.6) 64.8 (38.7) 34.9 (40.8) 11.9 (24.1)
specificity EB 94.2 (4.1) 95.7 (3.3) 98.2 (2.5) 97.7 (2.5) 96.7 (2.4)
(%) WGCNA 0.0 (0.0) 6.8 (4.2) 90.6 (4.5) 98.9 (0.8) 99.5 (0.5)
tight 26.3 (5.3) 60.5 (4.0) 63.9 (3.7) 61.2 (3.8) 62.3 (3.7)
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Figure 7.7 – Rand index, number of false positives, number of true positives, sensitivity and
specificity for the simulations with scattered genes for the comparison of our method using
the GPD mixture to select scattered genes, WGCNA and tight clustering.
7.3. Modules in real data
7.3 Modules in real data
Modules provide a way to reduce the dimension of our problem. We now want to apply
the model developed in Chapter 3 to modules defined by our empirical Bayes model and
clustering method. Model (3.2) only needs slight modifications to take into account module
sizes. We detail the modifications for each data type separately. Suppose we found m modules
M1, . . . ,Mm , of sizes M1, . . . , Mm . We now want to summarize the G genes into m module
representatives.
For Type 1 data, on which the modules were defined, we need to obtain an m×N matrix of
module representatives. Langfelder and Horvath (2007) suggest using the module eigengene,
which is the first right singular vector of the data matrix restricted to the set of genes of
each module. This choice is motivated by the fact that the first singular vector, which also
corresponds to the first principal component, explains the most variability of the genes in this
module. Denoting by Y (Mi ) the data matrix restricted to genes of moduleMi , the eigengene
ei is defined using the singular value decomposition of Y (Mi ),
Y (Mi ) =U (Mi )D (Mi )V (Mi )T , ei =V (Mi )1 ,
where ei is the first column of the matrix of right singular vectors V (Mi ). However, the dis-
tribution of the first singular vector is difficult to obtain (Johnstone, 2001), and cannot be
modeled by a normal distribution, as specified in our model (3.2). For this reason, we choose
to summarize the information inside each module by the average gene expression. Therefore,
ei = 1
Mi
∑
g∈Mi
Yg ,
where Yg denotes the g th row of the data matrix, containing the gene expression for all N
individuals. Recalling that Yg j |µg ,β(1)g ,σ2g ∼N
(
µg +β(1)g I j≤n1 ,σ2g
)
, and noticing that genes
inside a module are not independent, we get
E(ei )= 1
Mi
∑
g∈Mi
µg +β(1)g I{ j≤n1}, var(ei )=
1
M 2i
∑
g∈Mi
[
σ2g +
∑
k 6=g
ρg kσgσk
]
,
where ρg k = corr(Yg ,Yk ). We therefore choose to model the module expression Y˜i j as
Y˜i j |β(1)i ,µi ,σi ∼N
(
µi +β(1)i I{ j≤n1},
σ2i
Mi
)
, i = 1, . . . ,m, j = 1, . . . , N .
µi =
N∑
j=n1+1
Y˜i j
We use the same symbols for the parameters as in model (3.2), whereas the parameters
represent different quantities. However we believe using the same symbols is more helpful
than confusing.
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For Type 2 data, we need to reduce the vector Z of length G to an m-dimensional vector
containing the module scores. Here again, recall that gene score was modeled as
Z (2)g |β(2)g ,δ2g ∼N
(
β(2)g
√
νδ2g ,1
)
, ν= (N −n1)n1/N .
To summarize gene scores into module scores, we use the maxmean statistic defined by Efron
and Tibshirani (2007), which has power against both shift and scale differences. We use their
definition, except that we choose to keep the sign of the shift,
ei =
(
I{
s(+)>s(−)
}− I{
s(+)<s(−)
})max{|s(+)|, |s(−)|} , { s(+) =∑g∈Mi zg I{zg>0},
s(−) =∑g∈Mi (−zg )I{zg<0}.
Writting n+ = #
{
g : zg > 0
}
and n− = #
{
g : zg < 0
}
, and noting that genes are not independent,
we obtain
E(ei )= 1
Mi
∑
g∈Mi
βg
√
νδ2g I{zg∈S }, S = {+,−},
var(ei )= 1
M 2i
(
n++
∑
g∈Mi
∑
k 6=g
ρg k I{zg ,zk∈S }
)
.
We therefore choose to model the module score Z˜i as
Z˜i |β(2)i ,δi ∼N
β(2)i
√
νδ2i
vi
,1
 , vi = n(S )+∑g∈Mi ∑k 6=g ρ̂g k I{zg ,zk∈S }
M 2i
, S = {+,−},
where ρ̂g k is the (g ,k) entry of the estimated common correlation matrix R˜ defined in Sec-
tion 6.4.
For the Type 3 data, we can encounter three situations:
• all genes in the module are observed — in this case, the module is summarized exactly
as the Type 2 data presented previously;
• all genes in the module are missing — in this case the entire module is missing and we
impute, similarly as in Chapter 3, writting z˜ref for the smallest module score observed,
Z˜i ∼N |z˜ref|−|z˜ref|
β(3)i
√
νδ2i
vi
,1
 ; or
• some genes are missing and some are observed in the module, in which case we summa-
rize exactly as for Type 2, dividing by Mi . This implies that missing genes are arbitrarily
set to 0, which makes sense as missing genes are those with small z-scores, not reported
as being differentially expressed in the study.
128
7.3. Modules in real data
Type 4 data, i.e., ranks, need also to take into account that modules may only be partially
observed. For this reason, we first transform the observed ranks to the normal distribution
scale, prior to combination:
R˜g =Φ−1
(
Rg
G+1
)
, g = 1, . . . ,G ,
The module score is then computed by averaging the observed values inside the module, and
modules are attributed a rank based on this score. Here we do not use the maxmean approach
previously described, as we do not observe the sign of the underlying statistics. The module
rank is modeled using a latent variable u˜ as follows:
u˜i ∼N
(
β(4)i
p
ν,
σ2u,i
Mi
)
.
To summarize, the complete hierarchical Bayesian model for module i (i = 1, . . . ,m) is
Yi j |β(1)i ,σ2i ,µi ∼N
(
µi +β(1)i I{ j≤n1},
σ2i
Mi
)
, j = 1, . . . , N , σ−2i ∼Gamma(b1,b2),
Z (l )i |β(l )i ,δi ∼N
β(l )i
√
νδ2i
vi
,1
 , vi = n(S )+∑g∈Mi ∑k 6=g ρ̂g k I{zg ,zk∈S }
M 2i
, S = {+,−}, l = 2,3,
ui |β(4)i ,σ2u,i ∼N
(
β(4)i
p
ν,
σ2u,i
Mi
)
, σ−2u,i ∼Gamma(d1,d2),
β(l )i | γi ,σ2β ∼N
(
γi ,
σ2
β
Mi
)
, σ−2β ∼Gamma(e1,e2).
(7.4)
We use the same symbols as in (3.2), whereas the quantities they represent are different.
However it simplifies and help identifying the similarities between the two versions of the
model.
7.3.1 Differentially expressed modules
The 11 studies presented in Chapter 5 were considered for analysis of module differential
expression. As motivated in Chapter 6, summarizing genes into modules prior to fitting our
model could be very interesting both statistically, by fulfilling the independence assumption
and reducing the dimension, and biologically.
Modules were identified based on the 9884 genes common to all four Type 1 datasets. For each
study, the sample correlation matrices were obtained and the empirical model was applied.
It took 445 seconds to get the resulting common correlation matrix. From the transformed
matrix on the Fisher scale, we calculated − log(Tθ,var), defined in equation (7.2), and applied
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Figure 7.8 – Detection of scattered genes for real data. Left: mean residual life plot for real data,
right: identification of scattered genes (red crosses) and non scattered genes (blue triangles)
Table 7.7 – Estimates and standard errors of the parameters of the mixture of GPD distributions
for the detection of scattered genes in real data.
σ̂1 σ̂2 ξ̂ logit(p̂)
0.71 (0.14) 0.38 (0.03) −0.19 (0.05) logit(0.12)= −1.99(0.86)
our mixture of GPDs, which identified only 11 scattered genes. Figure 7.8 shows the mean
residual life plot for our real data, which suggests taking a threshold larger than 6.5, and a plot
of the identified scattered genes, where our procedure places the threshold at 7.4. The number
of identified scattered genes is very low, so there may be scattered genes in the modules
defined hereafter. Hierarchical clustering with Ward’s link was performed on the estimated
correlation matrix of the remaining genes. This part of the procedure is very fast, as the
tree could be obtained within 18 seconds. The GAP procedure being very computationally
intensive and not successful in detecting an appropriate number of clusters, we chose to cut
the tree to obtain 500 modules, a number large enough to obtain clusters of reasonable sizes,
as shown in Figure 7.9.
With the modules thus defined, we added all genes present in the union of all the other types
of data, but not present in the modules, as scattered genes, and summarized the module
information as described in Section 7.3. This left us with 1962 elements, 500 modules and
1462 scattered genes. We applied the hierarchical model (7.4) with the spike and slab prior
to our summarized data. We performed 65000 iterations, using a warmup of 5000 iterations
and thinning of 10, which took less than 5 hours, and resulted in 6000 roughly independent
samples from the posterior distributions.
With the dimension reduced, we did not even need to run the rank part of the MCMC algorithm
more than the other steps. Based on graphical exploration, the convergence of the chain
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and independence of the realizations seem to be attained, as presented for one module in
Figure 7.10, for the parameter γ. More formal tests were applied and gave no evidence against
convergence.
To discriminate between differentially and non-differentially expressed modules, we use again
the quantity w defined in Section 3.4. The posterior mean of w identifies 93 elements, 34 of
which are single genes, whereas the posterior median of w better separates differentially and
non-differentially expressed modules and gives 86 differentially expressed elements. Values of
the posterior mean and median of w are presented in Figure 7.11. This figure also has several
jumps in the values of the posterior quantities, which are explained by the number of studies
in which each module is found, as presented in the right panel of Figure 7.11. The results
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Figure 7.10 – Graphical diagnostics for the convergence of γ.
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Figure 7.11 – Results for the real data analysis. Left: estimate of w based on the posterior mean,
with 0.5 threshold to discriminate between differentially and non-differentially expressed
genes; center: estimate of w based on the posterior median with threshold 0.5; right: number
of studies to which each module belongs.
for the posterior mean, median and standard deviation of w , along with posterior mean and
standard deviation of γ are presented in Table 7.8 for the differentially expressed modules.
We also present the probability that a module present in the top 50 appears in the top r , with
r = 1, 10, 50, 100 and 500, in Table 7.9. It appears that modules found in the top 50 by our
analysis, have a high probability of being in the top 100, whereas posterior probabilities for
modules ranked 1000–1050 are not significant, which suggests that our results are quite stable.
7.3.2 Enrichment analysis of modules
The analysis conducted in the previous section identifies several modules as being differen-
tially expressed. We now want to assess the enrichment of these modules, in order to highlight
their biological functions, if any. To this end, we used the Molecular Signature database (Liber-
zon et al., 2011, MSig DB), which provides pathways from several repositories. For our analysis,
we kept the pathways from KEGG, Biocarta, Reactome and GO, available to download from
MSig under the c2 and c5 collections.
After downloading all the pathways, we removed those too large and too small, keeping only
pathways containing between 5 and 200 genes, as suggested in Tseng et al. (2012). We also
only selected those having common genes with our module set. The enrichment analysis
included 1200 genes and 724 pathways. Enrichment of each module in each pathway was
tested using Fisher’s exact test, and the test with the smallest p-value, or the most enriched
term, was recorded for each module. Results are presented in Table 7.10, for the differentially
expressed modules identified by our analysis. Differentially expressed scattered genes are
included as a module called scattered in Table 7.10. Almost all modules are enriched in one
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Table 7.8 – Differentially expressed modules ordered according to the posterior mean of w ,
ŵ . Presented values are the posterior median and mean of w , ŵ and w˜ , with corresponding
standard errors, and the posterior mean of γ with corresponding standard error. The three
first columns are in percent.
Module ID w˜ (%) ŵ (%) sd(w)(%) γ̂ sd(γ)
176 100.0 100.0 0.0 1.6 0.1
48 100.0 100.0 0.0 −0.6 0.1
274 100.0 100.0 0.0 0.4 0.1
129 100.0 100.0 0.0 −0.5 0.1
5 100.0 100.0 0.0 −0.4 0.1
255 100.0 100.0 0.0 −0.4 0.1
92 100.0 100.0 0.0 −0.7 0.1
137 100.0 100.0 0.0 −0.7 0.1
221 100.0 100.0 0.0 −0.5 0.1
40 100.0 100.0 0.0 −0.9 0.1
161 100.0 100.0 0.0 −0.6 0.1
279 100.0 100.0 0.0 −0.4 0.1
27 100.0 100.0 0.0 0.5 0.1
322 100.0 100.0 0.0 −1.5 0.1
74 100.0 100.0 0.0 −0.4 0.1
39 100.0 100.0 0.0 −0.6 0.1
241 100.0 100.0 0.0 −0.7 0.1
337 100.0 100.0 0.0 −0.6 0.1
273 100.0 100.0 0.0 −0.5 0.1
242 100.0 100.0 0.0 −0.7 0.1
117 100.0 100.0 0.0 −0.6 0.1
145 100.0 100.0 0.8 −0.4 0.1
67 100.0 100.0 0.0 −0.5 0.1
138 100.0 100.0 0.0 −0.6 0.1
146 100.0 99.9 2.1 0.4 0.1
317 100.0 99.9 2.6 −0.5 0.1
438 99.9 99.9 2.5 −0.5 0.1
165 100.0 99.9 2.4 −0.3 0.1
303 100.0 99.8 3.7 −0.4 0.1
257 100.0 99.6 5.2 0.5 0.1
86 99.9 99.5 6.4 −0.6 0.1
DLGAP5 99.5 99.4 0.2 1.5 0.3
307 100.0 99.4 6.2 0.4 0.1
ITLN1 99.4 99.4 0.3 −2.0 0.4
EVI1 99.4 99.4 0.3 1.8 0.4
14 100.0 99.3 7.3 0.5 0.1
CTRB1 99.3 99.3 0.3 1.8 0.4
240 100.0 99.2 6.9 0.3 0.1
459 99.9 99.1 8.8 0.5 0.1
PEG3 99.5 98.6 8.8 −1.5 0.4
HOXC4 /// HOXC6 99.3 98.5 8.6 −1.8 0.4
CD24 99.5 98.4 9.8 1.5 0.4
201 100.0 97.5 13.4 −0.4 0.1
75 100.0 97.1 12.3 −0.2 0.1
180 100.0 97.1 11.7 −0.3 0.1
GINS1 99.4 96.7 16.1 1.3 0.4
ABCB5 99.4 95.1 20.1 1.2 0.4
Module ID w˜ (%) ŵ (%) sd(w) (%) γ̂ sd(γ)
366 99.9 94.6 21.3 −0.5 0.2
EPCAM 99.4 93.5 23.4 1.2 0.4
HBA1 /// HBA2 99.4 93.2 23.7 −1.4 0.5
IFNA4 99.4 92.9 24.5 1.2 0.4
51 100.0 92.1 23.1 −0.3 0.1
PTH2R 99.4 92.0 25.9 1.2 0.5
SCN1B 99.4 91.0 27.6 1.2 0.5
NY−REN−7 99.0 90.3 28.0 1.6 0.7
321 100.0 88.8 27.7 −0.3 0.1
CNGA2 99.3 88.2 31.1 1.3 0.6
LOC221061 99.0 86.4 32.9 −1.5 0.8
SPA17 99.3 86.1 33.6 −1.1 0.5
9 100.0 85.6 26.3 0.2 0.1
295 100.0 85.2 28.4 −0.2 0.1
ADH4 99.4 85.1 34.7 1.0 0.5
208 100.0 84.4 30.5 −0.2 0.1
6 100.0 83.0 25.2 −0.2 0.1
3 100.0 82.6 31.5 0.2 0.1
MT4 99.4 82.1 37.4 1.0 0.5
356 100.0 77.7 35.8 −0.2 0.1
ARHI 98.9 74.2 42.7 1.2 0.9
289 100.0 74.1 37.3 −0.2 0.1
172 100.0 72.0 37.1 −0.2 0.1
CFH /// CFHR1 99.2 70.5 44.8 −0.9 0.6
KIAA0186 98.8 69.0 45.3 −1.2 0.9
LOC152573 99.0 68.8 45.4 1.0 0.8
PRSS7 99.2 67.8 45.9 0.9 0.7
KIAA1536 98.8 66.5 46.3 1.1 0.9
143 56.8 65.9 30.5 −0.1 0.1
CDC2 99.2 65.6 46.7 0.8 0.6
HTR6 99.2 65.2 46.8 0.7 0.6
GPR21 99.2 63.3 47.4 0.7 0.6
KCNJ2 99.2 62.0 47.7 −0.7 0.6
407 99.9 60.1 44.2 0.2 0.2
C4A 98.7 59.8 48.2 1.0 0.9
57 44.7 59.6 35.2 −0.1 0.1
83 42.5 58.7 34.9 0.1 0.1
368 49.9 57.9 42.3 0.2 0.2
100 32.8 56.3 42.3 −0.2 0.2
205 40.5 56.1 33.2 −0.1 0.1
LOC114977 98.3 53.5 49.0 −0.8 0.8
32 52.3 53.2 11.8 −0.0 0.0
401 23.6 52.9 43.2 −0.2 0.2
STIL 98.8 51.7 49.1 0.5 0.5
FLJ20059 98.1 51.4 49.2 −0.8 0.9
126 34.9 50.5 32.7 −0.1 0.1
Table 7.9 – Probability (%) of being in the top r for the 50 first differentially expressed modules
according to the posterior mean of w , and for modules ranks 1000 to 1049.
r
Rank Module ID 1 10 50 100 500
1 176 32.1 94.2 100 100 100
2 48 11.8 76.6 100 100 100
3 274 3.3 44.4 100 100 100
4 129 2.1 31.4 99.8 100 100
5 5 1.5 28.9 99.8 100 100
6 255 1.2 25 99.6 100 100
7 92 0.9 21.3 99 100 100
8 137 0.9 18.9 98.7 100 100
9 221 0.6 16.9 98.8 100 100
10 40 0.5 16.1 98.4 100 100
11 161 0.7 14.2 97.8 100 100
12 279 0.4 13.8 97.5 100 100
13 27 0.4 11.6 96.8 100 100
14 322 0.4 6.9 93 100 100
15 74 0.2 6.1 92.3 100 100
16 39 0.2 5.8 90.8 100 100
17 241 0.1 5 90.7 100 100
18 337 0.2 4.8 88.2 100 100
19 273 0.1 4 85.8 100 100
20 242 0.1 3.5 86 100 100
21 117 0.1 4.1 84.8 100 100
22 145 1.7 28.9 99.7 100 100
23 67 0 2.4 77.5 100 100
24 138 0.1 2.4 77.3 100 100
25 146 0.1 5.9 90 99.9 100
26 317 0.1 3.7 84.7 99.9 100
27 438 0 0.4 39.2 99.9 100
28 165 3.1 42.5 99.7 99.8 100
29 303 0.3 8.8 94.8 99.7 100
30 257 0 1 61.9 99.6 100
31 86 0 0.4 38.1 99.5 99.8
32 DLGAP5 0 0 0 64.9 100
33 307 1.6 28.4 98.7 99.1 100
34 ITLN1 0 0 0 58.5 100
35 EVI1 0 0 0 57.6 100
36 14 0.1 2.5 77.7 99.1 100
37 CTRB1 0 0 0 46.6 100
38 240 1.5 24.9 98.1 98.6 100
39 459 0 0.1 23.7 99 99.6
40 PEG3 0 0 0 64.8 99.2
41 HOXC4 /// HOXC6 0 0 0 45.8 99.2
42 CD24 0 0 0 64.5 99
43 201 0.5 10.6 93 96.6 100
44 75 4 50.2 94.3 94.3 100
45 180 13.7 78.1 93.5 93.5 100
46 GINS1 0 0 0 62.7 97.2
47 ABCB5 0 0 0 61.5 95.6
48 366 0 0 15.6 94.2 96.6
49 EPCAM 0 0 0 60 94
50 HBA1 /// HBA2 0 0 0 52.4 93.8
r
Rank Module ID 1 10 50 100 500
1000 AFAP1 0 0 0 1 1.7
1001 ACR 0 0 0 0.8 1.1
1002 RTCD1 0 0 0 0.8 1.3
1003 KRT76 0 0 0 0.8 1.2
1004 CYCS 0 0 0 0.6 1.1
1005 TWF1 0 0 0 1.6 2.3
1006 POLA1 0 0 0 0.7 1
1007 PRKCB 0 0 0 1 1.5
1008 C19orf57 0 0 0 0.6 1.1
1009 DIS3 0 0 0 1 1.4
1010 C12orf24 0 0 0 0.8 1.3
1011 RASIP1 0 0 0 0.6 1.1
1012 EXOC5 0 0 0 0.6 0.9
1013 SEPT2 0 0 0 0.5 1
1014 RPS17 0 0 0 0.6 1.1
1015 CLCNKB 0 0 0 0.8 1.3
1016 SLC2A2 0 0 0 0.9 1.3
1017 ALX1 0 0 0 0.6 0.8
1018 ATF6B 0 0 0 0.6 0.9
1019 PFKFB2 0 0 0 0.5 0.9
1020 TCF20 0 0 0 0.6 1.1
1021 RAB7A 0 0 0 0.8 1.2
1022 SCGB1A1 0 0 0 0.4 0.9
1023 KIF2A 0 0 0 0.7 1.2
1024 RPL6 0 0 0 1 1.8
1025 AGAP2 0 0 0 1 1.5
1026 ZBTB48 0 0 0 0.9 1.3
1027 TLK2 0 0 0 0.7 1.2
1028 SLC39A7 0 0 0 1.2 2.2
1029 EFR3A 0 0 0 0.7 1
1030 FKBP1B 0 0 0 1 1.5
1031 PON1 0 0 0 1 1.6
1032 VHL 0 0 0 0.9 1.5
1033 CHP 0 0 0 1 1.9
1034 CYP51A1 0 0 0 0.4 1
1035 SRRD 0 0 0 0.6 1
1036 RCAN1 0 0 0 0.7 1.2
1037 SNRNP35 0 0 0 0.8 1.1
1038 RPS7 0 0 0 0.7 1.1
1039 HOXA9 0 0 0 0.6 1
1040 MUC5B 0 0 0 0.8 1.3
1041 KIAA0146 0 0 0 0.6 1.1
1042 EEF1G 0 0 0 0.7 1.1
1043 POLD3 0 0 0 0.7 1.2
1044 THRSP 0 0 0 1 1.5
1045 AKAP9 0 0 0 0.8 1.2
1046 HTT 0 0 0 1.1 1.7
1047 SFRS11 0 0 0 0.8 1.5
1048 FTSJD2 0 0 0 1 1.4
1049 PDCD11 0 0 0 0.8 1.1
7.4. Conclusion
of the pathways included, while some are strongly enriched with a very small p-value. This
strongly suggests that the modules formed by our empirical Bayes method are biologically
relevant.
Finally we also compared our list of differentially expressed genes found in the analysis of
Section 5.4, with genes included in differentially expressed modules, which revealed that
most of the differentially expressed genes are included in differentially expressed modules.
However, differentially expressed genes tend to be distributed among the modules rather than
all grouped in one module.
7.4 Conclusion
In this chapter we developed methods for the automatic selection of gene modules. From the
common correlation matrix estimated in Section 6.4, we identified scattered genes by fitting
a mixture of generalized Pareto distributions to the tail of the distribution of − log(Tθ,var), a
method which seems to work well in our simulations, but does not detect many genes in
the real data application. Using standard hierarchical clustering methods, we could easily
identify modules, and simulations showed that our method was equivalent to or better than
competitors. Application to our set of real data also showed promising results. First, the
computational time is drastically reduced, which makes the Bayesian meta-analysis easier and
more practical to use. The assumptions underlying the model are satisfied and convergence of
the MCMC algorithm occurs more rapidly. We found that many differentially expressed genes
found in Section 5.4 were retrieved in the module analysis, and most of the modules detected
as being differentially expressed are enriched in some biological pathway. The only part of
the method which is not automatic yet is the choice of the number of clusters or modules. In
simulations where the number of modules was usually small, we could use the GAP statistic,
but this method failed on real data and was too computationally intensive.
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Table 7.10 – Enrichment analysis of the differentially expressed modules and scattered genes,
in terms of the GO, KEGG, Reactome and Biocarta pathways from the MSig database. The
p-values are obtained from Fisher’s exact test and only the most enriched pathway is presented
for each module.
Rank Module ID p-value pathway
1 176 1.03e-21 cell cycle process
2 48 1.4e-03 KEGG melanoma
3 274 9.59e-15 cell cycle process
4 129 3.84e-03 sexual reproduction
5 5 4.36e-04 substrate specific channel activity
6 255 1.3e-05 extracellular matrix part
7 92 3.39e-06 actin binding
8 137 6.35e-05 KEGG tgf beta signaling pathway
9 221 3.25e-04 protein kinase regulator activity
10 40 1.96e-04 Reactome ncam signaling for neurite out growth
11 161 1.07e-03 cell projection
12 279 1.61e-03 Reactome peptide ligand binding receptors
13 27 2.07e-07 Reactome cell cell junction organization
14 322 2.16e-03 inorganic cation transmembrane transporter activity
15 74 6.18e-05 organ morphogenesis
16 39 3.22e-06 KEGG complement and coagulation cascades
17 241 1.33e-04 KEGG vascular smooth muscle contraction
18 337 1.77e-03 chromatin assembly
19 273 2.2e-03 regulation of g protein coupled receptor protein signaling pathway
20 242 3.73e-03 lipid raft
21 117 1.5e-02 KEGG small cell lung cancer
22 145 5.66e-03 activation of mapk activity
23 67 1.73e-03 Reactome g alpha z signalling events
24 138 2.3e-06 Reactome biological oxidations
25 146 1.96e-03 Reactome adherens junctions interactions
26 317 2.4e-02 KEGG cell adhesion molecules cams
27 438 3.52e-02 Reactome adherens junctions interactions
28 165 7.79e-03 Biocarta par1 pathway
29 303 1.78e-04 Reactome sphingolipid metabolism
30 257 2.76e-04 calcium ion binding
31 86 3.52e-02 mitochondrial part
33 307 2.44e-25 Reactome interferon signaling
36 14 5.3e-03 peptide binding
38 240 1.02e-11 Reactome DNA replication
39 459 5.47e-04 Reactome striated muscle contraction
43 201 2.36e-04 RNA polymerase ii transcription factor activity
44 75 3.69e-04 response to other organism
45 180 6.69e-05 Reactome toll receptor cascades
48 366 2.47e-02 sarcomere
52 51 6.45e-04 microtubule associated complex
56 321 2.54e-08 Reactome smooth muscle contraction
60 9 2.6e-03 lipid biosynthetic process
61 295 9.47e-05 KEGG gap junction
63 208 2.91e-03 Reactome signaling by ils
64 6 5.32e-03 protein amino acid dephosphorylation
65 3 5.62e-03 lyase activity
67 356 3.25e-03 Reactome pi3k cascade
69 289 1.77e-03 KEGG amino sugar and nucleotide sugar metabolism
70 172 9.96e-03 KEGG pyrimidine metabolism
76 143 3.72e-08 positive regulation of signal transduction
81 407 3.52e-02 Reactome nrage signals death through jnk
83 57 9.76e-06 RNA processing
84 83 1.71e-04 icosanoid metabolic process
85 368 2.51e-05 magnesium ion binding
86 100 3.39e-03 transcription corepressor activity
87 205 1.47e-03 g protein signaling coupled to cyclic nucleotide second messenger
89 32 1.26e-04 amino acid catabolic process
90 401 6.89e-04 positive regulation of cell differentiation
93 126 4.71e-03 damaged DNA binding
- scattered 2.36e-03 response to other organism
8 Conclusion and Discussion
This thesis highlighted the need for a model to combine heterogeneous types of microarray
data. When only a few studies about the question of interest are published, and even fewer
make raw data accessible, it is useful to be able to use all the information available. Our
hierarchical Bayesian model, either applied to genes or modules, allows integration of vari-
ous types of study results, avoiding loss of information, which is common when performing
meta-analysis or list aggregation, while maintaining or even increasing the power of detection
of differentially expressed genes. Our model is adaptive, but is not heavily influenced by the
choice of the hyperparameters. Choosing priors that shrink the parameters of interest close to
zero for uninteresting genes aids the detection of the differentially expressed genes, contribut-
ing to the high power of our approach. Comparisons of our procedure with existing methods
show a clear increase in the number of correctly identified genes and strong control of false
positives. The gain of power from including all possible studies is highly significant. Moreover,
the simulation design used in this thesis is intended to be realistic: it was constructed to mimic
real microarray data; this reinforces the strength of our results, and suggests that our model
should be efficient for real data. We emphasize that our simulations were performed from an
independent design and not from our model, which is not favored in the simulations.
Application to meta-analysis of 11 real datasets shows promising results by retrieving many
genes known to be involved in ovarian cancer and showing significant enrichment, while
being robust to false positive housekeeping genes. The criterion for detection of differential
expression is a simple thresholding rule which is easy to apply using the posterior output.
An important advantage is the absence of multiplicity correction, unlike that needed in the
frequentist approach.
One drawback of our model is its large computational requirements. It is infeasible to fit
the model to the union of all genes from all studies, so gene selection was essential in the
application of Chapter 5. Even if our gene selection is not based on differential expression,
we might discard important genes. Including only the best candidate genes is unrealistic and
is not appropriate for the chosen priors, which require the inclusion of a large proportion of
uninteresting genes. The real data example of Chapter 5 performs gene selection independent
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of the model, as we only select genes corresponding to unions or intersections of groups of
genes.
In this work, all studies contribute equally to the model and to the detection of differentially
expressed genes. However, one might have more confidence in full studies, for example, where
the analysis and preprocessing steps are entirely reproducible, rather than in lists of interesting
genes that are not reproducible. We could easily associate weights to each of the studies to be
combined, reflecting prior confidence in each. Another way of improving the computations
would be to use an empirical Bayes approach rather than a purely Bayesian one. Obtaining
the posterior densities of each data types given the parameter γ is only possible in closed form
for Types 1, 2 and 3 (full studies and z-scores), the posterior densities for the ranks given γ
involving an intractable integral. However, one could imagine estimating the hyperparameters
from the three first types of studies, using maximum likelihood estimation, and estimating
the integral in the posterior density of the ranks by Laplace approximation. Because of
the large amount of data available, we believe that the estimation of the hyperparameters
would be quite accurate. The entire process should not be too computationally intensive and
would drastically reduce the computational time required by our MCMC version. Another
necessary assumption that we made concerned the missing values in the Type 1 data, which
we suppose to be missing at random. Missing values being usually due to technical problems,
the assumption seems reasonable. Moreover, it would make the modeling of these data more
complicated, or even impossible, if it was not the case.
In the first part of this thesis, we also assumed that genes are independent, which is not true
in practice, though it is a common assumption in the literature, even for single study analysis.
Correlations between the genes are included in the simulation design, and do not seem to
affect the efficiency of the model. However we believe our procedure would perform even
better if the elements on which it is applied are independent. We thus define modules, sets
of genes that are correlated or related in some sense, by noticing that genes belonging to the
same modules have correlated expression. Using an empirical Bayes model, we estimate a
correlation matrix common to all studies for which gene expression matrix is available. Even if
this matrix is close to the truth, it is not a correlation matrix per se, as it is not positive definite.
We did not need positive definiteness in this work, as the matrix was to be used as input to
a hierarchical clustering method. However, it may be possible to impose conditions on the
estimates to obtain this property.
With a common correlation matrix thus obtained, we could apply standard hierarchical
clustering methods to define modules. The procedure that we defined is particularly attractive
due to its simplicity. The empirical Bayes model has only a few parameters, and an explicit
expression for the likelihood allows the estimation of the hyperparameters. The posterior
median can be obtained explicitly, without resorting to MCMC methods, which resulted in a
sparse matrix by performing soft thresholding, thus helping module definition. We did not
look at the theoretical properties of our estimator, in terms of risk for example. However, the
posterior median was shown to have good properties by Johnstone and Silverman (2005) in
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the context of curve estimation using wavelets. Similar theoretical results could be obtained
for our method.
The entire process for defining modules is very fast, and could therefore easily be applied as a
preprocessing step in every microarray data analysis. In this work, we did not discuss negative
correlation. Langfelder et al. (2013) consider signed networks, where negatively correlated
variables are unconnected, and unsigned networks where the strongly negatively correlated
variables are highly related. We assume that negatively correlated genes should belong to
different clusters. Indeed, if two genes are negatively correlated, it means they have opposite
effect on the response of interest, and therefore it does not make any sense to cluster them
together when studying differential expression of modules. However, as a result, we obtain
modules that are not uncorrelated, by possibly having a negative correlation.
We also developed a simple method to identify scattered genes, using extreme-value theory.
This method was shown to be very robust to false positives, even if the number of true positives
was a bit low. Since we would rather not discard genes that might prove to be important, it is
better for our method to have high sensitivity rather than high specificity; accidently adding
scattered genes to modules is less problematic than incorrectly declaring genes to be scattered.
Even if the procedure seems to perform well in simulations, application to real data detects
only very few scattered genes, which indicates that we probably miss many scattered genes.
We also tried another version of the method, where we fitted a mixture of GPD with different
shape parameters, but this led to instability of the estimates and of identified scattered genes,
and gave results that did not seem to be accurate. Using only one shape parameter common
to the two distributions helps the estimation of the parameters, but seems too stringent.
We illustrate by simulations that even if it is very simple, our entire method, comprising
the empirical Bayes model, the identification of scattered genes, and hierarchical clustering
to define modules, can equal or surpass competing methods by retrieving modules more
accurately. This performance was measured in terms of the Rand index in several simulation
studies.
Our method is therefore almost entirely automatic, except for the choice of the optimal
number of clusters. Finding the optimal number of clusters has been considered and some
solutions exist (Dudoit and Fridlyand, 2002; Tibshirani et al., 2001; Monti et al., 2003), usually
based on resampling. These methods work well when one wants to cluster a few objects,
such as cancer subtypes in microarray gene expression data. However, when it comes to gene
clustering, the resampling part becomes computationally expensive and the methods tend to
have very low power, as noticed by Thalamuthu et al. (2006). Indeed, to be able to identify the
optimal number of clusters of G genes, with G of the order of thousands, one needs to perform
hierarchical clustering B times for a number of clusters k going from 1 to G . Moreover, B must
be large to obtain p-values with sufficient precision, hence its intractability. In this work we
choose the number of modules arbitrarily to obtain modules of reasonable size, but being
able to select the optimal number of clusters automatically is certainly a very interesting topic
for future research.
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Automatic module detection on real data was very fast. The hierarchical Bayes model devel-
oped in Chapter 3 was then applied on the module set plus some scattered genes. All genes
coming from Types 2, 3 and 4 studies that were not present in modules had to be included as
scattered genes, as we have no way of knowing whether they could be correlated with other
genes based on the information that we have, i.e. z-scores or ranks. This is another argument
in favor of making raw data available. Enrichment analysis of the differentially expressed
modules showed statistical significance, indicating that the modules automatically defined
were biologically meaningful. Moreover, fitting the model to the module set is much faster
than on the gene set and does not require gene selection. We also noticed that with a smaller
set of objects, latent variables for modeling the ranks tend to be less correlated and therefore
we did not need to run that part of the algorithm more than the rest to obtain acceptable
correlation between the draws, which further reduced the computational time.
Other ideas for further development include a more powerful method to test for the equality of
covariance matrices. Indeed, we saw in Chapter 6 that existing methods have very low power
when the sample size is small, even when the number of variables is smaller than the number
of samples.
Concerning applications to real data, and more particularly to ovarian cancer data, there are
some more interesting questions we could look at. In our real data application, we compared
serous ovarian cancer patients with healthy subjects. We did not separate the patients having
different characteristics, like different cancer grades. An interesting application could be to
compare grade 1 and grade 3 patients. In this case, according to recent knowledge, the type of
healthy tissue matters in the comparison. Therefore, it would be more informative to compare
grade 1 patients with healthy tissues from the ovary and grade 3 patients with healthy tissues
from tube. The control group was also selected as a whole. It could be interesting to make
a comparison of two groups of healthy subjects, to see whether there really is no difference
between them. This question is especially important in ovarian cancer studies. Indeed the
procedure to get healthy samples being so invasive, one can wonder why the patient undertook
such surgery in the first place, meaning she certainly has no ovarian cancer but probably has
another disease, which is not recorded, but may change gene expression of the tissue collected.
The genes or modules found in our analyses could be used to build a prediction model which
would help to classify individuals into the cancer or the control groups. This model would be
very useful to make a first, less invasive, selection of potential women at risk of ovarian cancer,
before undergoing surgery.
Finally, we make some comments concerning development of tools to facilitate microarray
gene expression data analysis. When performing gene set enrichment analysis, we noticed
that there exist a lot of different methods and databases. A guide to enrichment analysis
similar to the one published by Irizarry et al. (2009), but for all types of results that one can
obtain through an analysis of gene differential expression, would be very useful. Consensus for
publication concerning enrichment analysis would also be useful. Development of packages
such as the curatedOvarianData R package (Ganzfried et al., 2013), regularly updated, with
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preprocessed and normalized datasets, for every type of cancer, would greatly simplify the
search for studies to include in meta-analyses. With results from this thesis in mind, such
packages could also include published lists of differentially expressed genes and not just raw
data or gene expression data.
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A Appendix
A.1 Computation of the posterior densities
In this section, we present the details of the calculations needed to obtain the posterior
densities of the model parameters. We suppose we have Li studies of type i . For simplicity,
superscripts indicating the study or its type will be omitted in the calculations when not
necessary. In what follows, pi(·) denotes prior densities, whereas, pi(· | ·) denotes the posterior.
A.1.1 Realisations of pi
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A.1.2 Realisations of pi
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A.1.3 Realisations of pi
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−(zg −βg
√
δ2gν)
2
2

∝ exp

−β2g +2βgγg −γ2g − z2gσ2β+2zgβgσ2β
√
δ2gν−β2gσ2βδ2gν
2σ2
β

∝ exp

−β2g (1+δ2gνσ2β)+2βg (γg + zgσ2β
√
δ2gν)
2σ2
β

∼N
γg + zgσ2β
√
δ2gν
1+δ2gνσ2β
,
σ2
β
1+δ2gνσ2β

The calculations are the same for β(3)g .
A.1.4 Realisations of pi
(
β(4)g | rest
)
pi(β(4)g | rest)∝pi(βg | γg ,σ2β)pi(ug |βg ,σ2u,g )
∝ exp
{
−(βg −γg )2
2σ2
β
− (ug −βg
p
ν)2
2σ2u,g
}
∝ exp
{−β2g (σ2u,g +σ2βν)+2βg (γgσ2u,g +ugσ2βpν)
2σ2
β
σ2u,g
}
∼N
(
γgσ
2
u,g +ugσ2β
p
ν
σ2u,g +νσ2β
,
σ2
β
σ2u,g
σ2u,g +σ2βν
)
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A.1.5 Realisations of pi
(
ug | rest
)
We have
pi(ug | rest)∝pi(Rg | ug−1,ug ,ug+1)pi(ug |β(4)g ,σ2u,g )
∝ I{|ug+1|<|ug |<|ug−1|} exp
{
−(ug −βg
p
ν)2
2σ2u,g
}
∼N |ug−1||ug+1|
(
βg
p
ν,σ2u,g
)
,
whereN ab corresponds to a truncated normal between a and b. To generate from the trun-
cated normal, we first center and scale the random variable ug , and obtain
Zg =
ug −β(4)g
p
ν
σu,g
, z+ =
ug−1−β(4)g
p
ν
σu,g
, z− =
ug+1−β(4)g
p
ν
σu,g
.
Then
α= P (Z ≤ z | z− < z < z+)
= P (Z ≤ z, z
− < z < z+)
P (z− < z < z+)
= P (z
− < Z < z)
Φ(z+)−Φ(z−)
= Φ(z)−Φ(z
−)
Φ(z+)−Φ(z−) .
Therefore, z =Φ−1 [α{Φ(z+)−Φ(z−)}+Φ(z−)], and thus,
ug =Φ−1
[
α
{
Φ(z+)−Φ(z−)}+Φ(z−)]σu +β(4)g pν,
where α ∼U (0,1). The calculations here are for a positive ug , the negative version being
similar. As the sign of u is not observed and interest only lies in the expected value of this
variable, we fix the sign of ug to be the same that of the corresponding β
(4)
g .
A.1.6 Realisations of pi
(
σ−2u,g | rest
)
pi(σ−2u,g | rest)∝pi(σ−2u,g | d1,d2)pi(ug |βg ,σ−2u,g )
∼Gamma
(
d1+ 1
2
,d2+
(ug −βg
p
ν)2
2
)
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A.1.7 Realisations of pi
(
σ−2
β
| rest
)
pi(σ−2β | rest)∝pi(σ−2β | e1,e2)
p∏
g=1
L∏
l=1
pi(β(l )g | γg ,σ−2β )
∝ (σ−2β )e1−1e−σ
−2
β
e2
p∏
g=1
L∏
l=1
exp
−(β
(l )
g −γg )2σ−2β
2
(√σ−2β )pL
∼Gamma
(
e1+ pL
2
,e2+
p∑
g=1
L∑
l=1
(β(l )g −γg )2
2
)
A.1.8 Posterior densities for the spike and slab prior
Realisations of pi (α | rest)
pi(α | rest)∝pi(α)
p∏
g=1
pi(cg | c?,α)
∝
p∏
g=1
(1−α)δc? +αδ1
∝ (1−α)#{g :cg=c?}α#{g :cg=1}
∼Beta(1+#{g : cg = 1},1+#{g : cg = c?})
Realisations of pi(cg | rest)
We have
pi(cg | rest)∝pi(cg | c?,α)pi(γg | cg )
∝ {(1−α)δc? +αδ1}
1p
cg
exp
( −γ2g
2cgτ2g
)
.
We define the following quantities:
w1,g = 1−αp
c?
exp
( −γ2g
2c?τ2g
)
, w2,g =αexp
(−γ2g
2τ2g
)
,
then
cg | rest∼
w1,g
wg ,1+wg ,2
δc? +
w2,g
w1,g +w2,g
δ1.
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Realisations of pi(τ−2g | rest)
pi(τ−2g | rest)∝pi(τ−2g | a1, a2)pi(γg | cg ,τ−2g )
∝ (τ−2g )a1−1e−τ
−2
g a2
√
τ−2g e
− γ
2
g τ
−2
g
2cg
∼Gamma
(
a1+1/2, a2+
γ2g
2cg
)
Realisations of pi(γg | rest)
pi
(
γg | rest
)∝pi(γg | cg ,τ2g ) L∏
l=1
pi
(
β(l )g | γg ,σ2β
)
∝ exp
{ −γ2g
2cgτ2g
}
exp

−∑Ll=1 (β(l )g −γg )2
2σ2
β

∝ exp
−γ
2
g
(
Lcgτ2g +σ2β
)
+2γg
(∑L
l=1β
(l )
g cgτ
2
g
)
2σ2
β
cgτ2g

∼N
(∑L
l=1β
(l )
g cgτ
2
g
Lcgτ2g +σ2β
,
σ2
β
cgτ2g
Lcgτ2g +σ2β
)
A.1.9 Posterior densities for the horseshoe prior
Realisations of pi(γg | rest)
pi(γg | rest)∝
L∏
l=1
pi(β(l )g | γg ,σ2β)pi(γg |λ2g ,τ2)
∝
L∏
l=1
exp
{−(γg −β(l )g )2
2σ2
β
}
exp
{ −γ2g
2λ2gτ2
}
∝ exp
−γ
2
g (Lλ
2
gτ
2+σ2
β
)+2γg ∑Ll=1β(l )g λ2gτ2
2σ2
β
λ2gτ
2

∼N
(∑L
l=1β
(l )
g λ
2
gτ
2
Lλ2gτ2+σ2β
,
σ2
β
λ2gτ
2
σ2
β
+Lλ2gτ2
)
Realisations of pi(λg | rest)
pi(λg | rest)∝pi(γg |λg ,τ)pi(λg )∝ 1
λgτ
exp
{ −γ2g
2λ2gτ2
}
1
1+λ2g
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It seems difficult to sample from this posterior distribution. Therefore, we follow the algorithm
described in Scott (2011), which was adapted from the method described in Damien (1999).
We first define
ηg = 1
λ2g
, ϕg =
γg
τ
.
We can now compute the posterior distribution of ηg ,
pi(ηg |ϕg )∝ exp
(−ϕ2gηg
2
)
1
1+ηg
.
Then the algorithm is:
• sample ug ∼U (0,1/(1+ηg ));
• generate ηg ∼ E(ϕ2g /2), truncated to have 0 probability outside the interval
[
0,
1−ug
ug
]
;
• transform back to the λ-scale to obtain a sample from the desired posterior distribution:
λg =
√
1/ηg .
In order to sample from a truncated exponential distribution, we first denote u+ = (1−ug )/ug
and omitting the subscript g ,
α= P (η< x | η< u+)= P (η< x)
P (η< u+) =
1−exp(−ϕ2x/2)
1−exp(−u+ϕ2/2) ,
x = −2
ϕ2
log
[
1−α
{
1−exp
(−ϕ2u+
2
)}]
,
where α∼U (0,1).
Realisations of pi(τ | rest)
In order to generate from the posterior distribution of τ, we will use a similar algorithm to that
used in Section A.1.9,
pi(τ |λ,γ)∝pi(τ)
p∏
g=1
pi(γg |λg ,τ)
∝ 1
1+τ2
p∏
g=1
1
λgτ
exp
( −γ2g
2λ2gτ2
)
∝ 1
(1+τ2)τp exp
(
−1
2τ2
p∑
g=1
γ2g
λ2g
)
.
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We now define the following quantities, inspired by the algorithm proposed by Scott (2011),
η= 1
τ2
,
dτ
dη
=
p
η
η2
ϕ=
p∑
g=1
γ2g
λ2g
.
We therefore obtain
pi(η |ϕ)∝ 1
1+ηη
p−1
2 exp(−ηϕ/2).
The algorithm is then
• sample u ∼U (0,1/(1+η));
• generate η ∼ Gamma((p+1)/2,ϕ/2), truncated to have probability 0 outside [0,(1−
u)/u];
• transform back to the τ-scale, by τ=√1/η.
If F (x; a,b) denotes the distribution function of a Gamma distribution evaluated at x, with
shape and rate parameters a and b, then sampling from a truncated Gamma is done as follows:
x = F−1
[
αF
(
u+;
p+1
2
,
ϕ
2
)
;
p+1
2
,
ϕ
2
]
, α∼U (0,1), u+ = 1−u
u
.
A.1.10 Posterior densities for the normal-gamma prior
Realisations of pi
(
γg | rest
)
pi(γg | rest)∝
L∏
l=1
pi(β(l )g | γg ,σ2β)pi(γg |ψg )
∝ exp
{−∑Ll=1(γg −β(l )g )2
2σ2
β
−
γ2g
2ψg
}
∼N
(∑L
l=1β
(l )
g ψg
Lψg +σ2β
,
σ2
β
ψg
Lψg +σ2β
)
149
Appendix A. Appendix
Realisations of pi
(
ψg | rest
)
We have
pi(ψg | rest)∝pi(ψg |λ,τ)pi(γg |ψg )
∝ 1√
2piψg
exp
(−γ2g
2ψg
)
ψλ−1g exp
(−ψg
τ
)
∼G IG
(
λ− 1
2
,
1
τ2
,γ2g
)
,
where
G IG(λ,ψ,χ)= (ψ/χ)
λ/2
2Kλ(
p
ψχ)
xλ−1 exp
{
−1
2
(
ψx+ χ
x
)}
,
and Kλ is the modified Bessel function of the third kind and the parameters satisfy one of the
conditions
λ> 0,ψ> 0, χ≥ 0,
λ= 0,ψ> 0, χ> 0,
λ< 0,ψ≥ 0, χ> 0.
If parameters are close to zero, limiting distributions can be used (Eberlein and Hammerstein,
2004):
• if λ> 0, ψ> 0 but χ= 0 or is close to zero, then a gamma distribution, Gamma(λ,ψ/2),
can be used instead of the generalized inverse Gaussian;
• if λ < 0, χ > 0 but ψ = 0 or is close to zero, then the inverse gamma distribution,
IG(−λ,χ/2), can be used instead of the generalized inverse Gaussian.
So, using our parameters, we obtain the following cases:
• if λ> 1/2, 1/τ2 > 0, β2g = 0, ψg | rest∼Gamma
(
λ− 12 , 12τ2
)
;
• if λ< 0, β2g > 0 and 1/τ2 = 0, then ψg | rest∼ IG
(
−λ+ 12 ,
β2g
2
)
.
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Realisation of pi(λ | rest)
Now
pi(λ | rest)∝pi(λ)
p∏
g=1
pi(ψg |λ)
∝ e−λ
p∏
g=1
(
ψλ−1g
(2τ2)λΓ(λ)
)
∝ e−λ
(
p∏
g=1
ψg
)λ−1 [
(2τ2)λΓ(λ)
]−p
.
As this distribution does not have a recognizable form, we use Metropolis–Hastings step to
generate from it. We put a random walk update on logλ leading to the proposal
λ′ = exp{σ2λz}λ,
where z is generated from a standard normal distribution, and σλ is chosen so that the overall
acceptance probability is about 30% in average. The corresponding τ′ can be taken to be
τ′ =
√
2λτ2/(2λ′). Then the acceptance probability is given by
α=min
1,e−λ′+λ ( p∏
g=1
ψ
)λ′−λ (
Γ(λ)
Γ(λ′)
)p (2τ2)pλ
(2τ′2)pλ′
λ′
λ
exp
{
p∑
g=1
ψg
(
1
2τ2
− 1
2τ2
)} ,
and
log(α)= (λ′−λ)
[
−1+
p∑
g=1
logψg
]
+ (logλ′− logλ)+p(logΓ(λ)− logΓ(λ′))
+pλ log(2τ2)−λ′p log(2τ′2)+
p∑
g=1
ψg
(
1
2τ2
− 1
2τ′2
)
.
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Realisation of pi(τ2 | rest)
pi(τ−2 | rest)∝
p∏
g=1
pi(ψg |λ,τ−2)pi(τ−2)
∝ τ−2 exp
{
−τ
−2M
2λ
} p∏
g=1
(
τ−2
2
)λ
exp
{
−ψgτ
−2
2
}
∝ (τ−2)2+λp−1 exp{−τ−2 (M
2λ
+
p∑
g=1
ψg
2
)}
∼Gamma
(
2+λp, M
2λ
+
p∑
g=1
ψg
2
)
A.2 Complete results for the real data analysis
In Section 5.4, we only provide the list of the top 100 differentially expressed genes identified
by our analysis. In this section, we give the complete list of all 296 differentially expressed
genes, sorted according to the parameter ŵ , the posterior mean of w . Tables A.2 and A.3
give the mean and standard deviation of the posterior mean of the parameters w , indicating
differential expression, and γ, giving information about the direction of the differentials, for
each gene.
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Table A.1 – List of the top 100 differentially expressed genes. Genes are ordered according to
the value of ŵ , from the most to the least differentially expressed genes. The estimates ŵ are
obtained from the fit of our model to the 11 studies selected for the analysis, γ̂ indicates the
magnitude and the direction of the differential expression. Genes in bold are known to be
involved in ovarian cancer.
Rank Genes ŵ sd(ŵ) γ̂ sd(γ̂)
1 CP 0.99 < 10−2 3.07 0.38
2 TOP2A 0.99 < 10−2 2.60 0.38
3 BCHE 0.99 0.01 -2.49 0.41
4 NEK2 0.99 0.01 2.48 0.38
5 TTK 0.99 0.01 2.48 0.38
6 CENPA 0.99 0.02 2.45 0.38
7 SPP1 0.99 0.02 2.31 0.39
8 MELK 0.99 0.02 2.35 0.39
9 PRAME 0.99 0.02 2.41 0.39
10 ADH1B 0.99 0.02 -2.33 0.41
11 KIAA0101 0.99 0.02 2.41 0.40
12 NMU 0.99 0.02 2.30 0.39
13 IGFBP6 0.99 0.03 -2.22 0.39
14 KLK6 0.99 0.02 2.24 0.39
15 EVI1 0.99 0.01 2.67 0.45
16 CLDN3 0.99 0.02 2.38 0.41
17 SST 0.99 0.02 2.27 0.41
18 FOLR1 0.99 0.03 2.22 0.39
19 WFDC2 0.99 0.03 2.30 0.40
20 UBE2C 0.99 0.03 2.22 0.38
21 CD24 0.99 0.03 2.47 0.45
22 HMGA2 0.99 0.04 2.21 0.43
23 SPARCL1 0.99 0.04 -2.00 0.38
24 KIF2C 0.99 0.04 2.08 0.40
25 ELF3 0.99 0.05 2.11 0.41
26 MAL 0.99 0.05 2.07 0.42
27 CDKN2A 0.98 0.05 2.09 0.41
28 PAX8 0.98 0.05 2.05 0.41
29 FOXM1 0.98 0.05 2.05 0.40
30 CENPF 0.98 0.06 2.02 0.40
31 TNNT1 0.98 0.06 2.01 0.42
32 CLDN4 0.98 0.06 2.05 0.42
33 HMMR 0.98 0.07 1.99 0.42
34 LCT 0.98 0.07 1.94 0.41
35 KIF11 0.98 0.07 1.92 0.41
36 TRIM31 0.98 0.08 1.92 0.43
37 CDC20 0.98 0.08 1.88 0.42
38 TACSTD1 0.98 0.08 2.61 0.63
39 CCNB1 0.97 0.09 1.87 0.44
40 PTTG1 0.97 0.10 1.93 0.48
41 PRSS8 0.97 0.10 1.87 0.46
42 CCNE1 0.97 0.11 1.80 0.45
43 RRM2 0.96 0.11 1.84 0.47
44 EHF 0.96 0.11 1.90 0.48
45 S100A1 0.96 0.11 1.82 0.47
46 ATP6V1B1 0.95 0.13 1.75 0.50
47 KLK7 0.95 0.13 1.72 0.48
48 ABCA8 0.95 0.13 -1.77 0.49
49 ALDH1A1 0.95 0.13 -1.70 0.47
50 SCNN1A 0.94 0.14 1.73 0.51
Rank Genes ŵ sd(ŵ) γ̂ sd(γ̂)
51 C7 0.94 0.14 -1.69 0.52
52 PDHA2 0.94 0.15 1.70 0.52
53 ANXA8 0.94 0.17 2.22 0.74
54 GLDC 0.94 0.15 1.66 0.49
55 LAMP3 0.94 0.16 1.72 0.54
56 KRT7 0.93 0.16 1.57 0.50
57 CKS2 0.93 0.16 1.61 0.50
58 AOX1 0.93 0.16 -1.63 0.53
59 EZH2 0.93 0.16 1.60 0.49
60 MYH11 0.93 0.16 -1.63 0.51
61 NY-REN-7 0.92 0.20 2.41 0.94
62 CCNA2 0.91 0.18 1.51 0.53
63 TK1 0.91 0.18 1.50 0.52
64 MAD2L1 0.91 0.18 1.51 0.54
65 ACTG2 0.91 0.18 -1.53 0.56
66 SCGB2A1 0.91 0.19 1.65 0.64
67 MUC1 0.90 0.19 1.52 0.57
68 SLC2A1 0.90 0.19 1.46 0.53
69 SULT1C2 0.89 0.20 1.47 0.57
70 MGP 0.87 0.21 -1.37 0.55
71 THBD 0.87 0.21 -1.38 0.57
72 IGF2BP3 0.86 0.22 1.36 0.58
73 SPINT2 0.86 0.22 1.36 0.58
74 ZIC1 0.86 0.22 1.38 0.60
75 CGN 0.85 0.24 1.44 0.66
76 RNASE4 0.85 0.22 -1.31 0.57
77 EFEMP1 0.85 0.22 -1.33 0.60
78 APOA1 0.85 0.23 1.31 0.59
79 DXYS155E 0.84 0.28 2.22 1.21
80 TFAP2A 0.83 0.23 1.25 0.57
81 NDP52 0.83 0.29 2.21 1.27
82 FRY 0.82 0.24 -1.25 0.62
83 DEFB1 0.79 0.25 1.12 0.59
84 TYMS 0.79 0.25 1.12 0.56
85 GRPR 0.79 0.25 1.15 0.60
86 MYBL2 0.79 0.25 1.13 0.58
87 MAOB 0.79 0.25 -1.11 0.56
88 CNN1 0.77 0.25 -1.08 0.57
89 CLDN7 0.77 0.26 1.14 0.64
90 BLM 0.77 0.25 1.09 0.59
91 CXCL10 0.76 0.25 1.07 0.61
92 KIF23 0.76 0.25 1.04 0.56
93 KLF4 0.76 0.25 -1.03 0.56
94 CDKN3 0.75 0.26 1.03 0.57
95 HTR3A 0.75 0.25 1.02 0.57
96 EPCAM 0.75 0.27 1.09 0.67
97 GNG11 0.75 0.26 -1.01 0.55
98 KIF14 0.74 0.25 1.00 0.55
99 NDN 0.74 0.25 -0.99 0.54
100 RAD54L 0.74 0.25 0.98 0.55
Table A.2 – List of top 101-200 differentially expressed genes. Genes are ordered according to
the value of ŵ , from the most to the least differentially expressed genes. The estimates ŵ are
obtained from the fit of our model to the 11 studies selected for the analysis.
Rank Genes ŵ sd(ŵ) γ̂ sd(γ̂)
101 CBS 0.74 0.26 0.99 0.57
102 TROAP 0.74 0.25 0.96 0.55
103 FXYD3 0.74 0.26 1.01 0.60
104 DKFZP586A0522 0.74 0.33 1.60 1.14
105 KIAA1536 0.72 0.33 1.52 1.14
106 GPR19 0.72 0.26 0.93 0.55
107 SE20-4 0.72 0.33 1.65 1.28
108 SFN 0.71 0.26 0.92 0.55
109 ISG15 0.70 0.26 0.91 0.58
110 SLC6A6 0.70 0.26 0.91 0.57
111 MAS1 0.70 0.26 0.90 0.56
112 KRT2 0.70 0.26 0.89 0.55
113 ESPL1 0.70 0.26 0.89 0.53
114 CDH6 0.69 0.26 0.89 0.58
115 SLPI 0.69 0.26 0.86 0.57
116 TRIP13 0.68 0.25 0.83 0.52
117 DCN 0.67 0.27 -0.87 0.57
118 RXRG 0.66 0.25 0.78 0.51
119 GRM8 0.66 0.25 0.79 0.50
120 MTHFD2 0.66 0.25 0.78 0.51
121 FLJ13236 0.66 0.32 1.09 0.86
122 SPINT1 0.65 0.27 0.83 0.58
123 UCP2 0.65 0.25 0.76 0.52
124 TACSTD2 0.65 0.25 0.76 0.55
125 DES 0.65 0.25 -0.74 0.51
126 MAGEA1 0.64 0.25 0.75 0.50
127 MCM4 0.64 0.25 0.75 0.49
128 LMNB1 0.64 0.25 0.76 0.52
129 GIF 0.64 0.25 0.75 0.50
130 CPT1B 0.64 0.30 0.93 0.76
131 TACR3 0.64 0.25 0.73 0.48
132 LAD1 0.64 0.25 0.74 0.50
133 LCN2 0.63 0.25 0.71 0.49
134 ETV4 0.62 0.25 0.69 0.48
135 DLC1 0.62 0.26 -0.73 0.55
136 MAOA 0.62 0.24 -0.68 0.48
137 AQP5 0.62 0.24 0.68 0.48
138 S100A8 0.61 0.24 -0.67 0.50
139 CAV1 0.61 0.24 -0.68 0.46
140 GCG 0.61 0.24 0.66 0.43
141 HOXB1 0.61 0.24 0.66 0.48
142 CDC25C 0.60 0.24 0.66 0.47
143 HNF4A 0.60 0.24 0.65 0.45
144 MMP13 0.60 0.24 0.64 0.46
145 PLK1 0.60 0.24 0.65 0.44
146 PTGIS 0.60 0.25 -0.66 0.50
147 DHCR24 0.60 0.24 0.65 0.44
148 KIFC1 0.60 0.24 0.64 0.44
149 SOX17 0.60 0.26 0.69 0.55
150 C4A 0.60 0.34 1.06 1.01
Rank Genes ŵ sd(ŵ) γ̂ sd(γ̂)
151 DUSP1 0.60 0.24 -0.63 0.49
152 EPHA1 0.60 0.24 0.63 0.44
153 SPRR1B 0.60 0.24 0.64 0.44
154 CFD 0.60 0.24 -0.64 0.43
155 ID3 0.60 0.24 -0.63 0.49
156 CDH1 0.59 0.24 0.63 0.45
157 FHL1 0.59 0.23 -0.61 0.43
158 PHOX2B 0.59 0.23 0.61 0.43
159 BIK 0.59 0.23 0.61 0.44
160 GLP1R 0.59 0.23 0.63 0.45
161 GABRR1 0.59 0.23 0.61 0.43
162 MMP7 0.59 0.24 0.62 0.47
163 WNT7A 0.59 0.23 0.60 0.44
164 HIST1H2BG 0.58 0.28 0.69 0.59
165 LMOD1 0.58 0.23 -0.59 0.43
166 MYCL1 0.58 0.23 0.59 0.43
167 PNOC 0.58 0.23 0.59 0.45
168 SLC15A1 0.58 0.23 0.59 0.43
169 SCGB1D2 0.57 0.26 0.61 0.57
170 DSC2 0.57 0.23 0.58 0.41
171 PLAG1 0.57 0.23 0.58 0.43
172 CR1 0.57 0.22 0.58 0.41
173 ALDH1A3 0.57 0.23 -0.57 0.46
174 SLC10A1 0.57 0.23 0.58 0.41
175 NAP1L3 0.57 0.22 -0.58 0.42
176 MEP1B 0.57 0.22 0.57 0.40
177 IL9 0.57 0.22 0.57 0.42
178 CDC25A 0.56 0.22 0.57 0.42
179 SPOCK1 0.56 0.22 -0.55 0.41
180 CYP2A6 0.56 0.22 0.56 0.41
181 FLJ14957 0.56 0.34 0.98 1.05
182 MCM2 0.56 0.22 0.55 0.40
183 PROCR 0.56 0.22 -0.55 0.41
184 COL19A1 0.56 0.22 0.54 0.41
185 ALDH3B2 0.56 0.22 0.55 0.39
186 HTR1D 0.56 0.21 0.54 0.39
187 RUNX2 0.55 0.22 0.54 0.40
188 TRIM29 0.55 0.22 0.53 0.42
189 PLS1 0.55 0.22 0.53 0.40
190 RTN1 0.55 0.21 -0.53 0.39
191 MCF2 0.55 0.22 0.52 0.39
192 NR2F6 0.55 0.22 0.52 0.38
193 CCL20 0.55 0.21 0.52 0.40
194 CACNB4 0.55 0.21 0.51 0.38
195 NPY1R 0.55 0.21 -0.53 0.40
196 LAMA2 0.55 0.21 -0.52 0.38
197 PLN 0.55 0.21 -0.52 0.38
198 IDH2 0.55 0.22 0.51 0.40
199 MSLN 0.55 0.21 0.52 0.39
200 RGS1 0.55 0.22 0.52 0.45
Table A.3 – List of top 201-296 differentially expressed genes. Genes are ordered according to
the value of ŵ , from the most to the least differentially expressed genes. The estimates ŵ are
obtained from the fit of our model to the 11 studies selected for the analysis.
Rank Genes ŵ sd(ŵ) γ̂ sd(γ̂)
201 KIF1A 0.54 0.21 0.51 0.40
202 PCDH11X 0.54 0.21 0.52 0.38
203 GPM6A 0.54 0.21 -0.51 0.37
204 SIM2 0.54 0.21 0.50 0.40
205 TNNI3 0.54 0.21 0.51 0.38
206 CDC7 0.54 0.21 0.52 0.39
207 ERBB3 0.54 0.21 0.51 0.38
208 IFI27 0.54 0.21 0.51 0.40
209 MMP1 0.54 0.21 0.50 0.39
210 SDC2 0.54 0.21 -0.50 0.37
211 ELAVL2 0.54 0.21 0.50 0.38
212 EFG1 0.54 0.33 0.94 1.07
213 MPZ 0.54 0.20 0.50 0.38
214 CXCR4 0.54 0.21 0.48 0.41
215 DEFA4 0.54 0.21 0.50 0.37
216 RFC4 0.53 0.21 0.49 0.38
217 BMP2 0.53 0.20 -0.47 0.36
218 KLF2 0.53 0.22 -0.53 0.39
219 ZNF165 0.53 0.20 0.48 0.36
220 IFNA5 0.53 0.20 0.48 0.36
221 LOC286286 0.53 0.33 0.85 0.98
222 PLK4 0.53 0.20 0.47 0.35
223 ST14 0.53 0.20 0.46 0.35
224 CASR 0.53 0.20 0.46 0.37
225 HK2 0.52 0.20 0.46 0.37
226 EPS8 0.52 0.20 -0.47 0.36
227 E2F3 0.52 0.20 0.46 0.36
228 DDR1 0.52 0.20 0.46 0.36
229 SLC5A1 0.52 0.20 0.46 0.35
230 PGR 0.52 0.19 -0.46 0.35
231 CXCL11 0.52 0.21 0.46 0.37
232 PTH 0.52 0.20 0.45 0.35
233 AP1M2 0.52 0.22 0.49 0.39
234 GGH 0.52 0.20 0.46 0.35
235 NPPB 0.52 0.21 0.45 0.40
236 BAMBI 0.52 0.20 -0.46 0.36
237 SMPDL3B 0.52 0.20 0.47 0.35
238 TYRP1 0.52 0.20 0.45 0.34
239 EMP3 0.52 0.19 -0.46 0.32
240 DFNA5 0.52 0.22 -0.49 0.41
241 BCAT1 0.52 0.20 0.45 0.36
242 XDH 0.52 0.19 0.44 0.34
243 HIST1H1C 0.52 0.19 0.44 0.34
244 GNAT1 0.52 0.19 0.45 0.33
245 KIAA0222 0.52 0.32 0.82 0.95
246 APOD 0.52 0.20 -0.47 0.34
247 MAL2 0.52 0.24 0.54 0.46
248 FRMPD4 0.51 0.19 0.44 0.33
Rank Genes ŵ sd(ŵ) γ̂ sd(γ̂)
249 CRABP1 0.51 0.19 0.42 0.35
250 CHI3L1 0.51 0.22 0.48 0.45
251 COL4A6 0.51 0.19 -0.44 0.34
252 RAD51 0.51 0.19 0.46 0.35
253 SOX9 0.51 0.19 0.43 0.33
254 KRT23 0.51 0.22 0.48 0.41
255 TDO2 0.51 0.19 0.44 0.34
256 MCM7 0.51 0.19 0.43 0.32
257 TACR1 0.51 0.19 0.44 0.33
258 GRB7 0.51 0.19 0.42 0.32
259 HTR2C 0.51 0.19 0.43 0.32
260 AVPR1B 0.51 0.19 0.44 0.32
261 CD302 0.51 0.19 -0.43 0.32
262 GEM 0.51 0.19 -0.43 0.34
263 ANKRD1 0.51 0.18 0.42 0.32
264 MEST 0.51 0.19 0.42 0.33
265 MFAP4 0.51 0.19 -0.43 0.33
266 UGT8 0.51 0.19 0.42 0.35
267 CHRNB4 0.51 0.18 0.43 0.31
268 KRT19 0.51 0.23 0.52 0.44
269 CDKL5 0.51 0.19 0.43 0.32
270 AOC3 0.51 0.19 -0.42 0.34
271 NBEA 0.51 0.21 -0.47 0.36
272 KLK10 0.51 0.21 0.44 0.39
273 CSN2 0.51 0.18 0.42 0.31
274 APOF 0.51 0.19 0.42 0.34
275 PRKX 0.51 0.18 0.42 0.30
276 CHRM5 0.51 0.19 0.42 0.32
277 ABO 0.50 0.18 0.42 0.33
278 PAX3 0.50 0.18 0.41 0.33
279 PAFAH1B3 0.50 0.19 0.42 0.32
280 ARHI 0.50 0.32 0.78 0.95
281 JAK3 0.50 0.18 0.42 0.31
282 EPHA5 0.50 0.18 0.43 0.31
283 SIX1 0.50 0.19 0.39 0.33
284 CXADR 0.50 0.18 0.40 0.33
285 ITGB8 0.50 0.18 0.41 0.32
286 NPPA 0.50 0.18 0.39 0.33
287 MC4R 0.50 0.19 0.40 0.32
288 PRSS1 0.50 0.18 0.41 0.32
289 SCGB2A2 0.50 0.19 0.42 0.33
290 GNAO1 0.50 0.18 0.41 0.30
291 NT5E 0.50 0.18 -0.40 0.32
292 PRKCI 0.50 0.18 0.41 0.31
293 EDN2 0.50 0.18 0.41 0.31
294 E2F1 0.50 0.18 0.41 0.32
295 RAG1 0.50 0.19 0.41 0.33
296 CKM 0.50 0.18 0.41 0.32
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A.3 Computations of the posterior distributions and likelihood of
the empirical Bayes model
We start by computing the posterior density of θg . As the calculation is the same for all g , we
omit the subscript in what follows,
pi
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We compute the numerator:
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We now compute the denominator of (A.1):
156
A.4. List of notations
∫
θ
f
(
Z (1), . . . , Z (L1) | θ)pi(θ)dθ = ∫
θ
pi(θ)
L1∏
l=1
f
(
Z (l ) | θ
)
dθ
=w2+
∫
θ
pp
2piτ
exp
{−θ2
2τ2
} L1∏
l=1
1p
2piσl
exp
{
−(Z (l )−θ)2
2σ2l
}
dθ
=w2+ pp
2piτ
L1∏
L=1
1
σl
ϕ
(
Z (l )
σl
)
exp
{(
L1∑
l=1
Z (l )
2σ2l
)2
1
2b
}∫
θ
exp
{
−b
2
(
θ−
L1∑
l=1
Z (l )
bσ2l
)2}
dθ
=w2+ pp
bτ
L1∏
l=1
1
σl
ϕ
(
Z (l )
σl
)
exp
{(
L1∑
l=1
Z (l )
2σ2l
)2
1
2b
}∫
θ
p
bp
2pi
exp
{
−b
2
(
θ−
L1∑
l=1
Z (l )
βσ2l
)2}
dθ︸ ︷︷ ︸
=1
=w2+w1.
Therefore, with pz = w1w1+w2 , we obtain the posterior density for θ:
pi(θ | z(1), . . . , z(L1))= pz
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As it is possible to obtain an explicit expression for the likelihood, we adopt an empirical
Bayes approach, and estimate the parameters σ1, . . . ,σL1 , p,τ by maximum likelihood. The
likelihood is
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so the log likelihood is
l (σ1, . . . ,σL1 , p,τ)=
G∑
g=1
log
(1−p)w˜2+ pw˜2
τ
p
b
exp
 12b
(
L1∑
l=1
Z (l )g
σ2l
)2
 .
A.4 List of notations
In this section, we give a list of the notations used in this thesis.
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• DE : differentially expressed;
• SOC: serous ovarian cancer;
• SAS: spike and slab prior;
• HS: horseshoe prior;
• NG: normal-gamma prior;
• ϕ: standard normal density;
• Φ: standard normal distribution;
• zα: αth quantile of the standard normal distribution;
• N ab : truncated normal distribution on the interval [a;b];
•
d→: convergence in distribution;
• δx (θ): distribution with a spike at θ = x;
• I{A} indicator function which is equal to 1 when condition A is satisfied;
• |S|: determinant of S, with S a matrix;
• |S |: size of the setS ;
• XG×N : matrix X with G rows and N columns;
• ∼ F : follows distribution F ;
• T ∼
H0
F : under the null distribution, T follows the distribution F ;
A.5 List of model parameters
The following tables give lists of parameters encountered in model (3.2) and model of Sec-
tion 6.4, as well as the parameters used in simulations of Chapter 4 and Sections 6.4.2 and 7.2.
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Table A.4 – Parameters of model (3.2).
Type 1
Y (l )g j gene expression of gene g for individual j in study l
µ(l )g baseline expression mean of gene g in study l
β(1,l )g differential expression parameter for gene g in Type 1 study l
σ2(l )g variance of the expression of gene g among all patients in study l
b1, b2 hyperparameters for σg
Type 2 (Type 3 is similar)
Z (l )g z-score of gene g in study l
β(2,l )g differential expression parameter for gene g in Type 2 study l
Type 4
R(l )g Rank of gene g in study l
u(l )g latent variable for gene g in study l ; Rg = rank
(
|u(l )g |
)
β(4,l )g differential expression parameter for gene g in Type 4 study l
σ2(l )u,g variance of the latent variable ug in study l
d1, d2 hyperparameters for σ
2(l )
u,g
Table A.5 – Parameters used in the simulations of Chapter 4.
parameter meaning usual value
G number of genes 200
N number of samples 50
n1 number of cancer samples 40
N −n1 number of control samples 10
L number of studies 5
L1 number of Type 1 studies 2
L2,L3,L4 number of Types 2, 3 and 4 studies 1
a differential expression parameter 0.2, . . . ,2
k number of differentially expressed genes 10
Rsim number of simulations 100 or 500
R number of iterations in the Gibbs sampling algorithm 31500
B number of blocks in the simulated covariance matrix 1
Table A.6 – Parameters used in the empirical Bayesian model of Section 6.4 to estimate a
common correlation matrix.
parameter meaning
R(l ) G×G gene-gene correlation matrix of study l
r (l ) vectorized upper triangular part of R(l ) of length G(G−1)/2
Z (l ) Fisher transformed r (l )
θg mean of Z (l )
σl variance of Z
(l )
p probability that θg is not null
θ˜g posterior median of θg
pz vector of posterior probabilities that θ is not null
τ2 variance of θg
Table A.7 – Parameters used in the simulations of Sections 6.4.2 and 7.2.
parameter meaning usual value
G number of genes 100 or 500
X t true gene expression matrix size G×N
Σt true block diagonal covariance matrix size G×G , with B blocks
Rt true block diagonal correlation matrix size G×G , with B blocks
B number of blocks in Σt or Rt 5 or 10
² noise ∼N (0,σ2²)
σ2² variance of the noise 0.1,. . . ,1
ρb correlation of the elements in the bth block ∼U (0.5,1) or ∼U (0,1)
or fixed between 0.1 and 0.9
Rsim number of simulations 100
L number of studies 3
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